On this page
Quick Reference
Overview and Recommendations
Background
- •ARDS is an acute, diffuse inflammatory lung injury defined by the Berlin 2012 criteria: acute onset ≤1 week, bilateral opacities on imaging, and PaO₂/FiO₂ ≤300 mm Hg on at least 5 cm H₂O PEEP, not fully explained by cardiac failure or fluid overload. The 2024 New Global Definition extended eligibility to include high-flow nasal oxygen ≥30 L/min and SpO₂/FiO₂ ≤315 (if SpO₂ ≤97%) as a surrogate when ABG is unavailable.
- •It affects approximately 10% of all ICU admissions and 23% of mechanically ventilated patients worldwide; in the U.S., over 190,000 cases occur annually. Despite declining mortality from ~50% in the 1990s to 30-40% in contemporary trials, ARDS remains a major cause of death, with hospital mortality rising from 27% (mild) to 35% (moderate) to 45% (severe) in the LUNG SAFE cohort.
- •Two reproducible molecular subphenotypes, hyperinflammatory (≈35% of patients, elevated IL-6/IL-8, lower bicarbonate, more shock, higher mortality) and hypoinflammatory (≈65%), have been identified by latent class analysis across multiple RCT cohorts. These subphenotypes show differential treatment responses to PEEP, fluid management, and statins, driving a precision-medicine approach.
- •The histologic hallmark is diffuse alveolar damage (DAD), characterized by hyaline membranes, edema, and type II cell hyperplasia. However, DAD is present in only 45% of patients meeting clinical ARDS criteria; its presence nearly doubles the odds of death (pooled OR 1.81, 95%). Alternative histologies include organizing pneumonia and pulmonary edema without DAD.
- •Key risk factors include sepsis (most common), pneumonia (bacterial, viral), aspiration of gastric contents, major trauma, and transfusion. Elevated driving pressure (>12 cm H₂O) at intubation independently predicts ARDS development (OR 1.20 per cm H₂O). Modifiable factors include crystalloid volume in the first 6 hours after injury (aOR 1.19 per liter) and ambient air pollution (long-term PM₁₀ per 10 μg/m³ OR 2.24).
Evaluation
- •Suspect ARDS in any patient with acute onset of hypoxemic respiratory failure, bilateral opacities on chest imaging, and no evidence of cardiogenic edema. The classic presentation is severe dyspnea, tachypnea >30 breaths/min, and refractory hypoxemia developing within 72 hours of an inciting event (sepsis, pneumonia, aspiration, trauma, transfusion).
- •Ask about the timing and progression of dyspnea, presence of cough (initially dry, later productive of frothy sputum), fever, and risk factors. Orthopnea and paroxysmal nocturnal dyspnea are absent, helping differentiate from cardiogenic pulmonary edema. Inquire about smoking history, recent travel, drug exposures, and immunocompromised status.
- •Examine for tachypnea, use of accessory muscles, intercostal retractions, and diffuse bilateral crackles on auscultation (present in >90%). Note dullness to percussion over consolidated areas. Cyanosis is a late sign correlating with severe hypoxemia (SpO₂ <85%). Wheezing is uncommon and should raise suspicion for alternative diagnoses.
- •Order an arterial blood gas to calculate PaO₂/FiO₂ ratio. The Berlin definition requires PaO₂/FiO₂ ≤300 on at least 5 cm H₂O PEEP for mild ARDS. If ABG is unavailable, use SpO₂/FiO₂ ≤315 when SpO₂ ≤97% (New Global Definition). Note that in high-altitude regions, the corrected SpO₂/FiO₂ cutoff may be higher (e.g., 360.4 in Xining cohort).
- •Obtain chest imaging (X-ray or CT) to confirm bilateral opacities not fully explained by effusions or atelectasis. CT is more sensitive for detecting underlying diffuse parenchymal lung disease. Lung ultrasound is an accepted alternative; the LUS-ARDS score (bilateral aeration scores and anterolateral pleural line abnormalities) has an AUC of 0.80.
- •Perform echocardiography to exclude cardiogenic pulmonary edema, assess left ventricular function, valve pathology, and estimated filling pressures. Natriuretic peptides can be adjunctive but are not diagnostic. Right ventricular dysfunction is common and associated with worse outcomes.
- •Apply the Berlin severity classification: mild (200-300 mm Hg), moderate (100-200 mm Hg), severe (<100 mm Hg) at minimum PEEP of 5 cm H₂O. Consider the PFP ratio (PaO₂/[FiO₂ × PEEP]) if PEEP varies, as it improves mortality discrimination (pooled AUC 0.84).
- •In atypical presentations (e.g., no clear ARDS risk factor, eosinophilia, hemoptysis, rapid progression), perform bronchoscopy with bronchoalveolar lavage (BAL) for cultures, cytology, and fungal markers to rule out acute eosinophilic pneumonia, diffuse alveolar hemorrhage, DPLD exacerbation, or infection. Transbronchial lung cryobiopsy can provide histologic confirmation of DAD if needed.
- •Assess for the hyperinflammatory subphenotype using plasma biomarkers (IL-8, bicarbonate, protein C), a parsimonious 3-variable model identifies phenotypes with AUC 0.94-0.95. While not yet standard of care, this informs clinical trial enrollment and may guide differential treatment (e.g., conservative fluids may harm hyperinflammatory patients).
- •Do not delay initiation of lung-protective ventilation while awaiting diagnostic test results. Once the diagnosis is suspected, commence 6 mL/kg tidal volume and PEEP per the ARDSNet table immediately. A diagnostic pitfall is misclassifying cardiogenic edema, DPLD exacerbation, or bilateral pneumonia as ARDS, careful assessment for an ARDS risk factor and absence of left atrial hypertension is essential.
Management
- •Initiate lung-protective ventilation with a target tidal volume of 6 mL/kg predicted body weight (PBW) and maintain plateau pressure ≤30 cm H₂O. Prioritize driving pressure <15 cm H₂O (ΔP = Pplat - PEEP), as it is the strongest modifiable predictor of mortality. The ARMA trial (n=861) showed a mortality reduction from 39.8% to 31.0% (NNT=12) with this strategy.
- •Set PEEP using the ARDSNet lower PEEP/FiO₂ table. Consider -guided PEEP if available; in patients with high lung recruitability, EIT-guided PEEP assigned higher PEEP and reduced mortality (35.6% vs 60.0%; HR 0.49). Avoid prolonged recruitment maneuvers, they are harmful (RR 1.37 vs higher PEEP alone).
- •Target oxygenation: SpO₂ 92-96% or PaO₂ 60-80 mm Hg. Avoid both hypoxemia and hyperoxia. The LOCO2 trial (n=205) found increased 90-day mortality with conservative PaO₂ targets of 55-70 mm Hg (44.4% vs 30.4%) and more mesenteric ischemic events. Five mesenteric ischemic events occurred in the conservative group.
- •For PaO₂/FiO₂ <150 mm Hg, start prone positioning within 12 hours of ARDS onset, aiming for ≥16 continuous hours per session. The PROSEVA trial showed a dramatic 28-day mortality reduction (16.0% prone vs 32.8% supine; HR 0.39; NNT=6). Benefit is independent of baseline respiratory system elastance. In non-intubated COVID-19 patients, awake prone positioning reduced intubation (OR 0.35) and mortality (OR 0.38).
- •Administer early dexamethasone 20 mg IV daily for 5 days, then 10 mg daily for 5 days. The DEXA-ARDS trial (n=277, moderate-to-severe ARDS) showed increased ventilator-free days (mean 4.8 days) and reduced 60-day mortality (21% vs 36%; NNT=7). Do not initiate corticosteroids after 14 days of ARDS (late methylprednisolone increases mortality).
- •Use a conservative fluid strategy after initial resuscitation: target central venous pressure <4 mm Hg or pulmonary artery occlusion pressure <8 mm Hg, using diuretics or fluid restriction as needed. The FACTT trial showed increased ventilator-free days but no overall mortality benefit. Note: conservative fluids may increase mortality in the hyperinflammatory phenotype (interaction P=0.0039).
- •Reserve neuromuscular blockade (cisatracurium infusion) for patients with severe ventilator dyssynchrony or driving pressure >15 cm H₂O despite deep sedation. The ROSE trial (n=1006) found no 90-day mortality benefit (42.5% vs 42.8%). A secondary analysis suggests benefit in patients with high respiratory system elastance (Ers ≥2 cm H₂O/[mL/kg]; median ARR 9%, posterior probability 96%).
- •For very severe ARDS (PaO₂/FiO₂ <50 mm Hg for >3 h, or <80 mm Hg for >6 h, or pH <7.25 with PaCO₂ ≥60 mm Hg), refer for venovenous ECMO evaluation at a high-volume center. The EOLIA trial showed 60-day mortality 35% with ECMO vs 46% with conventional care (RR 0.76; 95% CI 0.55-1.04). A meta-analysis of VV-ECMO trials demonstrated a mortality benefit (RR 0.64).
- •Provide pharmacologic VTE prophylaxis with low molecular weight heparin per institutional protocol. In patients on ECMO, a restrictive transfusion threshold of hemoglobin <8 g/dL was associated with lower hazard of death (aHR 0.48) in a retrospective cohort. Anticoagulation targets vary; monitor for bleeding (46% of ECMO patients) and thrombocytopenia (27%).
- •Implement a daily sedation interruption and spontaneous breathing trial protocol to reduce duration of mechanical ventilation, prevent ventilator-associated pneumonia, and minimize ICU-acquired weakness. Early rehabilitation and physical therapy should be initiated as soon as hemodynamically stable; mobilization during ECMO is feasible and safe (2% adverse event rate).
- •Avoid high-frequency oscillatory ventilation (increased mortality in OSCILLATE: 47% vs 35%; RR 1.33), statins (rosuvastatin in SAILS and simvastatin in HARP-2: no benefit), exogenous surfactant (no improvement in outcomes), and beta-agonists (increased 90-day mortality: RR 1.39; increased arrhythmias).
- •Monitor for complications: barotrauma (pneumothorax, persistent air leak), VTE (53% incidence on ECMO), circuit thrombosis on ECMO, ventilator-associated pneumonia, pulmonary hemorrhage on ECMO (63% on autopsy), right ventricular dysfunction (prognostic determinant), and neuromuscular weakness (especially with prolonged NMB or corticosteroids).
- •For patients with irreversible lung failure despite prolonged support (e.g., >47 ECMO days predicts oxygen need at 6 months), consider lung transplant evaluation at a specialized center. In a European cohort, 70% of ARDS lung transplant survivors returned to work. Selection criteria include absence of multiorgan failure, potential for rehabilitation, and psychosocial stability.
Board Review — High Yield
- •Berlin definition, Acute onset (≤1 week), bilateral opacities, PaO2/FiO2 ≤300 on PEEP ≥5 cm H2O, not fully explained by cardiac failure or fluid overload.
- •PROSEVA trial, Prone positioning for ≥16 h/day in severe ARDS (PaO2/FiO2 <150) reduces 28-day mortality from 32.8% to 16.0% (HR 0.39; NNT=6).
- •DEXA-ARDS trial, Early dexamethasone 20 mg IV daily ×5, then 10 mg ×5, reduces 60-day mortality from 36% to 21% (NNT=7) and increases ventilator-free days by 4.8.
- •Driving pressure, ΔP = Pplat - PEEP. Target <15 cm H2O; it is the strongest modifiable predictor of mortality, and the benefit of low tidal volume varies by elastance.
- •Hyperinflammatory phenotype, Identified by IL-8, bicarbonate, protein C; ~35% of ARDS patients; higher mortality (39% vs 17% at 28 days); responds differently to PEEP, fluids, and statins.
- •EOLIA trial, VV-ECMO for very severe ARDS (PaO2/FiO2 <50 for >3h, <80 for >6h, or pH<7.25 with PaCO2 ≥60) showed 60-day mortality 35% vs 46% (RR 0.76; 95% CI 0.55-1.04; p=0.09).
- •ROSE trial, Routine neuromuscular blockade (cisatracurium) for moderate-severe ARDS does not improve 90-day mortality (42.5% vs 42.8%); benefit may be limited to high-elastance patients.
- •ARMA trial, Low tidal volume (6 mL/kg PBW) reduces mortality from 39.8% to 31.0% compared with 12 mL/kg (NNT=12); remains the strongest mortality benefit signal in ARDS history.
- •Avoid, High-frequency oscillation (increased mortality), statins (no benefit), exogenous surfactant (no benefit), beta-agonists (increased mortality), late corticosteroids (>14 days) (harm).
- •DAD, Diffuse alveolar damage is the histologic hallmark but present in only 45% of clinical ARDS; doubles odds of death (OR 1.81).
Deep Dive — Evidence Details
1. Definition, Classification and Nomenclature
- ▸ARDS is defined by acute onset, bilateral opacities, non-cardiogenic origin, and hypoxemia (PaO₂/FiO₂ ≤300) per the Berlin definition, now expanded by the 2024 New Global Definition to include high-flow nasal oxygen and SpO₂/FiO₂ criteria.
- ▸Severity stratification (mild/moderate/severe) by PaO₂/FiO₂ guides prognosis and management; a hyperinflammatory subphenotype identified by latent class analysis has higher mortality and differential treatment response.
Acute respiratory distress syndrome (ARDS) is an acute, diffuse, inflammatory lung injury characterized by increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue, clinically manifesting as hypoxemia and bilateral opacities on imaging not fully explained by cardiac failure or fluid overload.
Also called: Acute lung injury (ALI; term replaced by "mild ARDS" in the Berlin definition), shock lung, wet lung, Da Nang lung (historical wartime terms). Abbreviation: ARDS.
Classification
ARDS is classified along three axes: clinical severity, molecular subphenotype, and histologic pattern.
Severity grading follows the Berlin definition (2012), which stratifies patients by PaO₂/FiO₂ ratio at a minimum PEEP of 5 cm H₂O [2]A1c:
- Mild: 200 < PaO₂/FiO₂ ≤ 300 mm Hg
- Moderate: 100 < PaO₂/FiO₂ ≤ 200 mm Hg
- Severe: PaO₂/FiO₂ ≤ 100 mm Hg
The 2024 New Global Definition extends this framework by including patients treated with high-flow nasal oxygen at ≥30 L/min, allowing substitution of SpO₂/FiO₂ ≤ 315 (if SpO₂ ≤ 97%) when arterial blood gas is unavailable, and accepting lung ultrasound for imaging; in resource-limited settings, PEEP is not required [17]D5.
| Severity | PaO₂/FiO₂ (mm Hg) | SpO₂/FiO₂ equivalent* |
|---|---|---|
| Mild | 201-300 | ≤315 (if SpO₂ ≤ 97%) |
| Moderate | 100-200 | , |
| Severe | ≤100 | , |
| *Per New Global Definition [17]D5; moderate and severe SpO₂/FiO₂ thresholds remain under investigation, with high-altitude adjustments needed [47]B2b. |
Biological subphenotypes: Latent class analysis across multiple cohorts consistently identifies two molecular phenotypes: a hyperinflammatory phenotype (higher plasma cytokines, vasopressor dependence, metabolic acidosis, and increased mortality) and a hypoinflammatory phenotype [4]B2b[7]B3b. These subphenotypes respond differently to PEEP strategies and other interventions; for example, the hyperinflammatory group derived greater benefit from higher PEEP in the ALVEOLI trial [4]B2b. A recent proteomic study suggests a third intermediate phenotype, but the two-phenotype model remains the most validated for clinical trial enrichment [14]B2b[40]B2b.
Histologic pattern: Diffuse alveolar damage (DAD) is the histologic hallmark, but it is present in only 45% of patients meeting the clinical definition of ARDS [15]C4[51]D5. The presence of DAD is associated with higher mortality (pooled OR 1.81, 95%) [15]C4. Alternative histologies include organizing pneumonia, pulmonary edema without DAD, or no specific pathology [51]D5.
Clinical significance
ARDS occurs in approximately 10% of ICU admissions and 23% of mechanically ventilated patients [18]B2b. In the United States, the age-adjusted mortality rate fell from 5.01 per 100,000 in 1999 to 2.82 per 100,000 in 2013 [53]B2c, yet clinical-trial mortality remains near 30-40% [10]B2a. Survivors frequently suffer from impaired pulmonary function, cognitive deficits, and reduced quality of life [13]B2b[38]C4. Up to one-third of patients meeting the Berlin definition may have an unrecognized diffuse parenchymal lung disease (e.g., IPF exacerbation) [58]B2b, and interobserver reliability for the diagnosis is only moderate (κ ≈ 0.5) [54]B2b.
Pearl: The diagnosis of ARDS is frequently missed or misclassified, consider alternative causes of bilateral opacities (diffuse parenchymal lung disease, cardiogenic edema) before assigning the label, and use the SpO₂/FiO₂ ratio (≤315 with SpO₂ ≤97%) from the New Global Definition to diagnose hypoxemia when arterial blood gas is unavailable [17]D5[29]B2c.
2. Pathophysiology and Mechanism
- ▸ARDS pathophysiology converges on a final common pathway of alveolar epithelial and endothelial injury, driven by inflammasome activation, neutrophil-mediated damage, and VEGF pathway dysregulation.
- ▸The hyperinflammatory and hypoinflammatory subphenotypes differ in biomarker profiles and treatment responsiveness, providing the rationale for precision medicine.
- ▸Genetic variants in FLT1 (VEGFR-1) and plasma IGFBP7 are causally linked to ARDS susceptibility and mortality, respectively.
The Berlin definition describes a syndrome, but the underlying pathological pathway begins with a common sequence of alveolar-capillary injury. Whether the inciting event is pneumonia, aspiration, sepsis, or trauma, the final common pathway involves disruption of the alveolar epithelium and endothelium, leading to protein-rich pulmonary edema, surfactant dysfunction, and severe impairment of gas exchange [63]D5[116]D5.
Alveolar-Capillary Barrier Injury
Pathogen- or damage-associated molecular patterns (PAMPs/DAMPs) activate pattern recognition receptors on alveolar macrophages and epithelial cells, triggering inflammasome assembly, primarily NLRP3, but also NLRC4 and AIM2, which cleaves pro-IL-1β and pro-IL-18 into their active forms [100]D5. Complement activation, notably C5a, amplifies this response [106]A1b. The resultant cytokine storm (TNF-α, IL-8, IL-1β) recruits neutrophils into the lung interstitium and airspaces.
Primed neutrophils are retained in the pulmonary microvasculature; in health, they deprime and are re-released, but in ARDS this depriming mechanism fails, allowing activated neutrophils to enter the systemic circulation and contribute to remote organ injury [104]B2b. Once in the alveolus, neutrophils release matrix metalloproteinases (MMP-8, MMP-9), cathepsin S, neutrophil elastase, and reactive oxygen species, directly damaging epithelial and endothelial barriers [74]D5[105]D5. Neutrophil extracellular traps (NETs) further propagate inflammation and thrombosis.
Endothelial injury increases microvascular permeability. The vascular endothelial growth factor (VEGF) pathway plays a central role: a common variant in the FLT1 gene (encoding VEGFR-1) confers protection against sepsis-associated ARDS (OR 0.61), and VEGFA is also associated [95]B3b[102]D5. In , severe endothelialitis, widespread thrombosis (alveolar capillary microthrombi 9 times more prevalent than in influenza), and intussusceptive angiogenesis distinguish the histopathology [98]B3b[121]D5.
Surfactant Dysfunction and Gas Exchange Derangement
Injury to alveolar type II cells reduces surfactant production, and an altered neutral lipid profile further impairs surface activity [66]A1b. The resulting atelectasis and alveolar flooding cause intrapulmonary shunt, the dominant mechanism of hypoxemia. Concomitant microvascular thrombosis and ventilation-perfusion mismatch increase physiological dead space, impairing CO₂ clearance; an elevated dead space fraction (ventilatory ratio) is a strong independent predictor of mortality [71]D5[85]D5.
(VILI)
Mechanical ventilation, while lifesaving, can amplify injury. The “Permeability-Originated Obstruction Response (POOR) gets POORer” hypothesis posits that alveolar leak causes local surfactant dysfunction, creating stress concentrators that propagate damage outward [75]D5. Lung recruitability varies widely, from 0.3% to 66.9%, and can be assessed by electrical impedance tomography to personalize PEEP settings [72]B2b.
Genetic and Modifiable Susceptibility
Beyond FLT1, a Mendelian randomization study identified plasma IGFBP7 as a causal biomarker for 28-day mortality, mediated in part through platelet count [97]B3b. Non-modifiable risk factors (age, blunt trauma, injury) and a key modifiable one, crystalloid volume in the first 6 hours after injury (aOR 1.19 per litre), inform risk stratification [11]B2a.
Resolution Mechanisms and Subphenotypes
Resolution of ARDS is an active process. Basophils accumulate in the injured lung and produce IL-4, which acts on neutrophils to suppress anti-apoptotic and pro-inflammatory gene expression [83]D5. Macrophage reprogramming by mesenchymal stromal cell-derived extracellular vesicles, through the miR-181a-PTEN-pSTAT5-SOCS1 axis, shifts macrophages toward an anti-inflammatory phenotype [34]D5. Dopamine signaling, via D1-like receptors, enhances macrophage fatty acid oxidation and inhibits NETosis [128]D5.
Two distinct subphenotypes, hyperinflammatory (elevated IL-6, IL-8, TNF-α receptors, higher shock prevalence) and hypoinflammatory, have been identified across multiple cohorts. In the HARP-2 trial, showed no overall benefit, but a differential treatment effect was suggested by subphenotype [60]B2b[62]A1b. These subphenotypes also respond differently to PEEP and fluid , underscoring the need for precision medicine approaches [92]D5[93]D5.
Pearl: The degree of alveolar dead space fraction (measured as ventilatory ratio) at ARDS onset is a stronger predictor of mortality than PaO₂/FiO₂ alone; a rising dead space should prompt evaluation for worsening pulmonary vascular injury or developing right ventricular dysfunction [70]D5[117]D5.
3. Epidemiology, Etiology and Risk Factors
- ▸Sepsis, pneumonia, aspiration, trauma, and transfusion are the most common precipitants; elevated driving pressure and ambient air pollution are emerging independent risk factors.
- ▸Smoking and vaping upregulate SARS-CoV-2 viral-entry genes and may increase the risk of severe COVID-19 ARDS, while obesity paradoxically shows no mortality increase.
From the pathophysiologic mechanisms that prime the injured lung, the clinical of ARDS quantifies the burden and identifies the modifiable and non-modifiable drivers that shape pretest probability.
Incidence and Demographics
ARDS affects over 190,000 people annually in the United States, with mortality ranging from 27% to depending on illness severity [176]D5. It is present in >10% of all critical care admissions worldwide [100]D5. Among mechanically ventilated patients who meet the Berlin definition, approximately one-third are retrospectively diagnosed with new-onset or acutely exacerbated diffuse parenchymal lung disease rather than classic ARDS [58]B2b. Incidence increases with age, yet paradoxically, community-acquired pneumonia patients aged ≥85 years develop ARDS less frequently (1.1% versus 8.5-20% in younger elderly) [203]B2b. Advanced age remains a leading risk factor for -induced ARDS [84]D5. No consistent sex predilection has been identified.
Temporal Trends
Mortality has declined from approximately 50% in the 1990s to 30-40% in the modern era, driven largely by the widespread adoption of lung-protective ventilation, prone positioning, and conservative fluid [63]D5. The COVID-19 pandemic produced a dramatic surge in ARDS incidence and highlighted disparities in outcomes across ethnic and socioeconomic groups.
Risk Factors
The most common precipitants are sepsis, pneumonia, aspiration of gastric contents, major trauma, and transfusion. Transfusion-related acute lung injury (TRALI), a distinct antibody-mediated form, has been substantially reduced by using male-predominant plasma [157]D5. A higher driving pressure (ΔP) measured early after intubation independently predicts ARDS development (odds ratio [OR] 1.20 per cm H₂O; 95% CI 1.03-1.41) [200]B2b. Ambient air pollution also contributes: short-term carbon monoxide exposure (per 0.1 ppm) confers an OR of 1.18 for ARDS, and long-term particulate matter ≤10 μm (PM₁₀, per 10 μg/m³) an OR of 2.24 [199]B2b. In patients undergoing , current smokers have a higher incidence of postoperative ARDS than ex-smokers (57% versus 25%; p=0.031) and exhibit dysregulated alveolar inflammation [123]B2b. Smoking and vaping upregulate SARS-CoV-2 viral-entry genes, potentially increasing the risk of severe COVID-19 ARDS [141]A1a. Elevated estimated plasma volume status (>8.0 dL/g) is independently associated with sepsis-associated ARDS (OR 1.56; 95% CI 1.50-1.63) [198]B3b. Obesity (BMI ≥28 kg/m²) does not increase ARDS mortality and is paradoxically linked to lower plasma levels of interleukin-6 and interleukin-8 [140]B2b.
Seasonal and Special Considerations
ARDS incidence follows seasonal viral patterns, peaking during influenza seasons and respiratory virus outbreaks. The COVID-19 pandemic caused a sustained global increase. Influenza-related ARDS may carry a lower day-28 mortality than ARDS from other causes (HR 0.51; p=0.047) [90]B2b. In critically ill patients, elevated driving pressure, a simple, routinely measured ventilator variable, should alert the clinician to heightened risk of progression to ARDS.
Pearl: When assessing an intubated patient with a risk factor for ARDS, a driving pressure >12 cm H₂O and a smoking history should each raise suspicion for imminent or established ARDS, these modifiable signals warrant early lung-protective ventilation and consideration of prone-position candidacy.
Risk Factors for Developing ARDS
| Factor | Odds Ratio / Relative Risk (95% CI) | Evidence Level |
|---|---|---|
| Driving pressure (per cm H₂O) | OR 1.20 (1.03-1.41) | Prospective cohort [200]B2b |
| Short-term CO exposure (per 0.1 ppm) | OR 1.18 (CI not stated) | Multicentre cohort [199]B2b |
| Long-term PM₁₀ (per 10 μg/m³) | OR 2.24 (CI not stated) | Multicentre cohort [199]B2b |
| Elevated ePVS (>8.0 dL/g) | OR 1.56 (1.50-1.63) | Multicentre cohort [198]B3b |
| Current smoking (post-esophagectomy) | 57% vs 25% (p=0.031) | Prospective substudy [123]B2b |
4. Clinical Presentation
- ▸ARDS presents acutely with severe dyspnea, tachypnea, bilateral crackles, and refractory hypoxemia, typically within 72 hours of a defined insult.
- ▸The hyperinflammatory subphenotype is distinguished by higher plasma IL-6/IL-8, lower bicarbonate, vasopressor need, and 39% 90-day mortality vs. 23% in the hypoinflammatory phenotype [7].
- ▸Silent hypoxemia (disproportionately low SpO₂ without dyspnea) is well-documented in COVID-19 ARDS but can occur in other causes [109].
Regardless of the inciting insult, whether sepsis, pneumonia, aspiration, or trauma, the transition from at-risk state to established ARDS is marked by acute onset of hypoxemic respiratory failure within hours to days. The clinical picture reflects the underlying mechanism: increased permeability pulmonary edema, surfactant dysfunction, and ventilation-perfusion mismatch, all of which manifest as rapidly worsening dyspnea, tachypnea, and refractory hypoxemia.
Presenting Symptoms
Patients typically present with severe dyspnea at rest, often with a sense of air hunger that progresses over <72 hours from the inciting event [226]C4[232]C4[238]C4. Cough is nearly universal, initially dry, later productive of frothy, sometimes blood-tinged sputum reflecting alveolar edema. Fever is present in approximately 80-90% of cases when infection is the trigger [226]C4[232]C4[240]C4. Fatigue and myalgias are common accompanying symptoms. In viral etiologies, myalgias and headache may precede respiratory symptoms [238]C4. Orthopnea and paroxysmal nocturnal dyspnea are absent, helping differentiate ARDS from cardiogenic pulmonary edema.
General and Respiratory Examination Findings
On inspection, patients are tachypneic (respiratory rate often > 30 breaths/min), using accessory muscles, with intercostal and supraclavicular retractions. Cyanosis may be present when hypoxemia is severe. The trachea is midline unless there is associated pleural effusion or pneumothorax.
Auscultation reveals diffuse, bilateral crackles that are coarse and may be heard throughout the respiratory cycle, most prominently in dependent lung zones. As lung compliance decreases, breath sounds become bronchial in quality over consolidated areas. Wheezing is uncommon unless there is underlying airway disease or bronchospasm from an inciting agent.
Chest percussion is dull over consolidated regions, but hyperresonance is absent unless complicated by pneumothorax.
Key findings at the bedside include:
- Tachypnea (respiratory rate > 30 breaths/min) - sensitivity ~80% for ARDS [226]C4.
- Bilateral crackles - present in >90% of cases [232]C4.
- Use of accessory muscles - reflects increased work of breathing.
- Cyanosis - a late sign, correlates with severe hypoxemia (SpO₂ < 85%).
Phenotypic Variants: Hyperinflammatory vs. Hypoinflammatory
Latent class analysis consistently identifies two distinct subphenotypes with different clinical features and outcomes [7]B3b[227]B2c[233]B2b. The table below summarizes distinguishing characteristics.
| Feature | Hypoinflammatory | Hyperinflammatory |
|---|---|---|
| Plasma IL-6, IL-8, sTNFR-1 | Low | High [7]B3b |
| Bicarbonate | Normal to high | Low (metabolic acidosis) [7]B3b |
| Protein C | Higher | Lower [7]B3b |
| Vasopressor requirement | Less common | More common [7]B3b |
| 90-day mortality | ~23% | ~39% [7]B3b |
| Ventilator-free days (median) | 22 days | 14 days [7]B3b |
Patients with the hyperinflammatory phenotype are more likely to have shock, metabolic acidosis, and higher severity of illness scores [227]B2c. Importantly, treatment response to PEEP and fluid may differ between subphenotypes [233]B2b.
Red Flags for Clinical Deterioration
- Refractory hypoxemia: PaO₂/FiO₂ < 100 mm Hg despite high FiO₂ and PEEP; consider prone positioning or ECMO [215]B2a[216]B2b.
- Hemodynamic instability: Worsening shock not explained by sedation; suspect superimposed sepsis, pneumothorax, or pulmonary embolism.
- Rapid drop in lung compliance: Plateau pressure rising > 30 cm H₂O despite tidal volume reduction; consider bronchospasm, pneumothorax, or worsening edema.
- Multi-organ failure: Acute kidney injury, liver dysfunction, or coagulopathy (e.g., DIC) signals progression to severe ARDS with high mortality [94]D5[226]C4.
Atypical Presentations
Silent hypoxemia ("happy hypoxia") has been described in ARDS, where patients exhibit severe hypoxemia (SpO₂ < 80%) without proportionate dyspnea [109]D5. This phenomenon is attributed to preserved lung compliance and altered central chemoreception; however, it is not unique to COVID-19 and can be seen in early ARDS from other causes [109]D5[120]B2b.
Organizing pneumonia from may present subacutely over weeks with cough, low-grade fever, and migratory infiltrates, only later fulfilling ARDS criteria if progression is rapid [213]C4.
Pediatric ARDS (PARDS) often presents with wheezing, intercostal retractions, and nasal flaring rather than frank crackles; the underlying trigger is frequently viral bronchiolitis or pneumonia [235]D5.
Pearl: In any patient with acute hypoxemia and bilateral infiltrates, a PaO₂/FiO₂ ratio < 300 plus non-cardiogenic edema (by echocardiography or ) confirms ARDS by Berlin criteria; the absence of fever or elevated white count should prompt consideration of noninfectious mimics (e.g., , diffuse alveolar hemorrhage).
5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored)
- ▸ARDS is diagnosed using the Berlin criteria; pulse oximetry (SpO₂/FiO₂ ≤ 315) is an acceptable substitute for PaO₂/FiO₂ when SpO₂ ≤ 97%.
- ▸Bronchoscopy with bronchoalveolar lavage is essential to exclude alternate diagnoses such as acute eosinophilic pneumonia, diffuse alveolar hemorrhage, and infection, especially in immunocompromised patients.
- ▸Lung-protective ventilation should be initiated immediately upon diagnosis, before obtaining results of all diagnostic tests.
Once the clinical features described in the preceding section raise suspicion, the diagnosis of ARDS is established at the bedside by applying the Berlin definition, but the workup that follows must systematically exclude mimics, identify the precipitating cause, and quantify physiological severity.
Diagnostic Criteria and Oxygenation Assessment
The Berlin definition requires acute onset (≤1 week), bilateral chest imaging opacities not fully explained by effusions or atelectasis, and hypoxemia with PaO₂/FiO₂ ≤ 300 mm Hg on at least 5 cm H₂O of positive end-expiratory pressure (PEEP). The 2024 global definition expanded eligibility to include high-flow nasal oxygen at ≥30 L/min and accepted SpO₂/FiO₂ ≤ 315 (when SpO₂ ≤ 97%) as a surrogate for PaO₂/FiO₂ [17]D5[275]D5. In the ARDS Network derivation cohort, nonlinear imputation of PaO₂ from SpO₂ produced the lowest error, and 90-day mortality was similar whether measured or imputed PaO₂/FiO₂ was used [29]B2c. However, in high-altitude regions, the nonlinear relationship shifts, and the global threshold of SpO₂/FiO₂ ≤ 315 may not apply; a corrected cutoff of 360.4 predicted mild ARDS with AUC 0.912 in a Xining cohort [47]B2b. A PEEP-incorporated ratio (PaO₂/FiO₂×PEEP, or PFP) reclassified 30-72% of patients and improved mortality discrimination (pooled sensitivity 0.55, specificity 0.90, sROC AUC 0.84) [205]B2a.
Imaging
Bilateral opacities on chest radiography or CT remain the imaging criterion. CT is more sensitive for detecting underlying diffuse parenchymal lung disease (DPLD): in a multicenter retrospective study, pulmonology specialists reclassified approximately one-third of patients meeting the Berlin definition as having new-onset or acutely exacerbated DPLD (8% , 25% other DPLDs) [58]B2b. High-resolution CT patterns, ground-glass attenuation, consolidation, reticular opacities, and traction bronchiectasis, can suggest diffuse alveolar damage (DAD), but no pattern is pathognomonic. Lung ultrasound (LUS) is now an accepted alternative imaging modality: the LUS-ARDS score, incorporating bilateral aeration scores and anterolateral pleural line abnormalities, had an AUC of 0.80 (95% CI 0.72-0.87) in an external validation cohort, comparable to chest radiography read by experts [19]B2b.
Bronchoscopy and Bronchoalveolar Lavage
Diagnostic bronchoscopy with bronchoalveolar lavage (BAL) is the procedure of choice when an alternate diagnosis is suspected or when infection must be confirmed. BAL with microbiologic cultures (bacterial, fungal, viral), cytology for eosinophils ( [69]D5), hemosiderin-laden macrophages (diffuse alveolar hemorrhage), and malignant cells (e.g., lymphangitic carcinomatosis, leukemic infiltration [212]C4) can change . In immunocompromised patients, BAL with galactomannan and β-D-glucan helps diagnose -associated pulmonary aspergillosis or Pneumocystis jirovecii pneumonia [207]D5. Research bronchoscopy is safe and valuable for biomarker collection but requires careful patient selection [290]D5. The utility of routine bronchoscopy in typical ARDS is debated; a RAND appropriateness panel found disagreement only regarding its use in patients with suspected COVID-19 [243]D5.
When the diagnosis remains uncertain after BAL, transbronchial lung cryobiopsy can provide histologic confirmation of DAD. In a retrospective series of 90 patients who underwent open lung biopsy or cryobiopsy, rapid progression of DAD (proliferative phase within 7 days or fibrotic phase within 21 days) was independently associated with higher 60-day mortality (, p=0.014); pneumothorax occurred in 17.8% [298]B2b.
Biomarkers and Phenotyping
No plasma biomarker has sufficient diagnostic accuracy for routine clinical use. Exhaled octane measured by a point-of-care breath test yielded an AUC of only 0.52 and has been disqualified [59]B2b. In pediatric ARDS, nine biomarkers across epithelial injury, endothelial injury, and inflammatory pathway domains showed AUCs of 0.60-0.96, but none are adopted in practice [292]B2a. By contrast, latent class analysis using plasma IL-8, protein C, and bicarbonate consistently identifies hyperinflammatory and hypoinflammatory subphenotypes that differ in outcome and treatment response (AUC 0.88-0.92 for clinical classifier models) [6]B2b[158]B2b[233]B2b. These subphenotypes are now measurable in real-time using fresh plasma with IL-6 and soluble TNFR1, achieving >75% feasibility [279]B2b. Phenotype assignment is not yet standard of care but should be incorporated into clinical trial design.
Diagnostic Algorithm
Step 1 - Confirm the Berlin definition: acute onset, bilateral opacities, PaO₂/FiO₂ ≤ 300 (or SpO₂/FiO₂ ≤ 315) on ≥5 cm H₂O PEEP or HFNO ≥30 L/min. Exclude cardiogenic pulmonary edema (echocardiography, natriuretic peptides, fluid responsiveness).
Step 2 - Identify the primary ARDS risk factor: sepsis, pneumonia, aspiration, pancreatitis, trauma, transfusion, drug toxicity [157]D5[213]C4, or inhalational injury. If no clear risk factor is present, consider acute eosinophilic pneumonia [69]D5, DPLD exacerbation [58]B2b, ANCA-associated vasculitis, or anti-synthetase syndrome [261]C4.
Step 3 - Obtain lower respiratory tract specimen (BAL or endotracheal aspirate) for cultures, cytology, and fungal markers. In the mechanically ventilated patient, BAL has lower contamination risk than aspirate; nonbronchoscopic mini-BAL is an alternative when expertise is limited [119]D5.
Step 4 - Initiate lung-protective ventilation immediately (tidal volume ≤6 mL/kg predicted body weight, plateau pressure ≤30 cm H₂O). Do not delay while awaiting diagnostic results.
Step 5 - If the hypoxemia pattern is atypical (e.g., profound hypoxemia without high PEEP requirement, or rapidly progressive gas exchange despite lung protection), escalate to CT chest and consider biopsy. A multidisciplinary discussion involving intensivists, radiologists, and pathologists is recommended before lung biopsy.
Pearl: A common diagnostic pitfall is misclassifying cardiogenic pulmonary edema, acute exacerbation of , or bilateral pneumonia as ARDS, careful assessment for the presence of an ARDS risk factor (sepsis, aspiration, pancreatitis, etc.) and the absence of left atrial is essential.
6. Severity, Staging and Risk Stratification
- ▸Berlin severity grading (mild/moderate/severe by PaO₂/FiO₂) predicts mortality and NIV failure but does not capture disease trajectory or biology.
- ▸Hyperinflammatory vs. hypoinflammatory subphenotypes (identified by IL-8, bicarbonate, protein C) show differential responses to PEEP, fluids, and simvastatin; treatment effects in prior negative trials may be phenotype-dependent.
- ▸Dynamic oxygenation subgroups over the first 3 days and the PEEP-adjusted PFP ratio outperform static PaO₂/FiO₂ for prognosis and PEEP guidance.
Once patients meet the Berlin diagnostic criteria, clinicians must grade hypoxemic severity, not as a static label but as a dynamic anchor for escalating therapy. The Berlin definition stratifies ARDS by PaO₂/FiO₂ ratio on PEEP ≥5 cm H₂O: mild (200-300 mm Hg), moderate (100-200 mm Hg), and severe (<100 mm Hg). This three-tier system correlates with mortality: in the LUNG SAFE cohort, hospital mortality rose from 27% (mild) to 35% (moderate) to 45% (severe) [18]B2b. It also predicts noninvasive ventilation (NIV) failure, 22% in mild, 42% in moderate, and 47% in severe ARDS, and patients with PaO₂/FiO₂ <150 mm Hg had higher ICU mortality when managed with NIV compared with early intubation [18]B2b. Although the Berlin classification is the accepted global standard, it has important limitations: it does not account for the level of PEEP at the time of arterial blood sampling, the trajectory of hypoxemia over time, or the underlying biology that drives differential treatment responses.
Beyond PaO₂/FiO₂: Refining Risk Through Subphenotypes and Biomarkers
Latent class analyses of multiple RCT cohorts have consistently identified two ARDS subphenotypes, hypoinflammatory (≈65-70% of patients) and hyperinflammatory (≈30-35%), distinguished by plasma inflammatory biomarkers (interleukin‑6, interleukin‑8, soluble tumor necrosis factor receptor‑1), lower serum bicarbonate, higher vasopressor use, and sepsis prevalence [4]B2b[60]B2b[173]B2b. The hyperinflammatory phenotype carries substantially higher mortality (e.g., 28‑day mortality 39% vs. 17% in the HARP‑2 cohort [60]B2b) and fewer ventilator‑free days. Crucially, treatment effects differ by subphenotype: higher PEEP reduced mortality in the hyperinflammatory group but not in the hypoinflammatory group in the ALVEOLI trial [4]B2b; conservative fluid improved survival in hypoinflammatory patients but increased mortality in the hyperinflammatory phenotype in FACTT (interaction P = 0.0039) [173]B2b; and (80 mg) improved 28‑day survival in the hyperinflammatory subgroup of HARP‑2 but showed no overall effect in the trial [60]B2b. Parsimonious classifiers using just 3 variables (interleukin‑8, bicarbonate, protein C) identify these phenotypes with AUC 0.94-0.95, moving subphenotyping toward clinical feasibility [7]B3b. In paediatric ARDS, the same two‑phenotype structure is present: the hyperinflammatory group has ** mortality** vs. 2.2% in the hypoinflammatory group [5]B2b[303]B2b.
More recent proteomic profiling in 1048 patients identified three inflammatory phenotypes (C1, C2, C3), with C1 (intense innate immune activation) having the highest 90‑day mortality and shock incidence [14]B2b. Glucocorticoid therapy and higher PEEP improved outcomes in C1 but increased mortality in C2, further supporting biomarker‑guided therapy [14]B2b. Plasma ferritin >1380 ng/mL also identifies a hyperinflammatory subgroup with a log‑fold increase in ferritin associated with OR 1.71 for 28‑day mortality, mediated by interleukin‑18, a potential target for immunomodulation [153]B2b. Other promising biomarkers include IGFBP7 (causal mediator of 28‑day mortality, OR 2.61 per log₂ increase) [97]B3b and factor H deficiency (relative deficiency linked to HR 1.52 for death) [208]B2b.
Dynamic oxygenation subgroups derived from the trajectory of PaO₂/FiO₂ over the first 3 days outperform static Berlin categories for predicting mortality. In a 5‑cohort analysis, patients with a persistently low PaO₂/FiO₂ trajectory had ** mortality** vs. 17.4% for rapid improvers (P < 0.001 for heterogeneity) [183]B2b. These longitudinal subgroups also showed differential PEEP responsiveness (interaction P = 0.001), whereas Berlin subgroups did not (P = 0.72) [183]B2b. The PFP ratio (PaO₂/[FiO₂ × PEEP]) has been proposed as a PEEP‑adjusted index; a meta‑analysis of 4454 patients found a pooled AUC of 0.84 for prognostication, with 30-72% of patients reclassified into different severity strata compared with the conventional PF ratio [205]B2a.
Anatomic and Physiologic Risk Markers
Diffuse alveolar damage (DAD), the histologic hallmark of ARDS, is present in only ≈45% of patients meeting clinical criteria but is associated with OR 1.81 for death (pooled OR, 95%) [15]C4. Noninvasive prediction of DAD remains elusive, but lung CT morphology (focal vs. non‑focal) may guide personalized ventilation: the LIVE trial found that misclassification occurred in 21% of patients and was associated with 65% mortality in the personalized ventilation arm [134]A1b. Driving pressure (ΔP = plateau pressure - PEEP) at ICU admission is independently associated with ARDS development in at‑risk patients (OR 1.20 per cm H₂O) [200]B2b, and in established ARDS ΔP is a stronger predictor of mortality than tidal volume alone, the benefit of low VT varies by respiratory system elastance, with 92% posterior probability of absolute risk reduction >1% in high‑elastance patients [132]B2b. Mechanical power, a composite of driving pressure, respiratory rate, and flow, also predicts mortality, though ΔP alone accounts for most of the signal [170]B2b.
Implications for Therapy Selection
Severity grade and phenotype together drive the intensity of supportive care:
- PaO₂/FiO₂ <150 mm Hg with PEEP ≥5 cm H₂O: early prone positioning for ≥16 h/day reduces 28‑day mortality from 32.8% to 16.0% (HR 0.39) [142]A1b. This threshold should trigger immediate consideration of proning unless contraindicated.
- Very severe ARDS (PaO₂/FiO₂ <50 mm Hg for >3 h, <80 mm Hg for >6 h, or pH <7.25 with PaCO₂ ≥60 mm Hg): referral for venovenous ECMO can be considered; the EOLIA trial showed 60‑day mortality 35% with ECMO vs. 46% with conventional care (RR 0.76, 95% CI 0.55-1.04) [143]A1b.
- Higher PEEP without recruitment maneuvers is associated with reduced mortality compared with lower PEEP (RR 0.77, high‑certainty evidence) in moderate‑severe ARDS; prolonged recruitment maneuvers were harmful (RR 1.37 vs. higher PEEP alone) [136]A1a.
- Hyperinflammatory phenotype: consider conservative fluid management cautiously (may increase mortality in this subgroup) [173]B2b, and ongoing trials target interleukin‑18 for ferritin‑elevated patients [153]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should phenotype‑directed therapy be standard? | Proponents argue sufficient RCT evidence from secondary analyses (PEEP, fluid, statin) supports phenotype‑guided protocols [4]B2b[60]B2b[173]B2b. | Guidelines (ATS/ESICM) recommend against routine biomarker‑based phenotyping due to lack of prospective validation [12]D5[63]D5. | Moderate | Phenotyping remains a research tool; clinicians should be aware of differential risks but await confirmatory trials. |
| What is the best PEEP‑selection strategy? | Higher PEEP without LRM is associated with lower mortality (RR 0.77) [136]A1a. | Esophageal pressure‑guided and higher PEEP with brief LRM have 87% and 96% posterior probabilities of benefit, respectively [136]A1a. | Moderate (network meta‑analysis) | Higher PEEP alone is simple and effective; prolonged LRMs should be avoided. |
Pearl: Use the Berlin PaO₂/FiO₂ threshold of <150 mm Hg as the immediate trigger for prone positioning, the therapy with the largest mortality reduction in ARDS, and consider biomarker‑defined subphenotypes (e.g., IL‑8, bicarbonate, protein C) to refine risk and anticipate differential responses to PEEP, fluids, and future immunomodulators.
| Tool / Classifier | Threshold / Target | Prognostic Value | Clinical Action |
|---|---|---|---|
| Berlin PaO₂/FiO₂ (with PEEP ≥5) | Mild 200-300, Moderate 100-200, Severe <100 mm Hg | Mortality 27%→45% [18]B2b; NIV failure 22%→47% [18]B2b | Grade severity; consider early intubation if PaO₂/FiO₂ <150 [18]B2b |
| PROSEVA criteria for prone | PaO₂/FiO₂ <150, FiO₂ ≥0.6, PEEP ≥5 | 28-d mortality 16% vs. 32.8% (HR 0.39) [142]A1b | Initiate ≥16 h/d prone positioning |
| EOLIA criteria for ECMO | PaO₂/FiO₂ <50 × >3 h, or <80 × >6 h, or pH <7.25 + PaCO₂ ≥60 | 60-d mortality 35% vs. 46% (RR 0.76) [143]A1b | Consider VV-ECMO referral |
| Inflammatory subphenotype (LCA) | Hyperinflammatory: high IL-6, IL-8, sTNFR-1, low HCO₃, vasopressor use | 28-d mortality 39% hyper vs. 17% hypo [60]B2b | Differential response to PEEP, fluids, statin [4]B2b[60]B2b[173]B2b |
| Parsimonious classifier (3-var) | IL-8, bicarbonate, protein C | AUC 0.94 vs. LCA gold standard [7]B3b | Bedside phenotype identification (research stage) |
| PFP ratio (PaO₂/[FiO₂×PEEP]) | Various cut-points (derived) | AUC 0.84 for mortality [205]B2a | Reclassifies severity; may refine prognostication |
| Ferritin | >1380 ng/mL | OR 1.71 per log-fold increase for 28-d mortality [153]B2b | Identifies hyperinflammatory subgroup; target for IL-18 blockade trials |
| IGFBP7 | Per log₂ increase | OR 2.61 per log₂ for 28-d mortality [97]B3b | Causal biomarker; platelet-mediated pathway |
| Factor H deficiency | Relative deficiency (lowest quartile) | HR 1.52 for death [208]B2b | Complement exhaustion subtype; potential therapeutic target |
| Diffuse alveolar damage (DAD) | Present on lung biopsy | OR 1.81 for death vs. no DAD [15]C4 | Only half of clinical ARDS has DAD; poor noninvasive prediction |
| Driving pressure at ICU admission | Per cm H₂O increase | OR 1.20 for developing ARDS in at-risk patients [200]B2b | May identify patients for early preventive strategies |
| Mechanical power | Per unit increase | Predicts mortality; ΔP accounts for most of the signal [170]B2b | Targets for lung-protective ventilation optimization |
| Lung morphology (CT) | Focal vs. non-focal ARDS | Misclassification (21%) → harm (65% mortality) [134]A1b | Personalized ventilation feasible but error-prone |
7. Acute Management and Exacerbation Rescue
- ▸Initiate lung-protective ventilation with Vt 6 mL/kg PBW, plateau pressure ≤30, and driving pressure <15 cmH2O; high elastance predicts greater benefit from low Vt.
- ▸Prone positioning (≥16 h/d) is indicated for PaO2/FiO2 <150; NNT=6 to prevent one death (PROSEVA).
- ▸Early dexamethasone (20 mg IV daily d1-5, 10 mg d6-10) reduces 60-day mortality from 36% to 21% (NNT=7).
After severity classification and diagnosis, proceeds through a structured sequence of interventions. The goal is to maintain gas exchange while minimising (VILI) and supporting lung recovery.
Figure 1: Acute management pathway for ARDS (adapted from [142]A1b[143]A1b[146]A1b[133]A1b[310]A1b).
Step 1: Lung‑Protective Ventilation
of 6 mL/kg predicted body weight (PBW) and plateau pressure ≤30 cmH2O remain the cornerstone [131]A1b. The mortality benefit of low Vt varies by respiratory system elastance (Ers): absolute risk reduction ≥5% occurred in 82% of patients with high Ers (>3 cmH2O/[mL/kg]) vs 29% with low Ers [132]B2b (2b). Target driving pressure <15 cmH2O; a driving pressure‑limited strategy (4-8 mL/kg aiming for ΔP 10 cmH2O) achieved a 4.6 cmH2O lower driving pressure than conventional lung‑protective ventilation [320]A1b (1b).
Step 2: PEEP Titration
Set according to the ARDSNet lower PEEP/FiO2 table. (EIT)‑guided PEEP did not reduce 28‑day mortality vs the table (55.9% vs 52.6%; HR 0.96) [305]A1b (1b), though in patients with high lung recruitability, EIT‑guided PEEP assigned higher PEEP and decreased mortality (35.6% vs 60.0%; HR 0.49) [305]A1b. ‑guided PEEP improves oxygenation but outcome benefits remain unproven [308]A1b (1b).
Step 3: Oxygenation Targets
Avoid both hypoxemia and hyperoxia. The LOCO2 trial (n=205) found a trend toward higher 28‑day mortality with conservative PaO2 55-70 mm Hg (34.3% vs 26.5%) and significantly increased 90‑day mortality (44.4% vs 30.4%) [310]A1b (1b). Five mesenteric ischemic events occurred in the conservative group. Target SpO2 92-96% or PaO2 60-80 mm Hg.
Step 4: Prone Positioning
For PaO2/FiO2 <150, initiate prone positioning ≥16 hours per session. The PROSEVA trial demonstrated a dramatic mortality reduction (28‑day: 16.0% prone vs 32.8% supine; HR 0.39) [142]A1b (1b); NNT = 6 to prevent one death at 28 days. Benefit is independent of baseline Ers [330]B2b (2b). In non‑intubated patients with COVID‑19, awake prone positioning reduced intubation (OR 0.35) and mortality (OR 0.38) [323]C4 (4).
Step 5: Neuromuscular Blockade
The ROSE trial (n=1006) found no 90‑day mortality difference with early continuous for 48 h (42.5% vs 42.8%) [146]A1b (1b). However, in a secondary analysis of ROSE, patients with Ers ≥2 cmH2O/(mL/kg) had a 96% posterior probability of benefit (median ARR 9%; 90% CrI 0.5-17.9) [3]B2b (2b). Reserve NMB for patients with severe ventilator dyssynchrony or driving pressure >15 cmH2O despite deep sedation.
Step 6: Corticosteroids
Early (20 mg IV daily days 1-5, then 10 mg days 6-10) increased ventilator‑free days (mean difference 4.8 days) and reduced 60‑day mortality from 36% to 21% (between‑group difference -;) in moderate‑severe ARDS [133]A1b (1b); NNT = 7 to prevent one death. Corticosteroids initiated after 14 days of ARDS ( ) increase mortality [147]A1b (1b).
Step 7: Fluid Management
A conservative fluid strategy (central venous pressure <4 mm Hg or pulmonary artery occlusion pressure <8 mm Hg) increases ventilator‑free days vs liberal strategy without affecting mortality (FACTT) [138]B2b (2b). Diuretics or fluid restriction should be used after initial resuscitation.
Step 8: Rescue Therapies
is indicated for very severe ARDS (PaO2/FiO2 <80 for >6 h or pH <7.25 with PaCO2 ≥60 for >6 h). The EOLIA trial showed 60‑day mortality 35% with ECMO vs 46% with conventional care (RR 0.76; 95% CI 0.55-1.04) [143]A1b (1b). Meta‑analysis of venovenous ECMO trials showed a mortality benefit (RR 0.64) [166]B2a (2a). Transfusion threshold: hemoglobin <8 g/dL was associated with lower hazard of death (aHR 0.48) vs no threshold in a retrospective ECMO cohort [318]C4 (4). transiently improves oxygenation but does not reduce mortality and increases renal impairment [194]A1a (1a). is not recommended due to increased mortality in recent trials. ( [149]A1b, [62]A1b) and surfactant [137]A1b do not improve outcomes.
Drug Comparison
| Intervention | Dose / Regimen | Key Trial | Outcome | NNT | Evidence Level |
|---|---|---|---|---|---|
| 20 mg IV d1-5, 10 mg d6-10 | DEXA‑ARDS [133]A1b | ↑ VFD 4.8 d; ↓60d mortality 36%→21% | 7 | 1b | |
| (NMB) | Continuous infusion 48 h (median 1807 mg) | ROSE [146]A1b / substudy [3]B2b | No overall mortality benefit; may benefit high‑Ers subgroup (ARR 9%) | Not calculable | 1b / 2b |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine NMB in moderate‑severe ARDS? | ROSE trial [146]A1b - no 90‑d mortality benefit; more CV events | Subgroup analysis [3]B2b - high Ers (≥2 cmH2O/(mL/kg)) may benefit (ARR 9%, posterior probability 96%) | Strong (overall negative trial vs promising phenotype‑specific signal) | Reserve NMB for elevated driving pressure after optimizing sedation; reassess phenotype eligibility in future |
| Corticosteroid timing and agent | Early dexamethasone [133]A1b - reduces mortality (NNT=7) | Late methylprednisolone (>14 d) [147]A1b - no benefit, possibly harm | Moderate (different agents, timing) | Initiate dexamethasone early; do not start corticosteroids after 14 days |
Pearl: Early prone positioning for PaO2/FiO2 <150 and lung‑protective ventilation targeting driving pressure <15 cmH2O are the most impactful interventions; adjunctive dexamethasone improves survival in moderate‑severe ARDS (NNT=7) [133]A1b[142]A1b.
| Intervention | Dose / Regimen | Key Trial | Outcome | NNT | Evidence Level |
|---|---|---|---|---|---|
| Dexamethasone | 20 mg IV d1-5, 10 mg d6-10 | DEXA-ARDS [133]A1b | ↑ VFD 4.8 d; ↓60d mortality 36%→21% | 7 | 1b |
| Cisatracurium (NMB) | Continuous infusion 48 h (median 1807 mg) | ROSE [146]A1b / substudy [3]B2b | No overall mortality benefit; may benefit high-Ers subgroup (ARR 9%) | Not calculable | 1b / 2b |
8. Long-term and Definitive Management
- ▸Early prone positioning for >16 hours and dexamethasone (20/10 mg daily for 10 days) independently reduce mortality in severe ARDS, each with NNT of 6 to 7.
- ▸Neuromuscular blockade does not reduce mortality in unselected moderate-to-severe ARDS but may benefit patients with high respiratory system elastance (Ers ≥2 cm H₂O/[mL/kg]).
- ▸ECMO is a rescue therapy for very severe ARDS with a trend toward lower mortality; bleeding and thrombocytopenia are the main complications.
After initial stabilization, long-term targets the underlying pathology with a ladder of adjunctive therapies, ranging from systemic corticosteroids to extracorporeal support, and, in the most refractory cases, lung transplantation. The evidence base for each intervention is structured by trial design and effect size, with some therapies showing clear benefit and others demonstrating futility or harm.
Corticosteroids
The largest positive trial is the DEXA-ARDS study, which enrolled 277 patients with moderate-to-severe ARDS (PaO₂/FiO₂ ≤200 mm Hg at PEEP ≥10 cm H₂O). Dexamethasone 20 mg IV once daily for 5 days, then 10 mg daily for 5 days increased ventilator-free days by a mean 4.8 days (95%; p<0.0001) and reduced 60‑day mortality from 36% to 21% (absolute difference -; NNT=7) [133]A1b (1b). These effects were achieved on a background of lung‑protective ventilation. In contrast, the ARDSNet trial of for persistent ARDS (≥7 days) found no 60‑day survival benefit (29.2% vs 28.6%; p=1.0) and a signal for harm if therapy was started after 14 days (increased mortality) [147]A1b (1b). The meta‑analysis of corticosteroids for ARDS confirms reduced mortality, but the effect is most consistent with early, short‑course dexamethasone [43]A1a (1a).
Neuromuscular Blockade
The ACURASYS trial reported that 48‑hour continuous cisatracurium reduced adjusted 90‑day mortality in severe ARDS (PaO₂/FiO₂ <150) from 40.7% to 31.6% (HR 0.68; 95% CI 0.48-0.98; p=0.04) [145]A1b (1b). However, the subsequent ROSE trial, which used a high‑PEEP strategy and lighter sedation in controls, found no mortality difference (42.5% vs 42.8%; p=0.93) [146]A1b (1b). A secondary analysis of ROSE suggests that the benefit of neuromuscular blockade is limited to patients with baseline respiratory system elastance (Ers) ≥2 cm H₂O/(mL/kg), where the posterior probability of benefit was 96% (median absolute risk reduction 9%; 90% CrI 0.5-17.9) [3]B2b (2b). This suggests a treatable trait: high elastance identifies those most likely to benefit.
Prone Positioning
The PROSEVA trial established prone positioning as a life‑saving intervention for severe ARDS (PaO₂/FiO₂ <150). Early prone sessions of at least 16 hours lowered 28‑day mortality from 32.8% to 16.0% (HR 0.39; 95% CI 0.25-0.63; NNT=6) and 90‑day mortality from 41.0% to 23.6% (HR 0.44; 95% CI 0.29-0.67; NNT=6) [142]A1b (1b). A post‑hoc analysis of PROSEVA found that the effect did not vary by baseline Ers, meaning all patients with severe ARDS derive similar benefit [330]B2b (2b). The Cochrane meta‑analysis confirms mortality reduction with prone positioning in severe hypoxemia (RR 0.74; 95% CI 0.61-0.88) [41]A1a (1a).
Extracorporeal Membrane Oxygenation (ECMO)
The EOLIA trial of venovenous ECMO for very severe ARDS (PaO₂/FiO₂ <50 for >3 h, or <80 for >6 h, or pH <7.25 with PaCO₂ ≥60) did not reach statistical significance for 60‑day mortality (35% vs 46%; RR 0.76; 95% CI 0.55-1.04; p=0.09) [143]A1b (1b). Crossover to ECMO occurred in 28% of controls, and a Bayesian re‑analysis estimates a high probability of benefit. ECMO is associated with more bleeding events leading to transfusion (46% vs 28%; absolute risk difference 18 percentage points) and severe thrombocytopenia (27% vs 16%) [143]A1b. In COVID‑19 ARDS, a cohort of patients requiring ECMO for >28 days had 51.7% survival to hospital discharge; age and an awake ECMO strategy (patient awake and participating in rehabilitation) were independent predictors of survival [370]B2b (2b). Among immunocompromised patients, ECMO carries higher hospital mortality (RR 1.38 vs immunocompetent), but outcomes vary by diagnosis: hematologic malignancy (OR 3.76), autoimmune disease (OR 2.50), solid organ transplant (OR 1.40) [373]A1a (2a).
High‑Frequency Oscillation
Two large trials, OSCILLATE and OSCAR, demonstrated no benefit and potential harm from high‑frequency oscillatory ventilation (HFOV). OSCILLATE was stopped early for harm: in‑hospital mortality was 47% with HFOV vs 35% with low‑tidal‑volume ventilation (RR 1.33; 95% CI 1.09-1.64; p=0.005) [352]A1b (1b). OSCAR found no mortality difference (41.7% vs 41.1%; p=0.85) [150]A1b (1b). HFOV is not recommended for routine use in ARDS, although intermittent recruitment with HFOV plus tracheal gas insufflation showed a survival signal in one small trial [306]B2b (2b).
Pharmacological Adjuncts
| Intervention | Key trial / meta‑analysis | Primary outcome | Effect estimate | Evidence level |
|---|---|---|---|---|
| Methylprednisolone | ARDSNet [147]A1b | 60‑d mortality | No difference (28.6% vs 29.2%) | 1b |
| Cisatracurium | ACURASYS [145]A1b / ROSE [146]A1b | 90‑d mortality | HR 0.68 (0.48-0.98) / no difference | 1b |
| Prone positioning | PROSEVA [142]A1b | 28‑d mortality | 16% vs 32.8% (NNT=6) | 1b |
| ECMO | EOLIA [143]A1b | 60‑d mortality | 35% vs 46% (RR 0.76; p=0.09) | 1b |
| HFOV | OSCILLATE [352]A1b | In‑hospital mortality | 47% vs 35% (RR 1.33; p=0.005) | 1b |
| SAILS [149]A1b | 60‑d mortality | 28.5% vs 24.9% (p=0.21) | 1b | |
| HARP‑2 [62]A1b | VFD | 12.6 vs 11.5 (p=0.21) | 1b | |
| Surfactant (calfactant) | CALFACTANT [137]A1b | 90‑d mortality | No difference | 1b |
| β‑agonists | Meta‑analysis [365]A1a | 90‑d mortality | RR 1.39 (95% CI 1.03-1.89; p=0.03) | 1a |
| Mesenchymal stromal cells | STAT [348]A1b | Oxygenation index at 36 h | No difference | 1b |
(rosuvastatin, simvastatin) consistently fail to improve clinical outcomes in ARDS [62]A1b[149]A1b (1b). In the HARP‑2 trial, simvastatin showed a signal of benefit in the hyperinflammatory subphenotype (improved survival) [60]B2b (2b), but this hypothesis requires prospective confirmation. Surfactant replacement, beta‑agonists (which increase 90‑day mortality and arrhythmias), and mesenchymal stromal cells have not demonstrated clinical efficacy [137]A1b[348]A1b[365]A1a. Sivelestat, a neutrophil elastase inhibitor, reduced ARDS incidence after cardiovascular surgery in a single‑center trial (16.8% vs 31.2%; p<0.001) and 90‑day mortality (1.1% vs 5.2%; p=0.02) [364]A1b (1b), but its role in established ARDS remains unproven.
Lung Transplantation
For patients with irreversible lung damage despite prolonged support, lung transplantation has been successfully performed in highly selected cases. In a European registry (2011-2019), 40 patients were listed for ARDS/pneumonia, with 31 undergoing transplantation (0.25% of all indications); 1‑year survival improved in the 2015-2019 era (OR 10.5; p=0.006), and 70% of survivors returned to work [260]B2b (2b). In COVID‑19 ARDS, transplant is feasible with excellent midterm outcomes (0% 30‑day mortality in one national series; 74% alive at median 134 days) [359]B2b (2b). Selection criteria remain stringent and include absence of multiorgan failure, potential for rehabilitation, and psychosocial stability [327]D5 (5). Lung transplant should be considered early in centers with expertise when recovery is deemed impossible.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Neuromuscular blockade in moderate‑severe ARDS | ACURASYS [145]A1b supports early NMB for severe ARDS | ROSE [146]A1b shows no benefit when high PEEP and lighter sedation are used | Moderate (different control arms, eras, and patient populations) [145]A1b[146]A1b | NMB may benefit patients with high respiratory system elastance (Ers ≥2 cm H₂O/[mL/kg]) [3]B2b; individualized use is reasonable. |
| Corticosteroids: timing and agent | Dexamethasone early in moderate‑severe ARDS improves survival [133]A1b | Methylprednisolone in persistent ARDS (≥7 days) does not reduce mortality [147]A1b | Strong (different populations, agents, and outcomes) [133]A1b[147]A1b | Use dexamethasone (20 mg ×5d, then 10 mg ×5d) for early moderate‑to‑severe ARDS; avoid routine high‑dose methylprednisolone late in the course. |
Pearl: For patients with severe ARDS, early prone positioning (NNT=6) and dexamethasone (NNT=7) are the most robust adjuncts; ECMO is a rescue strategy for refractory hypoxemia, and lung transplantation remains a final option in carefully selected, irreversible cases.
History and Evolution of Treatment
- ▸The ARMA trial (2000) established low tidal volume ventilation (6 mL/kg PBW) as the cornerstone of ARDS management, reducing mortality from 39.8 % to 31.0 % (NNT = 12).
- ▸Prone positioning (PROSEVA, 2013) dramatically improved survival in severe ARDS (PaO₂/FiO₂ < 150; NNT = 6) and is strongly recommended.
- ▸Neuromuscular blockade, corticosteroids, and ECMO all have conditional recommendations; benefit is likely limited to specific subphenotypes or disease severity.
- ▸Numerous adjunctive therapies, surfactant, statins, MSC, high‑frequency oscillation, failed to improve outcomes and have been abandoned from routine use.
The therapeutic trajectory of ARDS over the past half‑century is a story of incremental, evidence‑driven shifts from supportive ventilation to lung‑protective strategies that have halved historical mortality rates. Early recognition that mechanical ventilation itself perpetuates lung injury reframed the goal of therapy from normalizing blood gases to minimizing ventilator‑induced lung injury (VILI).
The Low Tidal Volume Revolution
Before 2000, standard ventilation used tidal volumes of 10 - 15 mL/kg predicted body weight (PBW), aiming for normocapnia. The landmark ARMA trial (n = 861) abruptly changed practice: ventilation with 6 mL/kg PBW (plateau pressure < 30 cm H₂O) reduced mortality from 39.8 % to 31.0 % (P = 0.007; NNT = 12) compared with 12 mL/kg [378]A1b. This single finding remains the strongest mortality‑benefit signal in ARDS history. A subsequent Bayesian analysis of five trials confirmed that the benefit of low tidal volume is greatest in patients with high respiratory system elastance (Ers > 3 cm H₂O/[mL/kg]), supporting a driving‑pressure-targeted approach rather than a fixed volume [132]B2b.
Prone Positioning
Early prone‑positioning trials were negative, but the PROSEVA trial (2013) enrolled only patients with severe ARDS (PaO₂/FiO₂ < 150 mm Hg) and applied sessions of ≥16 hours. Twenty‑eight‑day mortality plummeted from 32.8 % in the supine group to 16.0 % (HR 0.39; 95 % CI 0.25 - 0.63; NNT = 6), with similar 90‑day benefit [142]A1b. Post‑hoc analysis of PROSEVA suggests the effect does not vary by baseline Ers, implying that the mechanism, improved ventilation‑perfusion matching and lung recruitment, is uniformly beneficial across the severe ARDS population [330]B2b.
Neuromuscular Blockade
The ACURASYS trial (2010) reported that a 48‑hour cisatracurium infusion in early severe ARDS (PaO₂/FiO₂ < 150) improved adjusted 90‑day survival (HR 0.68; 95 % CI 0.48 - 0.98) without increasing ICU‑acquired weakness [145]A1b. However, the larger ROSE trial (2019) found no mortality difference in moderate‑to‑severe ARDS (42.5 % vs 42.8 %; P = 0.93) and noted more adverse cardiovascular events with routine blockade [146]A1b. A secondary analysis of ROSE reconciled these findings: the mortality benefit of neuromuscular blockade is concentrated in patients with Ers ≥ 2 cm H₂O/(mL/kg) (median absolute risk reduction 9 %; posterior probability of benefit 96 %) [3]B2b. Current guidelines conditionally recommend neuromuscular blockers only when PaO₂/FiO₂ < 150 [1]A1c[28]A1c.
Corticosteroids
The use of corticosteroids has oscillated for decades. The ARDSNet trial (2006) found no 60‑day mortality benefit in persistent ARDS (29.2% vs 28.6%) and actual harm when started after 14 days [147]A1b. In contrast, the DEXA‑ARDS trial (2020) enrolled patients with moderate‑to‑severe ARDS within 24 hours of onset and administered 20 mg/day for 5 days, then 10 mg/day for 5 days. Ventilator‑free days increased by a mean 4.8 days, and 60‑day mortality fell from 36% to 21% (NNT = 7) [133]A1b. The 2024 ATS guideline now gives a conditional recommendation for corticosteroids in ARDS [1]A1c.
Extracorporeal Membrane Oxygenation
The CESAR trial (2009) suggested a survival benefit with referral to an ECMO center, but the EOLIA trial (2018), which mandated very severe ARDS (PaO₂/FiO₂ < 50 mm Hg for >3 h, or <80 mm Hg for >6 h, or pH < 7.25 with PaCO₂ ≥ 60 mm Hg), showed a 60‑day mortality of 35 % with venovenous ECMO versus 46 % with conventional (RR 0.76; 95 % CI 0.55 - 1.04; P = 0.09) [143]A1b. Though the primary endpoint did not reach statistical significance, a Bayesian re‑analysis and a meta‑analysis of venovenous ECMO trials support benefit, particularly in H1N1‑related ARDS [166]B2a[383]D5. The ATS 2024 guideline offers a conditional recommendation for ECMO in carefully selected patients [1]A1c.
Adjunctive Therapies Tried and Abandoned
Several strategies that appeared promising in preclinical models failed in rigorous trials. High‑frequency oscillatory ventilation increased mortality in two large RCTs and is now strongly discouraged [2]A1c. Exogenous surfactant (calfactant) did not improve survival or oxygenation in adults [137]A1b. ( , ) showed no mortality benefit in ARDS and no effect on long‑term physical function [60]B2b[314]B2b. Mesenchymal stromal cells failed to improve oxygenation or survival despite safety [348]A1b[329]A1b. Inhaled pulmonary vasodilators, , bronchodilators, and several immune‑modulating monoclonal antibodies (gimsilumab, , ravulizumab) also did not change outcomes in phase II/III trials [376]A1b[350]A1b[259]A1b[219]A1b[65]A1b.
Precision Phenotypes and Personalization
A critical advance has been the identification of ARDS subphenotypes using latent class analysis. The hyperinflammatory subphenotype (≈35 % of patients) consistently shows higher mortality and differential response to positive end‑expiratory pressure (PEEP) and statins [4]B2b[60]B2b. These subphenotypes are stable over the first 3 days [313]B2b. Personalized approaches, esophageal‑pressure‑guided PEEP, electrical‑impedance‑tomography‑guided PEEP, and morphological classification (focal vs non‑focal ARDS), have not yet translated into broad mortality benefit, but subgroup analyses suggest they may identify patients who respond [308]A1b[305]A1b[134]A1b. The field is moving toward biomarker‑enriched trial designs.
Pearl: The single intervention with the strongest evidence for mortality reduction in ARDS remains low tidal volume ventilation (6 mL/kg PBW, plateau < 30 cm H₂O), the ARMA benefit (NNT = 12) has never been surpassed by any subsequent pharmacological or device trial.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine neuromuscular blockade in moderate‑severe ARDS | ATS 2024: conditional for early severe (PaO₂/FiO₂ < 150) [1]A1c | SCCM 2026: conditional for PaO₂/FiO₂ < 150, equipoise on titratable vs fixed dose [28]A1c | Both conditional | Practice varies; consider physiological phenotype (high Ers) to select patients [3]B2b |
| Corticosteroids in early ARDS | ATS 2024: conditional recommendation for use [1]A1c | Older guidelines did not endorse; meta‑analysis showed heterogeneity [161]B2a | Moderate certainty | Dexamethasone regimen (20 mg/day × 5 d) supported by DEXA‑ARDS [133]A1b; avoid late initiation (>14 d) [147]A1b |
| ECMO for very severe ARDS | ATS 2024: conditional recommendation in selected patients [1]A1c | EOLIA primary analysis negative (P = 0.09) [143]A1b; Bayesian re‑analysis supports benefit | Low certainty | Use as rescue; refer to high‑volume centers; bleeding risk increased [143]A1b |
These controversies reflect the evolving evidence base and the reality that “one size fits all” does not apply to ARDS.
| Trial (Year) | Intervention | Key Result | NNT (if applicable) | Impact on Practice |
|---|---|---|---|---|
| ARMA (2000) [378]A1b | Low vs high tidal volume | 28‑d mortality 31.0 % vs 39.8 % (P = 0.007) | 12 | Definitive adoption of lung‑protective ventilation |
| PROSEVA (2013) [142]A1b | Prolonged prone vs supine | 28‑d mortality 16.0 % vs 32.8 % (P < 0.001) | 6 | Standard in severe ARDS |
| ACURASYS (2010) [145]A1b | Cisatracurium 48 h | Adjusted HR 0.68 (95 % CI 0.48‑0.98) for 90‑d death | ≈11 | Supported NMBA use before ROSE |
| ROSE (2019) [146]A1b | Cisatracurium vs usual care | 90‑d mortality 42.5 % vs 42.8 % (P = 0.93) | , | Tempered enthusiasm; phenotype‑dependent benefit |
| ALVEOLI (2004) [379]A1b | Higher vs lower PEEP | No mortality difference (27.5 % vs 24.9 %; P = 0.48) | , | Higher PEEP not routinely superior |
| EOLIA (2018) [143]A1b | Venovenous ECMO vs control | 60‑d mortality 35 % vs 46 % (RR 0.76; P = 0.09) | , | Conditional recommendation; cross‑over confounded |
| LIVE (2019) [134]A1b | Personalised vs standard ventilation | No overall difference; misclassification harmed | , | Personalisation requires accurate phenotyping |
| EITVent (2026) [305]A1b | EIT‑guided vs low PEEP/FiO₂ table | No difference overall (55.9 % vs 52.6 %) | , | Not superior; possible benefit in high recruitability |
9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive)
- ▸Bronchoscopy with BAL is safe in ARDS and provides diagnostic, prognostic, and therapeutic value; elevated VEGF and lower bacterial/fungal burden predict better outcomes.
- ▸An awake ECMO strategy and age independently predict hospital survival in prolonged (>28 day) ARDS; lung transplantation offers excellent midterm outcomes with 70% of survivors returning to work.
- ▸Early pulmonary rehabilitation after invasive ventilation improves respiratory function, reduces ICU stay, and increases 6-month survival (HR 0.66).
The evolution from rescue ventilation to advanced organ support has expanded the procedural repertoire, shifting the focus from acute stabilisation to bridging strategies, definitive repair, and long-term rehabilitation.
Bronchoscopy in ARDS
Bronchoscopy with bronchoalveolar lavage (BAL) serves diagnostic, therapeutic, and research roles in ARDS. In mechanically ventilated patients, research bronchoscopy is safe when performed in appropriately selected patients [290]D5. Noninvasive sampling alternatives, nonbronchoscopic BAL, endotracheal aspirate, heat-moisture exchange filter fluid, offer reduced cost and enhanced speed, but rigorous -to-head comparisons with standard bronchoscopy remain a priority [119]D5.
Diagnostic bronchoscopy is essential when infection is suspected, including in ARDS where multiple negative nasal swabs may warrant BAL to confirm or exclude SARS-CoV-2 [271]C4. The RAND expert panel found significant disagreement on the appropriateness of diagnostic bronchoscopy in confirmed or suspected COVID-19, but recommended no deviation from evidence-based supportive strategies otherwise [243]D5. In burns-related smoke inhalation injury, the Abbreviated Injury Score (AIS) grades 3-4 are associated with higher risk of pneumonia (RD 0.319, 95%) and ARDS (RD 0.242, 95%) compared to grades 1-2 [404]A1a. Aspergillus tracheobronchitis has substantial prevalence in COVID-19 ARDS, with overall mortality of 75% [151]B2b.
BAL also provides key prognostic information. Elevated vascular endothelial growth factor (VEGF) in epithelial lining fluid (ELF) predicts better outcome, with survivors showing initial VEGF levels of 5.5 ng/mL (IQR 2.3-19.7) vs 1.7 ng/mL (IQR 0.0-6.4) in non-survivors [285]C4. Endothelin-1 levels in ELF correlate with permeability oedema and oxygenation impairment [286]C4. Higher bacterial and fungal lung burdens in COVID-19 ARDS are associated with nonresolving ARDS, lower extubation success (subdistribution HR 0.64 and 0.59 per log10 increase), and higher mortality [399]B2b. A persistent alveolar innate immune response (CCL20, CXCL1) is associated with increased mortality; high-dose steroids decrease these alveolar concentrations [281]B2b.
Therapeutic bronchoscopy includes surfactant lavage and airway clearance, applied in pediatric ARDS in children with spinal muscular atrophy type 1, where aggressive protocols including bronchoscopy achieved 83.3% survival to discharge [411]C4. BAL combined with prone ventilation and VV-ECMO aided recovery in severe with diffuse alveolar hemorrhage [412]C4.
Extracorporeal Membrane Oxygenation (ECMO)
Beyond acute rescue, ECMO increasingly serves as a bridge to recovery or lung transplantation. In patients requiring ECMO for >28 days for COVID-19 ARDS, 53.3% survived decannulation and 50.8% were alive at 6-month follow-up [370]B2b. Age (HR 1.09 per year; 95%) and an awake ECMO strategy (HR 0.14; 95%) independently predicted hospital survival [370]B2b. A cutoff of 47 ECMO days had 100% sensitivity (95% CI 76.8-100%) and 60% specificity for need for oxygen therapy at 6 months, with 100% specificity at 97 days [370]B2b.
Early mobilization during ECMO is safe and feasible. Among 511 ECMO patients, 35% participated in active physical therapy, 78% of those achieved out-of-bed activity, and 61% ambulated [369]C4. Bridge-to-transplant status (OR 17.2; 95%) and venovenous ECMO (OR 2.83; 95%) increased odds of out-of-bed therapy; adverse events occurred in only 2% of sessions [369]C4. Femoral cannulation is compatible with ambulation but associated with lower odds of out-of-bed activity (OR 0.19; 95%) [369]C4.
Novel extracorporeal devices are emerging. A flow-adaptative total artificial lung (TAL) system permitted bilateral for source control in necrotizing pneumonia with refractory septic shock, successfully bridging to transplantation with excellent cardiopulmonary function at 2 years [409]C4.
Lung Transplantation for ARDS
Lung transplantation is a life-saving option for highly selected patients with irreversible ARDS. In a European cohort (2011-2019), 40 patients with ARDS were listed for transplantation; 31 (0.25% of all indications) underwent transplant, 90% on ECMO plus mechanical ventilation [260]B2b. Transplantation during 2015-2019 was independently associated with better 1-year survival (OR 10.493; 95%). Among survivors with known status, 70% returned to work [260]B2b.
For COVID-19 ARDS, lung transplantation has been successfully performed. In an Austrian nationwide study, 19 of 106 ECMO patients referred (18%) underwent transplant; 30-day mortality was 0% and at median follow-up of 134 days, 14 of 19 were alive [359]B2b. A multi-institutional series of 12 bilateral transplants for severe COVID-19 ARDS reported successful weaning from extracorporeal support in all, with no SARS-CoV-2 recurrence in allografts and short-term survival similar to non-COVID recipients [402]C4. In a US national cohort of 605 COVID lung transplant recipients (LTRs), survival at 3 years was 79.1%, comparable to non-COVID restrictive lung disease LTRs (73.7%) [401]B2b. COVID LTRs had improved retransplant- and bronchiolitis obliterans syndrome (BOS)-free survival (HR 0.76; 95%) [401]B2b.
Mechanical ventilation after lung transplantation follows lung-protective principles: most clinicians select 6 mL/kg predicted body weight, median minimum PEEP 5 cm H₂O, and a plateau pressure limit of 30 cm H₂O as a threshold to reduce tidal volume [405]C4. Donor characteristics are infrequently known by the ventilator team [405]C4. Donor-derived infections, such as human metapneumovirus, can cause fatal ARDS, emphasising the need for systematic viral testing of donor respiratory specimens [413]C4.
Challenges remain. In children bridged with ECMO to lung transplant, in-hospital mortality was higher (aOR 3.57; 95%), though no difference in 1-year mortality or retransplantation was seen [289]B2b. The selection process for transplantation in ARDS remains ethically and technically challenging [260]B2b.
Pulmonary Rehabilitation
Early pulmonary rehabilitation (PR) after discontinuation of improves outcomes. In a retrospective study of 240 ARDS patients, the PR group (vs control) showed significantly better short physical performance battery scores and respiratory muscle strength at 5 and 7 days, improved pulmonary function at 3 months (peak expiratory flow, FEV1/FVC, vital capacity), fewer sputum aspirations, shorter ICU stays after weaning (P <.05), and higher 6-month cumulative survival (HR 0.660; 95%) [414]B2b.
Other Interventions
Minimally invasive surgical approaches (video-assisted thoracoscopic surgery, robotic) for locally advanced lung cancer are associated with less operative time, blood loss, chest tube duration, and hospital stay compared to thoracotomy, but no difference in ARDS incidence, complications, or recurrence [407]A1a[408]A1a. Nonintubated anesthesia during results in less postoperative neutrophil-to-lymphocyte ratio elevation [403]A1b. Cell-based therapies (mesenchymal stromal cells, induced pluripotent stem cell-derived cells) remain investigational; no cell-based treatment has been shown safe and effective for any lung disease to date [341]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Timing of lung transplantation in COVID-19 ARDS | Early referral of ECMO patients to transplant centre is pivotal to select eligible candidates [359]B2b | Some argue for longer observation to allow potential recovery; limited knowledge of natural history of post-COVID fibrosis [327]D5 | Expert opinion | Case-by-case multidisciplinary assessment, incorporating serial imaging and lung function trends |
| Routine bronchoscopy in COVID-19 ARDS | Safe and valuable for excluding infection, guiding therapy [271]C4 | RAND expert panel showed significant disagreement on appropriateness [243]D5 | Weak | Use selectively when diagnostic uncertainty affects |
Pearl: In prolonged ARDS, an awake ECMO strategy and referral for lung transplant evaluation are independently associated with survival; the cutoff of 47 ECMO days predicts oxygen need at 6 months and can guide decisions [370]B2b.
| Intervention | Evidence | Key Outcome |
|---|---|---|
| Diagnostic bronchoscopy with BAL [290]D5[271]C4 | ATS workshop, cohort studies | Safe; identifies infection, biomarkers, lung microbiota |
| ECMO as bridge to recovery/transplant [370]B2b[369]C4 | Multicentre cohort | 50.8% alive at 6 months; ambulation feasible |
| Lung transplantation for ARDS [260]B2b[359]B2b[402]C4 | European/global cohorts | 1-year survival improved after 2015; 30-day mortality 0% in COVID series |
| Early pulmonary rehabilitation [414]B2b | Retrospective cohort | Improved 3-month lung function; 6-month survival HR 0.66 |
10. Complications
- ▸ARDS complications are both pulmonary (barotrauma, hemorrhage, VAP) and systemic (VTE, cardiac arrest, renal failure), with iatrogenic risks from ECMO and corticosteroids.
- ▸ECMO increases bleeding (46%) but may reduce ischemic stroke (0% vs 5%); restrictive transfusion thresholds (Hb <8 g/dL) are associated with lower mortality.
- ▸Early mobilization during ECMO is safe (2% adverse events) and improves functional recovery; social support is a modifiable factor in long-term mental health outcomes.
From the detailed respiratory support strategies detailed in Section 9, attention must now turn to the complications that define the clinical course of ARDS and influence survival. These span pulmonary, systemic, and iatrogenic domains - many are preventable or modifiable with disciplined ICU care.
Pulmonary Complications
Barotrauma, including pneumothorax and persistent air leak, occurs in patients requiring high airway pressures. In a case series of miliary tuberculosis with ARDS, pneumothorax complicated noninvasive ventilation [252]C4. Open lung biopsy in mechanically ventilated patients carries a 29% complication rate, most commonly persistent air leak [418]C4. Pulmonary hemorrhage is the most frequent histologic finding in ECMO-treated lungs, present in 63.2% of autopsies, and is associated with longer ECMO duration [425]B3b. Alveolar microthrombi are strikingly more prevalent in ARDS - 9 times more common than in influenza ARDS [98]B3b -and are identified in 57% of COVID-19 lung pathology specimens [416]C4.
Hemodynamic and Autonomic Complications
Right ventricular dysfunction is a prognostic determinant in ARDS, driven by pulmonary and increased afterload [422]D5[429]D5. Cardiac arrest occurred more frequently in the supine group than the prone group in the PROSEVA trial [142]A1b. In ECPELLA-supported patients, prone positioning was feasible but associated with manageable bleeding (6.7%) or pressure ulcers (26.7%) [431]B2b. Sustained hypocapnia in mild-to-moderate ARDS is associated with higher ICU mortality (38.1% vs 27.1%) [302]B2b, likely due to vasoconstriction and reduced cerebral perfusion.
Thromboembolic Complications and Prophylaxis
Venous thromboembolism (VTE) is common. Among VV-ECMO patients, the thrombosis rate is 53% , with deep venous thrombosis and circuit-related clotting predominating [419]C4. In COVID-19, elevated D‑dimer correlates with ARDS and mortality, and anticoagulant use reduces mortality (p=0.017) [79]D5. Pharmacologic prophylaxis with low molecular weight should be initiated per local protocol once bleeding risk is assessed; data from the PAMPer trial showed prehospital plasma did not increase ARDS or nosocomial infections [148]A1b.
Infectious and Iatrogenic Complications
(VAP) complicates ARDS . Early mobility protocols and spontaneous awakening/breathing trials reduce its incidence [152]D5. Neuromuscular weakness is increased with prolonged neuromuscular blockade or corticosteroid use; raised neuromuscular weakness rates in persistent ARDS [147]A1b. ECMO carries a high bleeding burden: 46% of patients had bleeding events requiring transfusion vs 28% with conventional ventilation (absolute risk difference 18 percentage points), and severe thrombocytopenia occurred in 27% vs 16% [143]A1b. ECMO also associated with pulmonary calcifications (28.9%) and hemorrhagic infarcts (21.1%) [425]B3b.
Rehabilitation and Long-Term Sequelae
Early mobilization during ECMO is safe and feasible: adverse events occurred in only 2% of sessions, and out-of-bed activity was achieved in 78% of patients participating in therapy [369]C4. ARDS survivors have persistent exercise limitation (median 6‑minute walk distance 76% of predicted at 5 years) and physical quality-of-life deficits that do not return to normal, especially in older patients [280]B2b. Social support is a modifiable factor that improves mental health-related quality of life up to 24 months after discharge [89]B2b.
| Complication | Frequency (reported range) | Prevention | Management |
|---|---|---|---|
| Pulmonary hemorrhage (ECMO) | 63.2% [425]B3b | Lower anticoagulation targets; hemoglobin threshold <8 g/dL [318]C4 | Transfusion protocol; minimize circuit changes |
| VTE / circuit thrombosis (ECMO) | 53% [419]C4 | aPTT target <60 s reduced bleeding but higher thrombosis [419]C4 | Anticoagulation adjusted to institutional protocol |
| Bleeding (ECMO vs conventional) | 46% vs 28% (ARR 18 pp) [143]A1b | Restrictive transfusion threshold | Reversal of anticoagulation; surgical hemostasis |
| Severe thrombocytopenia (ECMO) | 27% [143]A1b | Monitor platelet counts daily | Platelet transfusion if <20 000/μL or active bleeding |
| Ischemic stroke | 5% in control, 0% in ECMO [143]A1b | ECMO may protect? | Brain imaging; consider ECMO weaning if severe |
| Neuromuscular weakness | Increased with steroids/NMBAs [147]A1b[96]D5 | Limit NMBA duration; daily interruption of sedation [152]D5 | Physical and occupational therapy |
| Cardiac arrest | Higher in supine vs prone [142]A1b | Prone positioning for severe ARDS | Standard ACLS |
| Acute renal failure | OR 2.38 in severely obese [430]B2b | Avoid sustained hypercapnia/hypocapnia | Renal replacement therapy if indicated |
Pearl: The hyperinflammatory ARDS subphenotype drives mortality through extrapulmonary organ failure (46% mediation), not solely through respiratory mechanics - identify early with clinical classifiers to target supportive therapies and enrich trials [16]B3b[317]B2b[427]B3b.
11. Prognosis and Natural History
- ▸Contemporary mortality for moderate-to-severe ARDS ranges from 22% to 46%, with a direct causal mortality increment of 15% after confounder adjustment.
- ▸The hyperinflammatory subphenotype carries a 28-day mortality of 39% vs 17% for hypoinflammatory; three proteome-based phenotypes (C1-C3) show a further 3-fold gradient in 90-day mortality.
- ▸Driving pressure <15 cm H₂O is the most powerful modifiable predictor of survival; low-tidal-volume ventilation, prone positioning, and selected use of corticosteroids reduce mortality, while statins, surfactant, and HFOV do not.
Complications from ARDS, , barotrauma, and neuromuscular weakness, compound an already high mortality that is shaped by disease severity, host biology, and the quality of delivered care. Before the adoption of lung-protective ventilation, hospital mortality exceeded 60%; contemporary trials report 28-day mortality of 22-33% in moderate-to-severe ARDS and 60-day mortality of 35-46% in the most severe subsets [145]A1b[143]A1b[133]A1b[142]A1b. The syndrome itself carries a direct causal mortality increment: after controlling for confounders, ARDS increases the mortality rate by 15% (95% CI 3-26%), with severe ARDS adding 23% (95% CI 3-44%) [154]B2a.
Contemporary Outcomes by Subphenotype and Severity
The Berlin severity classification stratifies mortality: mild ARDS carries no independent mortality increase, while moderate and severe categories show attributable rate increases of 16% and 23%, respectively [154]B2a. Static PaO₂/FiO₂ alone, however, misses dynamic trajectories. Three longitudinal oxygenation subgroups, persistently low, gradually increasing, and rapidly improving, identify 90-day mortalities of 62.6%, 35.8%, and 17.4%, respectively, outperforming the Berlin static classification (χ² 55.65 vs 13.45) [183]B2b.
Molecular subphenotypes add even sharper discrimination. The hyperinflammatory subphenotype (30-35% of patients) has a 28-day mortality of 39% versus 17% in the hypoinflammatory group, with a hazard ratio for death persisting beyond 90 days [60]B2b[4]B2b. Three proteome-based phenotypes (C1-C3) have been validated: C1 (intense innate activation) shows the highest 90-day mortality and most shock; C2 (immune suppression) the best outcomes; C3 an intermediate state [14]B2b. Diffuse alveolar damage on biopsy, present in only one-half of clinical ARDS, raises the odds of death nearly two-fold (OR 1.81, 95%) [15]C4.
Factors That Bend the Curve
Several modifiable and non-modifiable factors influence survival. A meta-analysis of risk factors for post-traumatic ARDS identified crystalloid volume (adjusted OR 1.19 per litre in the first 6 h), age, blunt mechanism, and chest injury severity [11]B2a.
Ventilator strategy is the most powerful lever. Low-tidal-volume ventilation reduces 28-day mortality by 26% (RR 0.74, 95% CI 0.61-0.88) [192]A1a. The benefit is greatest in patients with high respiratory-system elastance: an absolute risk reduction ≥5% was seen in 82% of the high-elastance subgroup [132]B2b. Higher PEEP without prolonged recruitment maneuvers lowers mortality relative to lower PEEP (RR 0.77, high certainty) [136]A1a. Prolonged recruitment maneuvers, conversely, increase harm (RR 1.37 vs higher PEEP without LRM) [136]A1a.
Adjunctive therapies. Prone positioning for ≥16 h daily in severe ARDS (PaO₂/FiO₂ <150) cuts 28-day mortality from 32.8% to 16.0% (HR 0.39, NNT = 6) and 90-day mortality from 41% to 23.6% [142]A1b[164]A1a. Corticosteroids are recommended conditionally by the ATS; the DEXA-ARDS trial showed a ** absolute mortality reduction** at 60 days (21% vs 36%) and 4.8 additional ventilator-free days [133]A1b[1]A1c. Earlier meta-analyses had failed to show benefit and noted harm when steroids were started after day 14 [147]A1b[161]B2a. Neuromuscular blockade in early severe ARDS improved adjusted 90-day survival in the ACURASYS trial (HR 0.68), but a subsequent larger trial (ROSE) found no difference at 90 days (42.5% vs 42.8%), leaving equipoise [145]A1b[146]A1b. VV-ECMO for very severe ARDS did not reach statistical significance in EOLIA (60-day mortality 35% vs 46%, RR 0.76, 95% CI 0.55-1.04), though a meta-analysis of higher-quality VV-ECMO studies showed a mortality benefit (RR 0.64) [143]A1b[166]B2a.
Fluid and transfusion. Conservative fluid increases ventilator-free days but did not reduce overall mortality in FACTT; however, patients with low aldosterone levels derived a mortality benefit (19% vs 30%, p=0.03) [138]B2b. In patients on VV-ECMO, a hemoglobin threshold of <8 g/dL was associated with a lower hazard of death compared with no threshold (aHR 2.08) [318]C4.
Pharmacotherapies. ( , ) do not improve survival [62]A1b[149]A1b. Macrolide were associated with lower 180-day mortality (HR 0.46) in a secondary analysis of ARDS Network data [139]B2b. The anti-C5a antibody vilobelimab reduced 28-day mortality in ARDS from 42% to 32% (,; HR 0.67 in pre-specified analysis) [135]A1b. Exogenous surfactant, inhaled nitric oxide, and high-frequency oscillation have shown no benefit [137]A1b[167]A1a[194]A1a.
Long-term Sequelae
Survivors face a substantial burden. The fibroproliferative response, fibroblast accumulation and collagen deposition, leads to prolonged ventilator dependence and reduced health-related quality of life for years [176]D5. Delirium occurs in 41% of ARDS patients and is associated with longer ICU stay and cognitive impairment [188]A1a. Less than 1% of ARDS patients proceed to lung transplantation (31 of 40 listed patients in a European cohort), but 70% of survivors returned to work [260]B2b.
Pearl: The single strongest modifiable determinant of survival in ARDS is driving pressure, keep it below 15 cm H₂O by reducing tidal volume or increasing PEEP, as the mortality benefit of protective ventilation is four times more sensitive to driving pressure than to respiratory rate [170]B2b[132]B2b.
| Trial | Intervention | 28-day / 60-day mortality (intervention vs control) | NNT |
|---|---|---|---|
| ARMA [192]A1a | Low vs high tidal volume | Hospital mortality RR 0.80 | Not reported |
| PROSEVA [142]A1b | Prone ≥16 h/d | 28-day: 16.0% vs 32.8% (HR 0.39) | 6 |
| DEXA-ARDS [133]A1b | Dexamethasone 20→10 mg | 60-day: 21% vs 36% | 7 |
| ACURASYS [145]A1b | Cisatracurium 48 h | Adjusted 90-day HR 0.68 | Not calculable |
| ROSE [146]A1b | Cisatracurium 48 h | 90-day: 42.5% vs 42.8% (NS) | , |
| EOLIA [143]A1b | VV-ECMO | 60-day: 35% vs 46% (RR 0.76, p=0.09) | 9 (per-protocol) |
| HARP-2 [60]B2b | Simvastatin 80 mg | 28-day: 22.0% vs 26.8% (NS) | , |
| SAILS [149]A1b | Rosuvastatin | 60-day in-hospital: 28.5% vs 24.9% (NS) | , |
| LOCO2 [310]A1b | Conservative vs liberal O₂ | 28-day: 34.3% vs 26.5% (NS); 90-day: 44.4% vs 30.4% | , |
12. Special Populations & Pregnancy
- ▸Pediatric ARDS mortality (19%) is lower than adult ARDS (33%) despite similar severity; PALICC criteria improve prognostication over Berlin [276, 442].
- ▸In elderly patients, a driving pressure threshold of 11 cm H₂O is strongly associated with mortality; targeting lower driving pressure may be age-dependent [421].
- ▸Immunocompromised status carries an independent risk of poor ECMO outcomes, with hematologic malignancies conferring the highest odds of hospital mortality (OR 3.76) [373].
Prognosis diverges sharply across patient subgroups, driven by age, immunological status, and pregnancy-related physiological changes. Each population requires distinct diagnostic criteria, modified ventilation targets, and tailored adjunctive therapy selection.
Pediatrics
The Pediatric Acute Lung Injury Consensus Conference (PALICC) definition identifies more children with ARDS than the Berlin definition and better discriminates mortality, particularly when severity is assessed at 6 hours after diagnosis (AUC 0.69 vs 0.64) [276]B2b. Mortality in pediatric ARDS is notably lower than in adults: 19% in pediatric cohorts versus 33% in adult trials, despite comparable hypoxemia severity [442]B2b. The age-mortality relationship is nonlinear, with risk accelerating between 11 and 65 years [442]B2b.
Ventilatory in children must account for developmental differences. Airway pressure release ventilation (APRV) as a primary strategy was associated with a trend toward higher mortality compared with low-tidal-volume ventilation (risk ratio 2.02; 95%; P=0.05), and the trial was terminated early [439]A1b. High-frequency oscillatory ventilation (HFOV) in children with severe hypoxemia (oxygenation index ≥8) was associated with longer duration of mechanical ventilation (HR 0.75; 95% CI 0.64-0.89; P=0.001) and no survival benefit [446]B2b. Extracorporeal membrane oxygenation (ECMO) in pediatric severe ARDS did not demonstrate superior survival compared with matched non-ECMO controls (25% in both arms) [444]B2b. Closed-loop synchronization using the IntelliSync+ algorithm significantly reduced the asynchrony index from 12.4% to 5.1% (P<0.001) in spontaneously breathing children [447]A1b.
Regarding adjunctive therapies, continuous neuromuscular blockade is used in 31% of children, inhaled nitric oxide in 13%, and prone positioning in 10% [445]B2c. Corticosteroids are used empirically in pediatric ARDS despite lack of clear benefit, and concerns about growth and adrenal suppression limit systemic use [77]D5. Outcomes in pediatric ARDS are also influenced by etiology: adenovirus pneumonia carries a 22.5% incidence of bronchiolitis obliterans, compared with 3.1% for other viruses [451]B2b.
Pregnancy
Pregnancy was systematically excluded from most ARDS trials [279]B2b, and direct evidence is consequently limited. Physiological adaptations, increased blood volume, reduced functional residual capacity, and elevated oxygen consumption, lower pulmonary reserve and accelerate hypoxemia. Hormonal contraception confers an independent risk of venous thromboembolism, but the risk of ARDS progression in pregnant patients using estrogen-containing contraceptives is poorly quantified [391]A1a[392]A1a.
Management principles extrapolated from the general population apply with modifications: lung-protective ventilation targeting tidal volume 6 mL/kg predicted body weight remains the cornerstone. Prone positioning is feasible in pregnancy with left-lateral tilt to reduce aortocaval compression. Extracorporeal membrane oxygenation has been used successfully, but no randomized data exist. Neonatal delivery for maternal rescue is a case-by-case decision; delivery improves maternal respiratory mechanics and should be considered in refractory hypoxemia beyond 28 weeks gestation.
Elderly
Age is a dominant determinant of ARDS outcomes. The effect of driving pressure on mortality depends on age (P=0.01 for interaction): in very old patients (≥80 years), a driving pressure threshold of 11 cm H₂O is associated with increased mortality [421]B2b. Mortality risk increases at an accelerating rate between 11 and 65 years, then rises more slowly beyond 65 [442]B2b.
Paradoxically, ARDS develops less frequently in patients aged ≥85 years with community-acquired pneumonia (1.1% versus 8.5-20% in those aged <85) [203]B2b. When ARDS does occur in the elderly, mortality is high: 44% in patients ≥65 in one series [203]B2b. Comorbidities strongly influence outcomes: congestive heart failure (present in 6.3% of ARDS patients in trials) is associated with higher mortality, and its representation in trials has increased over time [32]B2b. Central sleep apnea is an independent predictor of postoperative pulmonary complications after cardiac surgery (OR 4.68; 95%) [181]B2b. Preoperative infection within 3 weeks of surgery increases risk of major pulmonary complications (OR 3.44) [449]B2b.
Obesity in older patients (≥65 years) is associated with higher risk of severe ARDS and invasive respiratory support [448]B2b. Ventilator settings should target plateau pressure ≤30 cm H₂O and driving pressure ≤11 cm H₂O in this population, and higher PEEP may be required to counter chest wall elastance.
Immunocompromised
Immunocompromised status is an independent risk factor for poor ARDS outcomes. In patients receiving ECMO, immunocompromised patients have higher hospital mortality (RR 1.38; 95%) and lower ECMO weaning rates (RR 0.77) compared with immunocompetent patients [373]A1a. Risk varies by type of immunocompromise:
| Subgroup | Odds Ratio for Hospital Mortality |
|---|
ECMO may be considered in selected low-risk subgroups (e.g., solid organ transplant recipients), but shared decision-making is critical [373]A1a.
Noninvasive ventilation (NIV) has a stronger evidence base in immunocompromised patients with acute respiratory failure, and may reduce the need for endotracheal intubation [229]D5[270]D5. However, progression to ARDS warrants timely intubation. Corticosteroids are used empirically but lack rigorous support in this population [77]D5.
In pediatric hematopoietic cell transplant recipients, pulmonary dysfunction is the leading cause of nonrelapse mortality, and early recognition of ARDS in this population is paramount [450]D5. Viral sepsis (including COVID-19) in immunocompromised children has a particularly poor prognosis, with ICU mortality 57% versus 43% in bacterial sepsis [206]B2b.
Pearl: In very old patients with ARDS, target a driving pressure below 11 cm H₂O, the age-dependent threshold that separates survivors from nonsurvivors [421]B2b. In immunocompromised patients with ARDS, ECMO outcomes are worst with hematologic malignancies (OR 3.76 for hospital mortality), and best with solid organ transplantation (OR 1.40) [373]A1a.
13. Prevention, Screening & Surveillance
- ▸COPD in sepsis is the only comorbidity with a significant independent association with ARDS (OR 1.43) [454]; optimisation of COPD care is a primary prevention target.
- ▸Systematic screening for invasive fungal infections (CAPA) is warranted in mechanically ventilated COVID-19 patients with risk factors (age >62, >14 days MV, combined immunosuppression) [452].
The risks of ARDS in special populations underscore the importance of prevention, early detection, and ongoing surveillance across all care settings. While no single intervention eliminates ARDS risk, a layered strategy, addressing primary exposures, identifying high-risk patients, and monitoring for complications, can reduce incidence and improve outcomes.
Primary Prevention
Infection control and vaccination remain the cornerstone. Annual influenza vaccination is recommended for all patients with chronic lung disease [221]D5. For SARS-CoV-2, vaccination reduces the risk of severe , though thrombotic complications are very rare and require awareness [423]D5. Early antiviral therapy with given within 5 days of symptom onset in hospitalized patients lowers the hazard of post-acute inpatient death and reduces the incidence of ARDS (for chronic pulmonary disease, 0.63 for ) [457]B2b. In immunocompromised hosts, third-party SARS-CoV-2-specific T cells (VSTs) have shown promise in preventing disease progression without causing ARDS or graft-versus-host disease [453]C4.
Air quality matters. Short-term exposure to carbon monoxide (per 0.1 ppm increase OR 1.18) and long-term exposure to PM₁₀ (per 10 μg/m³ OR 2.24) are associated with higher ARDS risk in moderate-to-severe COVID-19 [199]B2b. Public health policies to reduce ambient pollution may decrease population-level ARDS burden.
Comorbidity optimisation is critical. In sepsis, chronic obstructive pulmonary disease more than doubles the odds of developing ARDS (OR 1.43, 95%) [454]A1a. Optimising management, including inhaled corticosteroids, long-acting bronchodilators, and avoidance of exacerbations, may lower ARDS risk. Other comorbidities (diabetes, , CKD) did not show significant associations in meta-analysis [454]A1a.
Screening and Case-Finding
Retrospective ARDS identification using single-time-point Berlin criteria overestimates prevalence. A 72-hour hypoxaemia persistence rule improves cohort enrichment: expert adjudication confirmed ARDS in 49.7% (95% CI 48-52%) of patients meeting this threshold versus 6% with isolated measurements [461]C4. Radiology keyword searches offer limited sensitivity (49%), and ICD codes have low specificity (47%) [461]C4. For prospective screening, maintain a high index of suspicion in any patient with new bilateral opacities, PaO₂/FiO₂ < 300 on PEEP ≥ 5 cm H₂O, and no evidence of cardiogenic oedema, and reassess at 24 and 48 hours.
In mechanically ventilated patients, ventilator-associated event (VAE) surveillance provides objective monitoring. VAE rates per 100 ventilator episodes were higher in COVID-19 patients than in non-COVID-19 patients (29.0 vs 7.1), with progressive ARDS accounting for 53% of VAEs in the COVID-19 group [396]B3b.
Surveillance of the Diagnosed Patient
Once ARDS is established, surveillance focuses on complications. Invasive fungal infections are common in mechanically ventilated COVID-19: COVID-19-associated pulmonary aspergillosis (CAPA) occurred in 15% of patients in a French multicentre cohort [452]B2b. Risk factors include age >62 years, treatment with plus anti-IL-6, and mechanical ventilation >14 days [452]B2b. Systematic respiratory fungal screening (once or twice weekly) is warranted in high-risk patients.
ECMO surveillance has shifted from rescue therapy to a standardised treatment option with defined indications [424]D5. 90-day mortality in COVID-19 patients receiving ECMO was 42% overall, with independent predictors including age, immunocompromised status, longer time from ICU admission to intubation, need for renal replacement therapy, and higher haemodynamic score [440]B2b. Variant-specific mortality was highest with delta after adjustment [440]B2b.
Surveillance for emerging pathogens is also relevant. , caused by Chlamydia psittaci, has re-emerged and can progress to ARDS; metagenomic next-generation sequencing (mNGS) has become the leading diagnostic method, and a One Health surveillance approach is recommended [459]D5.
Pearl: The single most actionable preventive measure is early antiviral therapy (e.g., nirmatrelvir-ritonavir within 5 days of onset) in COVID-19 patients at risk for severe disease, which reduces the hazard of post-acute ARDS by approximately 30% (NNT not calculable from reported data) [457]B2b.
References
- [1]
Qadir N, Sahetya S, Munshi L et al.. “An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2024). PMID: 38032683 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History - [2]
Fan E, Del Sorbo L, Goligher EC et al.. “An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2017). PMID: 28459336 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment - [3]
Zalucky AA, Dianti J, Neyton LPA et al.. “Elastance May Determine the Neuromuscular Blockade Effect on Mortality in Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2025). PMID: 39998496 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [4]
Calfee CS, Delucchi K, Parsons PE et al.. “Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.” The Lancet. Respiratory medicine (2014). PMID: 24853585 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [5]
Dahmer MK, Yang G, Zhang M et al.. “Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis.” The Lancet. Respiratory medicine (2021). PMID: 34883088 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [6]
Sinha P, Kerchberger VE, Willmore A et al.. “Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials.” The Lancet. Respiratory medicine (2023). PMID: 37633303 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [7]
Sinha P, Delucchi KL, McAuley DF et al.. “Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.” The Lancet. Respiratory medicine (2020). PMID: 31948926 ↗
L3RCTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [8]
Richard JC, Terzi N, Yonis H et al.. “Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial.” The Lancet. Respiratory medicine (2023). PMID: 37453445 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature - [9]
McAuley DF, Cross LM, Hamid U et al.. “Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Respiratory medicine (2017). PMID: 28526233 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature - [10]
Phua J, Badia JR, Adhikari NK et al.. “Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review.” American journal of respiratory and critical care medicine (2008). PMID: 19011152 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature - [11]
Tran A, Fernando SM, Brochard LJ et al.. “Prognostic factors for development of acute respiratory distress syndrome following traumatic injury: a systematic review and meta-analysis.” The European respiratory journal (2022). PMID: 34625477 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [12]
Wick KD, Aggarwal NR, Curley MAQ et al.. “Opportunities for improved clinical trial designs in acute respiratory distress syndrome.” The Lancet. Respiratory medicine (2022). PMID: 36057279 ↗
L5TRIAL_NONRANDOMCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [13]
Brown SM, Wilson EL, Presson AP et al.. “Understanding patient outcomes after acute respiratory distress syndrome: identifying subtypes of physical, cognitive and mental health outcomes.” Thorax (2017). PMID: 28778920 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [14]
Lin M, Xu F, Deng Y et al.. “Large-scale proteomic profiling identifies distinct inflammatory phenotypes in acute respiratory distress syndrome: a multicentre, prospective cohort study.” The European respiratory journal (2026). PMID: 41067873 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [15]
Cardinal-Fernández P, Bajwa EK, Dominguez-Calvo A et al.. “The Presence of Diffuse Alveolar Damage on Open Lung Biopsy Is Associated With Mortality in Patients With Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.” Chest (2016). PMID: 26896701 ↗
L4SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [16]
Pensier J, Fosset M, Paschold BS et al.. “Effects of inflammatory phenotypes in acute respiratory distress syndrome on mortality and partitioning of lung and chest wall mechanics in patients in the USA and Canada: a retrospective cohort study.” The Lancet. Respiratory medicine (2026). PMID: 42155495 ↗
L3COHORTCited in: 1. Definition, Classification and Nomenclature, 10. Complications - [17]
Matthay MA, Arabi Y, Arroliga AC et al.. “A New Global Definition of Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2024). PMID: 37487152 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue - [18]
Bellani G, Laffey JG, Pham T et al.. “Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study.” American journal of respiratory and critical care medicine (2017). PMID: 27753501 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications - [19]
Smit MR, Hagens LA, Heijnen NFL et al.. “Lung Ultrasound Prediction Model for Acute Respiratory Distress Syndrome: A Multicenter Prospective Observational Study.” American journal of respiratory and critical care medicine (2023). PMID: 36790377 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [20]
Sarma A, Christenson SA, Shoshana BZ et al.. “Acute Respiratory Distress Syndrome Molecular Phenotypes Have Distinct Lower Respiratory Tract Transcriptomes.” American journal of respiratory and critical care medicine (2025). PMID: 40997225 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [21]
Hagens LA, Heijnen NFL, Smit MR et al.. “Systematic review of diagnostic methods for acute respiratory distress syndrome.” ERJ open research (2021). PMID: 33532455 ↗
L2SR_OBSCited in: 1. Definition, Classification and Nomenclature, 11. Prognosis and Natural History - [22]
Bos LDJ, Sinha P, Dickson RP. “The perils of premature phenotyping in COVID-19: a call for caution.” The European respiratory journal (2020). PMID: 32482788 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 10. Complications - [23]
Cilloniz C, Ferrer M, Liapikou A et al.. “Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.” The European respiratory journal (2018). PMID: 29545274 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue - [24]
Rezoagli E, Laffey JG, Madotto F et al.. “Prognostic value of disease severity and mechanical ventilation intensity in acute respiratory distress syndrome: analysis of the LUNG SAFE cohort.” The European respiratory journal (2026). PMID: 41198396 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 7. Acute Management and Exacerbation Rescue - [25]
Bos LD, Weda H, Wang Y et al.. “Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome.” The European respiratory journal (2014). PMID: 24743964 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [26]
Quesnel C, Nardelli L, Piednoir P et al.. “Alveolar fibroblasts in acute lung injury: biological behaviour and clinical relevance.” The European respiratory journal (2009). PMID: 19840966 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [27]
Guler SA, Ebner L, Aubry-Beigelman C et al.. “Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study.” The European respiratory journal (2021). PMID: 33419891 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [28]
Erstad BL, Cobas MA, Qadir N et al.. “Society of Critical Care Medicine Guidelines for the Administration of Neuromuscular Blockade in Adults With Acute Respiratory Distress Syndrome.” Critical care medicine (2026). PMID: 41773929 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment - [29]
Brown SM, Grissom CK, Moss M et al.. “Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome.” Chest (2016). PMID: 26836924 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [30]
Morandi A, Hughes CG, Girard TD et al.. “Statins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically ill.” Chest (2011). PMID: 21896517 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management - [31]
Wu S, Richard SA, Lan Z. “Perioperative nebulized budesonide and L-Cysteine reduce pulmonary complications after posterior skull base tumor resection: a randomized controlled trial.” BMC anesthesiology (2026). PMID: 42163118 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy - [32]
Gkirgkiris K, Charalampaki E, Margioula E et al.. “Congestive heart failure in patients with acute respiratory distress syndrome: A secondary analysis of large randomized controlled trials.” Anaesthesia, critical care & pain medicine (2026). PMID: 41866026 ↗
L2RCTCited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy - [33]
Li J, Liu K, Yang Q et al.. “High-Frequency Oscillation vs Mechanical Ventilation for Neonatal Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41801204 ↗
L1RCTCited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment - [34]
Su Y, Silva JD, Doherty D et al.. “Mesenchymal stromal cells-derived extracellular vesicles reprogramme macrophages in ARDS models through the miR-181a-5p-PTEN-pSTAT5-SOCS1 axis.” Thorax (2022). PMID: 35948417 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [35]
Millar FR, Summers C, Griffiths MJ et al.. “The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities.” Thorax (2016). PMID: 26968969 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [36]
Yang H, Xia J, Huang X et al.. “Generalisability of ARDS biological subphenotype models in Asians: an international, multicentre, prospective biomarker study.” Thorax (2026). PMID: 41167619 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [37]
Su H, Hopkins RO, Kamdar BB et al.. “Association of imbalance between job workload and functional ability with return to work in ARDS survivors.” Thorax (2021). PMID: 33927021 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [38]
Dinglas VD, Chessare CM, Davis WE et al.. “Perspectives of survivors, families and researchers on key outcomes for research in acute respiratory failure.” Thorax (2017). PMID: 28756400 ↗
L4OTHERCited in: 1. Definition, Classification and Nomenclature, 10. Complications - [39]
Chan KS, Aronson Friedman L, Dinglas VD et al.. “Are physical measures related to patient-centred outcomes in ARDS survivors?” Thorax (2017). PMID: 28108621 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management - [40]
Bos LD, Schouten LR, van Vught LA et al.. “Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis.” Thorax (2017). PMID: 28450529 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [41]
Bloomfield R, Noble DW, Sudlow A. “Prone position for acute respiratory failure in adults.” The Cochrane database of systematic reviews (2015). PMID: 26561745 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications - [42]
Dushianthan A, Cusack R, Burgess VA et al.. “Immunonutrition for acute respiratory distress syndrome (ARDS) in adults.” The Cochrane database of systematic reviews (2019). PMID: 30677127 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [43]
Lewis SR, Pritchard MW, Thomas CM et al.. “Pharmacological agents for adults with acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2019). PMID: 31334568 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [44]
Hermans G, De Jonghe B, Bruyninckx F et al.. “Interventions for preventing critical illness polyneuropathy and critical illness myopathy.” The Cochrane database of systematic reviews (2009). PMID: 19160304 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature - [45]
Szafran A, Dahms K, Ansems K et al.. “Early versus late tracheostomy in critically ill COVID-19 patients.” The Cochrane database of systematic reviews (2023). PMID: 37982427 ↗
L1SR_OBSCited in: 1. Definition, Classification and Nomenclature - [46]
Zhang M, Si Y, Hu Q et al.. “Nonlinear correlation between lactate levels and 28-day all-cause mortality in patients with sepsis complicated by acute respiratory distress syndrome (ARDS): a retrospective study based on the MIMIC-IV database.” BMC medical informatics and decision making (2026). PMID: 42243729 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature - [47]
Sun J, Zhang J, Guo L et al.. “Relationship between SpO2/FiO2 and PaO2/FiO2 in patients with acute respiratory distress syndrome: a single-center, retrospective cohort study from Xining, China.” Frontiers in medicine (2026). PMID: 42180766 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue - [48]
Liu X, Sun X, Zhou X et al.. “Machine Learning Predicts ICU In-Hospital Mortality in ARDS Patients Aged 80 and Above: A Multinational Multicenter Retrospective Study.” Shock (Augusta, Ga.) (2026). PMID: 41949844 ↗
L2COHORTCited in: 1. Definition, Classification and Nomenclature - [49]
Fujishima S, Gando S, Daizoh S et al.. “Infection site is predictive of outcome in acute lung injury associated with severe sepsis and septic shock.” Respirology (Carlton, Vic.) (2016). PMID: 27028604 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 11. Prognosis and Natural History - [50]
Bates JHT, Poynter ME, Frodella CM et al.. “Pathophysiology to Phenotype in the Asthma of Obesity.” Annals of the American Thoracic Society (2017). PMID: 29161090 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [51]
Cardinal-Fernández P, Lorente JA, Ballén-Barragán A et al.. “Acute Respiratory Distress Syndrome and Diffuse Alveolar Damage. New Insights on a Complex Relationship.” Annals of the American Thoracic Society (2017). PMID: 28570160 ↗
L5REVIEW_NARRATIVECited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [52]
Reilly JP, Bellamy S, Shashaty MG et al.. “Heterogeneous phenotypes of acute respiratory distress syndrome after major trauma.” Annals of the American Thoracic Society (2014). PMID: 24712298 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [53]
Cochi SE, Kempker JA, Annangi S et al.. “Mortality Trends of Acute Respiratory Distress Syndrome in the United States from 1999 to 2013.” Annals of the American Thoracic Society (2016). PMID: 27403914 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [54]
Sjoding MW, Hofer TP, Co I et al.. “Differences between Patients in Whom Physicians Agree and Disagree about the Diagnosis of Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2019). PMID: 30321489 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [55]
Sjoding MW, Cooke CR, Iwashyna TJ et al.. “Acute Respiratory Distress Syndrome Measurement Error. Potential Effect on Clinical Study Results.” Annals of the American Thoracic Society (2016). PMID: 27159648 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature - [56]
Munshi L, Gershengorn HB, Fan E et al.. “Adjuvants to Mechanical Ventilation for Acute Respiratory Failure. Adoption, De-adoption, and Factors Associated with Selection.” Annals of the American Thoracic Society (2017). PMID: 27737558 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [57]
Vande Vusse LK, Caldwell E, Tran E et al.. “The Epidemiology of Transfusion-related Acute Lung Injury Varies According to the Applied Definition of Lung Injury Onset Time.” Annals of the American Thoracic Society (2015). PMID: 26102516 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature - [58]
Norisue Y, Yamamoto R, Yamakawa H et al.. “Incidence of diffuse parenchymal lung disease in patients meeting the Berlin definition of acute respiratory distress syndrome on mechanical ventilation.” ERJ open research (2025). PMID: 40959165 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [59]
Hagens LA, Heijnen NFL, Smit MR et al.. “Octane in exhaled breath to diagnose acute respiratory distress syndrome in invasively ventilated intensive care unit patients.” ERJ open research (2023). PMID: 37850212 ↗
L2OTHERCited in: 1. Definition, Classification and Nomenclature, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [60]
Calfee CS, Delucchi KL, Sinha P et al.. “Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.” The Lancet. Respiratory medicine (2018). PMID: 30078618 ↗
L2RCTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [61]
. “Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 41240959 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [62]
McAuley DF, Laffey JG, O'Kane CM et al.. “Simvastatin in the acute respiratory distress syndrome.” The New England journal of medicine (2014). PMID: 25268516 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [63]
Matthay MA, McAuley DF, Ware LB. “Clinical trials in acute respiratory distress syndrome: challenges and opportunities.” The Lancet. Respiratory medicine (2017). PMID: 28664851 ↗
L5TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [64]
Coppo A, Bellani G, Winterton D et al.. “Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 32569585 ↗
L2TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications - [65]
Hamid U, Krasnodembskaya A, Fitzgerald M et al.. “Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.” Thorax (2017). PMID: 28082531 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [66]
Markart P, Ruppert C, Wygrecka M et al.. “Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids.” Thorax (2007). PMID: 17287298 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, History and Evolution of Treatment - [67]
Reddy MP, Subramaniam A, Chua C et al.. “Respiratory system mechanics, gas exchange, and outcomes in mechanically ventilated patients with COVID-19-related acute respiratory distress syndrome: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2022). PMID: 36335956 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism - [68]
Del Sorbo L, Goligher EC, McAuley DF et al.. “Mechanical Ventilation in Adults with Acute Respiratory Distress Syndrome. Summary of the Experimental Evidence for the Clinical Practice Guideline.” Annals of the American Thoracic Society (2017). PMID: 28985479 ↗
L5GUIDELINECited in: 2. Pathophysiology and Mechanism, 11. Prognosis and Natural History - [69]
De Giacomi F, Vassallo R, Yi ES et al.. “Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management.” American journal of respiratory and critical care medicine (2018). PMID: 29206477 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [70]
Slobod D, Zochios V, Yusuff H et al.. “Right Ventricular Hemodynamics in Acute Respiratory Distress Syndrome: Monitoring and Implications for Clinical Management.” American journal of respiratory and critical care medicine (2026). PMID: 40802599 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [71]
Radermacher P, Maggiore SM, Mercat A. “Fifty Years of Research in ARDS. Gas Exchange in Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2017). PMID: 28406724 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue - [72]
Jonkman AH, Alcala GC, Pavlovsky B et al.. “Lung Recruitment Assessed by Electrical Impedance Tomography (RECRUIT): A Multicenter Study of COVID-19 Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2023). PMID: 37097986 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism - [73]
Abrams D, Schmidt M, Pham T et al.. “Mechanical Ventilation for Acute Respiratory Distress Syndrome during Extracorporeal Life Support. Research and Practice.” American journal of respiratory and critical care medicine (2020). PMID: 31726013 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [74]
McKelvey MC, Abladey AA, Small DM et al.. “Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2022). PMID: 35073247 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [75]
Gaver DP, Nieman GF, Gatto LA et al.. “The POOR Get POORer: A Hypothesis for the Pathogenesis of Ventilator-induced Lung Injury.” American journal of respiratory and critical care medicine (2020). PMID: 33054329 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [76]
Reilly JP, Christie JD, Meyer NJ. “Fifty Years of Research in ARDS. Genomic Contributions and Opportunities.” American journal of respiratory and critical care medicine (2017). PMID: 28481621 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [77]
de Benedictis FM, Bush A. “Corticosteroids in respiratory diseases in children.” American journal of respiratory and critical care medicine (2012). PMID: 21920920 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy - [78]
Villalba JA, Hilburn CF, Garlin MA et al.. “Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2022). PMID: 35671465 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [79]
Vidali S, Morosetti D, Cossu E et al.. “D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review.” ERJ open research (2020). PMID: 32685436 ↗
L5SR_OBSCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [80]
Jorens PG, Van Marck E, Snoeckx A et al.. “Nonthrombotic pulmonary embolism.” The European respiratory journal (2009). PMID: 19648522 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications - [81]
Zhu C, Weng QY, Zhou LR et al.. “Homeostatic and early-recruited CD101- eosinophils suppress endotoxin-induced acute lung injury.” The European respiratory journal (2020). PMID: 32527738 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [82]
Gattinoni L, Camporota L, Marini JJ. “COVID-19 phenotypes: leading or misleading?” The European respiratory journal (2020). PMID: 32616591 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification - [83]
Takasawa S, Tateishi T, Sugihara J et al.. “Emerging roles of basophils in the resolution of acute respiratory distress syndrome.” The European respiratory journal (2025). PMID: 40744690 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [84]
Torres Acosta MA, Singer BD. “Pathogenesis of COVID-19-induced ARDS: implications for an ageing population.” The European respiratory journal (2020). PMID: 32747391 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation - [85]
Robertson HT. “Dead space: the physiology of wasted ventilation.” The European respiratory journal (2014). PMID: 25395032 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [86]
Herold S, Becker C, Ridge KM et al.. “Influenza virus-induced lung injury: pathogenesis and implications for treatment.” The European respiratory journal (2015). PMID: 25792631 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [87]
Probst CK, Montesi SB, Medoff BD et al.. “Vascular permeability in the fibrotic lung.” The European respiratory journal (2020). PMID: 32265308 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [88]
Brooks D, Barr LC, Wiscombe S et al.. “Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation.” The European respiratory journal (2020). PMID: 32299854 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [89]
Szymczak H, Brandstetter S, Blecha S et al.. “Social support and recovery in acute respiratory distress syndrome survivors: a prospective cohort study.” ERJ open research (2025). PMID: 40661929 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 10. Complications - [90]
Gacouin A, Lesouhaitier M, Reizine F et al.. “Short-term survival of acute respiratory distress syndrome patients due to influenza virus infection alone: a cohort study.” ERJ open research (2020). PMID: 33263066 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [91]
Nasa P, Bos LD, Estenssoro E et al.. “Defining and subphenotyping ARDS: insights from an international Delphi expert panel.” The Lancet. Respiratory medicine (2025). PMID: 40315883 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [92]
Beitler JR, Thompson BT, Baron RM et al.. “Advancing precision medicine for acute respiratory distress syndrome.” The Lancet. Respiratory medicine (2021). PMID: 34310901 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [93]
Reddy K, Sinha P, O'Kane CM et al.. “Subphenotypes in critical care: translation into clinical practice.” The Lancet. Respiratory medicine (2020). PMID: 32526190 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [94]
Ronco C, Reis T, Husain-Syed F. “Management of acute kidney injury in patients with COVID-19.” The Lancet. Respiratory medicine (2020). PMID: 32416769 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [95]
Guillen-Guio B, Lorenzo-Salazar JM, Ma SF et al.. “Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study.” The Lancet. Respiratory medicine (2020). PMID: 31982041 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [96]
deBacker J, Hart N, Fan E. “Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient.” Chest (2016). PMID: 27818334 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 10. Complications - [97]
Dong X, Zhu Z, Wei Y et al.. “Plasma Insulin-like Growth Factor Binding Protein 7 Contributes Causally to ARDS 28-Day Mortality: Evidence From Multistage Mendelian Randomization.” Chest (2020). PMID: 33189655 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 6. Severity, Staging and Risk Stratification - [98]
Ackermann M, Verleden SE, Kuehnel M et al.. “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.” The New England journal of medicine (2020). PMID: 32437596 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism, 10. Complications - [99]
Meng L, He Q, Chen S et al.. “USP4 controls neutrophil spreading through stabilising IQGAP1 during lung inflammation.” Thorax (2026). PMID: 42425898 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [100]
Flower L, Vozza EG, Bryant CE et al.. “Role of inflammasomes in acute respiratory distress syndrome.” Thorax (2025). PMID: 39884849 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [101]
Bridges JP, Vladar EK, Huang H et al.. “Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19.” Thorax (2021). PMID: 34404754 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management - [102]
Medford AR, Millar AB. “Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?” Thorax (2006). PMID: 16807391 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 11. Prognosis and Natural History - [103]
José RJ, Williams AE, Chambers RC. “Proteinase-activated receptors in fibroproliferative lung disease.” Thorax (2013). PMID: 24186921 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [104]
Summers C, Singh NR, White JF et al.. “Pulmonary retention of primed neutrophils: a novel protective host response, which is impaired in the acute respiratory distress syndrome.” Thorax (2014). PMID: 24706039 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy - [105]
Oakley C, Koh M, Baldi R et al.. “Ventilation following established ARDS: a preclinical model framework to improve predictive power.” Thorax (2019). PMID: 31278170 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [106]
Fang Y, Wang X, Qi L et al.. “Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults.” Frontiers in pharmacology (2026). PMID: 42394970 ↗
L1TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue - [107]
Battaglini D, Gualdi F, Cammarota G et al.. “Ventilation strategies and outcomes after out-of-hospital cardiac arrest: protocol for a pre-planned sub-analysis of the STEPCARE trial.” BMJ open (2026). PMID: 42297460 ↗
L5TRIAL_NONRANDOMCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications - [108]
Shashaty MG, Stapleton RD. “Physiological and management implications of obesity in critical illness.” Annals of the American Thoracic Society (2014). PMID: 25172506 ↗
L5CASE_REPORTCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management - [109]
Swenson KE, Ruoss SJ, Swenson ER. “The Pathophysiology and Dangers of Silent Hypoxemia in COVID-19 Lung Injury.” Annals of the American Thoracic Society (2021). PMID: 33621159 ↗
L5CASE_REPORTCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [110]
Kaushal A, McDonnell CG, Davies MW. “Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2013). PMID: 23450545 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications - [111]
Galvin IM, Steel A, Pinto R et al.. “Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2013). PMID: 23881653 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 8. Long-term and Definitive Management, 10. Complications - [112]
Hohmann F, Wedekind L, Grundeis F et al.. “Early spontaneous breathing for acute respiratory distress syndrome in individuals with COVID-19.” The Cochrane database of systematic reviews (2022). PMID: 35767435 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [113]
Hewitt N, Bucknall T, Faraone NM. “Lateral positioning for critically ill adult patients.” The Cochrane database of systematic reviews (2016). PMID: 27169365 ↗
L1SR_OBSCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [114]
Zhu YG, Hao Q, Monsel A et al.. “Adult stem cells for acute lung injury: remaining questions and concerns.” Respirology (Carlton, Vic.) (2013). PMID: 23578018 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [115]
Suzuki A, Taniguchi H, Kondoh Y et al.. “Soluble thrombomodulin in bronchoalveolar lavage fluid is an independent predictor of severe drug-induced lung injury.” Respirology (Carlton, Vic.) (2016). PMID: 27976836 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 10. Complications - [116]
Fanelli V, Ranieri VM. “Mechanisms and clinical consequences of acute lung injury.” Annals of the American Thoracic Society (2015). PMID: 25830831 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 10. Complications - [117]
Kreit JW. “Volume Capnography in the Intensive Care Unit: Potential Clinical Applications.” Annals of the American Thoracic Society (2019). PMID: 30742490 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [118]
Luks AM, Swenson ER. “COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications.” Annals of the American Thoracic Society (2020). PMID: 32735170 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [119]
Bain W, Sarma A, Morales-Nebreda L et al.. “Research Priorities for Noninvasive Sampling of the Lower Respiratory Tract during Acute Respiratory Failure: An Official American Thoracic Society Workshop Report.” Annals of the American Thoracic Society (2025). PMID: 40748053 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications - [120]
Sjoding MW, Admon AJ, Saha AK et al.. “Comparing Clinical Features and Outcomes in Mechanically Ventilated Patients with COVID-19 and Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2021). PMID: 33577740 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation - [121]
Kumar R, Lee MH, Mickael C et al.. “Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19.” ERJ open research (2020). PMID: 33313306 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [122]
Sharma R, Zhou M, Tiba MH et al.. “Breath analysis for detection and trajectory monitoring of acute respiratory distress syndrome in swine.” ERJ open research (2022). PMID: 35174248 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [123]
Lugg ST, Alridge KA, Howells PA et al.. “Dysregulated alveolar function and complications in smokers following oesophagectomy.” ERJ open research (2019). PMID: 30847351 ↗
L2OTHERCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History - [124]
Srinivas T, Hanumaiah G, Nagendra D et al.. “Immunometabolic reprogramming and mitochondrial dysfunction in acute respiratory distress syndrome: mechanisms, metabolic resilience, and therapeutic perspectives- a narrative review.” Journal of translational medicine (2026). PMID: 42432720 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [125]
Yan J, Liu K, Yan Y et al.. “Effects and mechanism of carrier-free self-assembled nanoparticles of natural products in attenuating pulmonary edema.” Journal of nanobiotechnology (2026). PMID: 42421105 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [126]
Nova A, Rezoagli E, Mietto C et al.. “Obesity: biomechanical implications for mechanical ventilation.” Critical care (London, England) (2026). PMID: 42415102 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [127]
Kaur N, Lewis S, Jenkinson H et al.. “Management of major thoracic trauma: a narrative review.” Anaesthesia (2026). PMID: 42405450 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [128]
Liao X, Deng C, Gao J et al.. “Dopamine signaling reprograms macrophage FAO to alleviate acute lung injury by inhibiting NETosis via the CXCL10-CXCR3 axis.” Molecular medicine (Cambridge, Mass.) (2026). PMID: 42401819 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [129]
Lin C, Huang S, Yang L et al.. “Macrophage spatiotemporal plasticity in pulmonary diseases: decoding the niche at single-cell resolution.” Frontiers in immunology (2026). PMID: 42396453 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology and Mechanism - [130]
Elitz A, Fernandes S, Cook KC et al.. “Early cell-autonomous and niche-mediated epithelial response to influenza infection in primary alveolar organoids.” JCI insight (2026). PMID: 42390927 ↗
L5OTHERCited in: 2. Pathophysiology and Mechanism - [131]
Mascia L, Fanelli V, Mistretta A et al.. “Lung-Protective Mechanical Ventilation in Patients with Severe Acute Brain Injury: A Multicenter Randomized Clinical Trial (PROLABI).” American journal of respiratory and critical care medicine (2024). PMID: 39288368 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [132]
Goligher EC, Costa ELV, Yarnell CJ et al.. “Effect of Lowering Vt on Mortality in Acute Respiratory Distress Syndrome Varies with Respiratory System Elastance.” American journal of respiratory and critical care medicine (2021). PMID: 33439781 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [133]
Villar J, Ferrando C, Martínez D et al.. “Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.” The Lancet. Respiratory medicine (2020). PMID: 32043986 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [134]
Constantin JM, Jabaudon M, Lefrant JY et al.. “Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial.” The Lancet. Respiratory medicine (2019). PMID: 31399381 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [135]
Vlaar APJ, Witzenrath M, van Paassen P et al.. “Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.” The Lancet. Respiratory medicine (2022). PMID: 36087611 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [136]
Dianti J, Tisminetzky M, Ferreyro BL et al.. “Association of Positive End-Expiratory Pressure and Lung Recruitment Selection Strategies with Mortality in Acute Respiratory Distress Syndrome: A Systematic Review and Network Meta-analysis.” American journal of respiratory and critical care medicine (2022). PMID: 35180042 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [137]
Willson DF, Truwit JD, Conaway MR et al.. “The Adult Calfactant in Acute Respiratory Distress Syndrome Trial.” Chest (2015). PMID: 25855884 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [138]
Semler MW, Marney AM, Rice TW et al.. “B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS.” Chest (2016). PMID: 27018313 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [139]
Walkey AJ, Wiener RS. “Macrolide antibiotics and survival in patients with acute lung injury.” Chest (2011). PMID: 22116799 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [140]
Stapleton RD, Dixon AE, Parsons PE et al.. “The association between BMI and plasma cytokine levels in patients with acute lung injury.” Chest (2010). PMID: 20435656 ↗
L2RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [141]
Bowsher R, Marczylo TH, Gooch K et al.. “Smoking and vaping alter genes related to mechanisms of SARS-CoV-2 susceptibility and severity: a systematic review and meta-analysis.” The European respiratory journal (2024). PMID: 38991709 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors - [142]
Guérin C, Reignier J, Richard JC et al.. “Prone positioning in severe acute respiratory distress syndrome.” The New England journal of medicine (2013). PMID: 23688302 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [143]
Combes A, Hajage D, Capellier G et al.. “Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.” The New England journal of medicine (2018). PMID: 29791822 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [144]
Sands BE, Sandborn WJ, Panaccione R et al.. “Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.” The New England journal of medicine (2019). PMID: 31553833 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [145]
Papazian L, Forel JM, Gacouin A et al.. “Neuromuscular blockers in early acute respiratory distress syndrome.” The New England journal of medicine (2010). PMID: 20843245 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [146]
Moss M, Huang DT, Brower RG et al.. “Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.” The New England journal of medicine (2019). PMID: 31112383 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [147]
Steinberg KP, Hudson LD, Goodman RB et al.. “Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.” The New England journal of medicine (2006). PMID: 16625008 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [148]
Sperry JL, Guyette FX, Brown JB et al.. “Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock.” The New England journal of medicine (2018). PMID: 30044935 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [149]
Truwit JD, Bernard GR, Steingrub J et al.. “Rosuvastatin for sepsis-associated acute respiratory distress syndrome.” The New England journal of medicine (2014). PMID: 24835849 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [150]
Young D, Lamb SE, Shah S et al.. “High-frequency oscillation for acute respiratory distress syndrome.” The New England journal of medicine (2013). PMID: 23339638 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management - [151]
Koehler P, von Stillfried S, Garcia Borrega J et al.. “Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study.” The European respiratory journal (2022). PMID: 35144992 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [152]
Ervin JN, Rentes VC, Dibble ER et al.. “Evidence-Based Practices for Acute Respiratory Failure and Acute Respiratory Distress Syndrome: A Systematic Review of Reviews.” Chest (2020). PMID: 32682771 ↗
L5SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [153]
Mehta P, Samanta RJ, Wick K et al.. “Elevated ferritin, mediated by IL-18 is associated with systemic inflammation and mortality in acute respiratory distress syndrome (ARDS).” Thorax (2024). PMID: 38148147 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [154]
Torres LK, Hoffman KL, Oromendia C et al.. “Attributable mortality of acute respiratory distress syndrome: a systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimation.” Thorax (2021). PMID: 33863829 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [155]
Kamdar BB, Suri R, Suchyta MR et al.. “Return to work after critical illness: a systematic review and meta-analysis.” Thorax (2019). PMID: 31704795 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [156]
Agarwal R, Srinivasan A, Aggarwal AN et al.. “Adaptive support ventilation for complete ventilatory support in acute respiratory distress syndrome: a pilot, randomized controlled trial.” Respirology (Carlton, Vic.) (2013). PMID: 23711230 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [157]
Toy P, Looney MR, Popovsky M et al.. “Transfusion-related Acute Lung Injury: 36 Years of Progress (1985-2021).” Annals of the American Thoracic Society (2022). PMID: 35045272 ↗
L5RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [158]
Sinha P, Delucchi KL, Chen Y et al.. “Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study.” Thorax (2021). PMID: 34253679 ↗
L2COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [159]
Peltan ID, Knighton AJ, Barney BJ et al.. “Delivery of Lung-protective Ventilation for Acute Respiratory Distress Syndrome: A Hybrid Implementation-Effectiveness Trial.” Annals of the American Thoracic Society (2023). PMID: 36350983 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [160]
Levitt JE, Festic E, Desai M et al.. “The ARREST Pneumonia Clinical Trial. Rationale and Design.” Annals of the American Thoracic Society (2021). PMID: 33493423 ↗
L5TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications - [161]
Agarwal R, Nath A, Aggarwal AN et al.. “Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis.” Respirology (Carlton, Vic.) (2007). PMID: 17587427 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History - [162]
Xiong B, Wang C, Tan J et al.. “Statins for the prevention and treatment of acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis.” Respirology (Carlton, Vic.) (2016). PMID: 27221951 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [163]
Luo J, Wang MY, Zhu H et al.. “Can non-invasive positive pressure ventilation prevent endotracheal intubation in acute lung injury/acute respiratory distress syndrome? A meta-analysis.” Respirology (Carlton, Vic.) (2014). PMID: 25208731 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [164]
Munshi L, Del Sorbo L, Adhikari NKJ et al.. “Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2017). PMID: 29068269 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [165]
Wayne MT, Valley TS, Cooke CR et al.. “Electronic "Sniffer" Systems to Identify the Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2019). PMID: 30521765 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [166]
Munshi L, Telesnicki T, Walkey A et al.. “Extracorporeal life support for acute respiratory failure. A systematic review and metaanalysis.” Annals of the American Thoracic Society (2014). PMID: 24724902 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [167]
Goligher EC, Munshi L, Adhikari NKJ et al.. “High-Frequency Oscillation for Adult Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2017). PMID: 29043832 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [168]
Goligher EC, Hodgson CL, Adhikari NKJ et al.. “Lung Recruitment Maneuvers for Adult Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2017). PMID: 29043837 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [169]
Walkey AJ, Goligher EC, Del Sorbo L et al.. “Low Tidal Volume versus Non-Volume-Limited Strategies for Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2017). PMID: 28846440 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [170]
Costa ELV, Slutsky AS, Brochard LJ et al.. “Ventilatory Variables and Mechanical Power in Patients with Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2021). PMID: 33784486 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [171]
Franchineau G, Jonkman AH, Piquilloud L et al.. “Electrical Impedance Tomography to Monitor Hypoxemic Respiratory Failure.” American journal of respiratory and critical care medicine (2024). PMID: 38127779 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [172]
Henderson WR, Chen L, Amato MBP et al.. “Fifty Years of Research in ARDS. Respiratory Mechanics in Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2017). PMID: 28306327 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [173]
Famous KR, Delucchi K, Ware LB et al.. “Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy.” American journal of respiratory and critical care medicine (2017). PMID: 27513822 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [174]
Konopka KE, Wilson A, Myers JL. “Postmortem Lung Findings in a Patient With Asthma and Coronavirus Disease 2019.” Chest (2020). PMID: 32360729 ↗
L4CASE_REPORTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation - [175]
Zambratto J, Gottesman E, Hasan Z et al.. “Extracorporeal Membrane Oxygenation in the Treatment of Acute Elemental Mercury Inhalation Toxicity.” Chest (2025). PMID: 40074498 ↗
L4CASE_REPORTCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History - [176]
Burnham EL, Janssen WJ, Riches DW et al.. “The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance.” The European respiratory journal (2013). PMID: 23520315 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [177]
Morrell ED, Wurfel MM. “Prone positioning for non-intubated hypoxaemic patients with COVID-19: cheap, easy and makes sense, but does it work?” The European respiratory journal (2022). PMID: 34649977 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors - [178]
Muthu V, Sehgal IS, Prasad KT et al.. “Is high-dose glucocorticoid beneficial in COVID-19?” The European respiratory journal (2021). PMID: 33509962 ↗
L5OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [179]
Lac J, Han S, Ahmad M et al.. “Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.” BMJ open respiratory research (2026). PMID: 42425738 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [180]
Calfee CS, Matthay MA. “Nonventilatory treatments for acute lung injury and ARDS.” Chest (2007). PMID: 17356114 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors - [181]
Tafelmeier M, Luft L, Zistler E et al.. “Central Sleep Apnea Predicts Pulmonary Complications After Cardiac Surgery.” Chest (2020). PMID: 32798522 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, 10. Complications, 12. Special Populations & Pregnancy - [182]
Martin-Loeches I, Reyes LF, Rodriguez A. “Severe community-acquired pneumonia (sCAP): advances in management and future directions.” Thorax (2025). PMID: 40360263 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [183]
Bai Y, Chen S, Yang H et al.. “Dynamic oxygenation subgroup bringing new insights in ARDS: more predictive of outcomes and response to PEEP than static PaO2/FiO2.” Thorax (2025). PMID: 40393717 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [184]
Keim G, Percy AG, Himebauch AS et al.. “Acute respiratory failure-related excess mortality in pediatric sepsis.” Thorax (2023). PMID: 37225415 ↗
L3OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [185]
Ge Q, Zheng L, Zhao M et al.. “The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial.” Frontiers in immunology (2026). PMID: 42358964 ↗
L4TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [186]
Yasuda T, Matsuda A, Hagiwara N et al.. “Rethinking Perioperative Corticosteroids in Esophageal Cancer Surgery: Evidence From an Integrative Meta-Analysis.” Annals of gastroenterological surgery (2026). PMID: 42395126 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [187]
Liu C, Huo J, Li YS et al.. “Prediction models for the occurrence and mortality of sepsis-associated lung injury: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42344506 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [188]
Othman MI, Nashwan AJ, Singh K et al.. “Unraveling the link: A systematic review and meta analysis of acute respiratory distress syndrome and delirium.” Respiratory medicine (2026). PMID: 42320602 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [189]
Bhandari AP, Nnate DA, Vasanthan L et al.. “Positioning for acute respiratory distress in hospitalised infants and children.” The Cochrane database of systematic reviews (2022). PMID: 35661343 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [190]
Hodgson C, Goligher EC, Young ME et al.. “Recruitment manoeuvres for adults with acute respiratory distress syndrome receiving mechanical ventilation.” The Cochrane database of systematic reviews (2016). PMID: 27855477 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [191]
Sud S, Sud M, Friedrich JO et al.. “High-frequency oscillatory ventilation versus conventional ventilation for acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2016). PMID: 27043185 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [192]
Petrucci N, De Feo C. “Lung protective ventilation strategy for the acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2013). PMID: 23450544 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [193]
Petrucci N, Iacovelli W. “Lung protective ventilation strategy for the acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2007). PMID: 17636739 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [194]
Gebistorf F, Karam O, Wetterslev J et al.. “Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.” The Cochrane database of systematic reviews (2016). PMID: 27347773 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [195]
Afshari A, Brok J, Møller AM et al.. “Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).” The Cochrane database of systematic reviews (2010). PMID: 20687093 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [196]
Beauchamp FO, Thériault J, Emeriaud G et al.. “Lung Recruitment Maneuvers During Invasive Mechanical Ventilation: Single-Center Retrospective PICU Cohort Study, 2016-2023.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2026). PMID: 42383786 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [197]
Zhao Y, Chi Y, Yuan S et al.. “Impact of BMI on optimal PEEP titrated by electrical impedance tomography in ARDS patients: A retrospective study.” Respiratory medicine (2026). PMID: 42302998 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [198]
Zhao L, Zong L, Wei W et al.. “Estimated plasma volume for predicting sepsis-associated ARDS risk: a multicentre retrospective cohort study.” BMJ open respiratory research (2026). PMID: 42270296 ↗
L3COHORTCited in: 3. Epidemiology, Etiology and Risk Factors - [199]
Kim S, Joo H, Kang HS et al.. “Ambient Air Pollution and Risk of ARDS and Mortality in Moderate to Severe COVID-19.” Respirology (Carlton, Vic.) (2026). PMID: 41979277 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance - [200]
Blondonnet R, Joubert E, Godet T et al.. “Driving pressure and acute respiratory distress syndrome in critically ill patients.” Respirology (Carlton, Vic.) (2018). PMID: 30183115 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [201]
Zhou Y, Wang Y, Wang L et al.. “Longitudinal Subphenotyping of Acute Respiratory Distress Syndrome: Implications in Prognostic Prediction and Clinical Intervention.” Respirology (Carlton, Vic.) (2026). PMID: 41865760 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History - [202]
Kido T, Muramatsu K, Yatera K et al.. “Efficacy of early sivelestat administration on acute lung injury and acute respiratory distress syndrome.” Respirology (Carlton, Vic.) (2016). PMID: 27990710 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [203]
Toba A, Yamazaki M, Mochizuki H et al.. “Lower incidence of acute respiratory distress syndrome in community-acquired pneumonia patients aged 85 years or older.” Respirology (Carlton, Vic.) (2010). PMID: 20070586 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 12. Special Populations & Pregnancy - [204]
Dunbar PJ, Peterson RA, McGrath M et al.. “Sedation Practices during Continuous Neuromuscular Blockade for Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2025). PMID: 40344163 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [205]
Prabhu V, Chaudhuri S, Rao S et al.. “Clinical Utility of Positive End-expiratory Pressure-incorporated PaO2/FiO2 Ratio in Prognosticating Mortality and Severity Reclassification in Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis.” Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine (2026). PMID: 42415884 ↗
L2SR_OBSCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [206]
Cao W, Xu J, Liu Z et al.. “Poor clinical outcomes in respiratory viral sepsis: a retrospective observational study.” ERJ open research (2025). PMID: 40470147 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [207]
Boyd S, Nseir S, Rodriguez A et al.. “Ventilator-associated pneumonia in critically ill patients with COVID-19 infection: a narrative review.” ERJ open research (2022). PMID: 35891621 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [208]
Bain W, Tabary M, Moore SR et al.. “Factor H preserves alternative complement function during ARDS, linked to improved survival.” ERJ open research (2023). PMID: 37377659 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [209]
Lemmers DHL, Abu Hilal M, Bnà C et al.. “Pneumomediastinum and subcutaneous emphysema in COVID-19: barotrauma or lung frailty?” ERJ open research (2020). PMID: 33257914 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [210]
Maamar A, Guillot P, Joussellin V et al.. “Moderate-to-severe ARDS: COVID-19 patients compared to influenza patients for ventilator parameters and mortality.” ERJ open research (2023). PMID: 37041986 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [211]
Wittermans E, van der Zee PA, Qi H et al.. “Community-acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies.” ERJ open research (2022). PMID: 35036417 ↗
L2OTHERCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue - [212]
Azoulay É, Canet E, Raffoux E et al.. “Dexamethasone in patients with acute lung injury from acute monocytic leukaemia.” The European respiratory journal (2011). PMID: 21828031 ↗
L4RCTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment - [213]
Lioté H, Lioté F, Séroussi B et al.. “Rituximab-induced lung disease: A systematic literature review.” The European respiratory journal (2009). PMID: 19608586 ↗
L4SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment - [214]
Proudfoot A, Bayliffe A, O'Kane CM et al.. “Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury.” Thorax (2018). PMID: 29382797 ↗
L5RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [215]
Tran A, Fernando SM, Rochwerg B et al.. “Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.” The Lancet. Respiratory medicine (2022). PMID: 36228638 ↗
L2SR_OBSCited in: 4. Clinical Presentation - [216]
Schmidt M, Hajage D, Lebreton G et al.. “Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 32798468 ↗
L2COHORTCited in: 4. Clinical Presentation, 10. Complications - [217]
Hashem MD, Hopkins RO, Colantuoni E et al.. “Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: secondary analysis of SAILS-ALTOS trial.” Thorax (2021). PMID: 34112703 ↗
L2TRIAL_NONRANDOMCited in: 4. Clinical Presentation - [218]
Spencer-Segal JL, Hyzy RC, Iwashyna TJ et al.. “Psychiatric Symptoms in Survivors of Acute Respiratory Distress Syndrome. Effects of Age, Sex, and Immune Modulation.” Annals of the American Thoracic Society (2017). PMID: 28358594 ↗
L1RCTCited in: 4. Clinical Presentation, History and Evolution of Treatment - [219]
Ford HJ, Anderson WH, Wendlandt B et al.. “Randomized, Placebo-controlled Trial of Inhaled Treprostinil for Patients at Risk for Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2021). PMID: 33095030 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications - [220]
Sjoding MW, Schoenfeld DA, Brown SM et al.. “Power Calculations to Select Instruments for Clinical Trial Secondary Endpoints. A Case Study of Instrument Selection for Post-Traumatic Stress Symptoms in Subjects with Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2017). PMID: 27788018 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [221]
Halpin DMG, Criner GJ, Papi A et al.. “Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.” American journal of respiratory and critical care medicine (2021). PMID: 33146552 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 13. Prevention, Screening & Surveillance - [222]
Moazed F, Hendrickson C, Jauregui A et al.. “Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic Markers.” American journal of respiratory and critical care medicine (2022). PMID: 35050845 ↗
L2OTHERCited in: 4. Clinical Presentation - [223]
Azoulay E, Pochard F, Argaud L et al.. “Resilience and Mental-Health Symptoms in ICU Healthcare Professionals Facing Repeated COVID-19 Waves.” American journal of respiratory and critical care medicine (2024). PMID: 38163380 ↗
L4OTHERCited in: 4. Clinical Presentation - [224]
Reilly JP, Zhao Z, Shashaty MGS et al.. “Low to Moderate Air Pollutant Exposure and Acute Respiratory Distress Syndrome after Severe Trauma.” American journal of respiratory and critical care medicine (2019). PMID: 30067389 ↗
L2OTHERCited in: 4. Clinical Presentation - [225]
Chommeloux J, Valentin S, Winiszewski H et al.. “One-Year Mental and Physical Health Assessment in Survivors after Extracorporeal Membrane Oxygenation for COVID-19-related Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2023). PMID: 36150112 ↗
L2OTHERCited in: 4. Clinical Presentation - [226]
Du Y, Tu L, Zhu P et al.. “Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study.” American journal of respiratory and critical care medicine (2020). PMID: 32242738 ↗
L4OTHERCited in: 4. Clinical Presentation - [227]
Sinha P, Churpek MM, Calfee CS. “Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data.” American journal of respiratory and critical care medicine (2020). PMID: 32551817 ↗
L2OTHERCited in: 4. Clinical Presentation - [228]
Estenssoro E, Ríos FG, Apezteguía C et al.. “Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation.” American journal of respiratory and critical care medicine (2010). PMID: 20203241 ↗
L2OTHERCited in: 4. Clinical Presentation - [229]
Ambrosino N, Vagheggini G. “Noninvasive positive pressure ventilation in the acute care setting: where are we?” The European respiratory journal (2008). PMID: 18378782 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 12. Special Populations & Pregnancy - [230]
Xu T, Qiao J, Zhao L et al.. “Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice.” The European respiratory journal (2009). PMID: 19129272 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [231]
Qin W, Chen S, Zhang Y et al.. “Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up.” The European respiratory journal (2021). PMID: 33574077 ↗
L4OTHERCited in: 4. Clinical Presentation - [232]
Gao R, Cao B, Hu Y et al.. “Human infection with a novel avian-origin influenza A (H7N9) virus.” The New England journal of medicine (2013). PMID: 23577628 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 10. Complications - [233]
Maddali MV, Churpek M, Pham T et al.. “Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis.” The Lancet. Respiratory medicine (2022). PMID: 35026177 ↗
L2OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 10. Complications - [234]
Parotto M, Gyöngyösi M, Howe K et al.. “Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations.” The Lancet. Respiratory medicine (2023). PMID: 37475125 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [235]
Kneyber MCJ, Khemani RG, Bhalla A et al.. “Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome.” The Lancet. Respiratory medicine (2022). PMID: 36566767 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management - [236]
George PM, Wells AU, Jenkins RG. “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.” The Lancet. Respiratory medicine (2020). PMID: 32422178 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management - [237]
Lutchmansingh DD, Knauert MP, Antin-Ozerkis DE et al.. “A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY: Learning From the Past, Looking to the Future.” Chest (2020). PMID: 33159907 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term and Definitive Management, 10. Complications - [238]
Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al.. “Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.” The New England journal of medicine (2009). PMID: 19564631 ↗
L4OTHERCited in: 4. Clinical Presentation, 10. Complications - [239]
Malhotra A. “Low-tidal-volume ventilation in the acute respiratory distress syndrome.” The New England journal of medicine (2007). PMID: 17855672 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [240]
Gao HN, Lu HZ, Cao B et al.. “Clinical findings in 111 cases of influenza A (H7N9) virus infection.” The New England journal of medicine (2013). PMID: 23697469 ↗
L4OTHERCited in: 4. Clinical Presentation - [241]
Antcliffe DB, Mi Y, Santhakumaran S et al.. “Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes.” Thorax (2024). PMID: 38471792 ↗
L2OTHERCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [242]
Latronico N, Peli E, Calza S et al.. “Physical, cognitive and mental health outcomes in 1-year survivors of COVID-19-associated ARDS.” Thorax (2021). PMID: 34588274 ↗
L4OTHERCited in: 4. Clinical Presentation - [243]
Griffiths M, Meade S, Summers C et al.. “RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemic.” Thorax (2021). PMID: 34045363 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [244]
Zhang C, Xiong W, Diao K et al.. “Development and validation of a predictive model for acute respiratory distress syndrome in moderate-to-late preterm infants: a multicenter retrospective study.” European journal of pediatrics (2026). PMID: 42053829 ↗
L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [245]
Barsosio HC, Tangara B, Marlais T et al.. “Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study.” The Lancet. Global health (2026). PMID: 41999717 ↗
L2COHORTCited in: 4. Clinical Presentation, History and Evolution of Treatment - [246]
Li W, Li Y, Wang Y et al.. “Development and validation of a prognostic model for acute respiratory distress syndrome in critically Ill patients with intra-abdominal sepsis: a multicenter cohort study.” Frontiers in medicine (2026). PMID: 41907259 ↗
L2COHORTCited in: 4. Clinical Presentation, History and Evolution of Treatment - [247]
Cobb NL, Sathe NA, Duan KI et al.. “Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza.” Annals of the American Thoracic Society (2021). PMID: 33183067 ↗
L2OTHERCited in: 4. Clinical Presentation - [248]
Weidman K, LaFond E, Hoffman KL et al.. “Post-Intensive Care Unit Syndrome in a Cohort of COVID-19 Survivors in New York City.” Annals of the American Thoracic Society (2022). PMID: 34936536 ↗
L4OTHERCited in: 4. Clinical Presentation - [249]
Brodsky MB, Huang M, Shanholtz C et al.. “Recovery from Dysphagia Symptoms after Oral Endotracheal Intubation in Acute Respiratory Distress Syndrome Survivors. A 5-Year Longitudinal Study.” Annals of the American Thoracic Society (2017). PMID: 27983872 ↗
L2OTHERCited in: 4. Clinical Presentation - [250]
Haaksma ME, Heldeweg MLA, Lopez Matta JE et al.. “Lung ultrasound findings in patients with novel SARS-CoV-2.” ERJ open research (2020). PMID: 33257915 ↗
L4OTHERCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue - [251]
Wang L, Jiang Y, Yan W. “Acute toxic encephalopathy induced by chloropicrin: case report.” Frontiers in medicine (2026). PMID: 42359056 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue - [252]
Lin F, Tang X, Fei X et al.. “Successful treatment by high dose glucocorticoid of miliary tuberculosis complicated with acute respiratory distress syndrome: a case report.” BMC infectious diseases (2026). PMID: 42265561 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications - [253]
Rubio-Duarte AF, Garcés-Rodríguez MP, Hurtado-Ortiz A et al.. “Severe Pneumocystis jirovecii Pneumonia as the Sentinel Presentation of BENTA Disease: Case Report of a 3-month-old Infant.” The Pediatric infectious disease journal (2026). PMID: 42144651 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [254]
Zhang L, Peng Z, Wang D et al.. “Rescue strategies combining ultra-protective ventilation and veno-venous ECMO in a patient with near-drowning-related severe ARDS: a case report and literature review.” BMC anesthesiology (2026). PMID: 42104249 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [255]
Zhuang TL, Lin SH, Chuang DE et al.. “Integrating ultra-prolonged prone ventilation with mechanical power monitoring in refractory acute respiratory distress syndrome (ARDS): a case report.” Frontiers in medicine (2026). PMID: 42051697 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [256]
Pan J, Kong H, Liang M et al.. “Pneumonia caused by co-infection with Mycobacterium tuberculosis and Pneumocystis jirovecii leading to acute respiratory distress syndrome in an HIV-negative immunocompromised patient: a case report and literature review.” BMC infectious diseases (2026). PMID: 42026490 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [257]
Gorman EA, Rynne J, Gardiner HJ et al.. “Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.” American journal of respiratory and critical care medicine (2023). PMID: 37154608 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [258]
Ferrando C, Carramiñana A, Piñeiro P et al.. “Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial.” The Lancet. Respiratory medicine (2023). PMID: 38065200 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [259]
Annane D, Pittock SJ, Kulkarni HS et al.. “Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.” The Lancet. Respiratory medicine (2023). PMID: 36958364 ↗
L1RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, History and Evolution of Treatment - [260]
Gottlieb J, Lepper PM, Berastegui C et al.. “Lung transplantation for acute respiratory distress syndrome: a retrospective European cohort study.” The European respiratory journal (2022). PMID: 34824051 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History - [261]
Guglielmi S, Merz TM, Gugger M et al.. “Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus.” The European respiratory journal (2008). PMID: 18166599 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [262]
van Amstel RBE, Bartek B, Vlaar APJ et al.. “Temporal Transitions of the Hyperinflammatory and Hypoinflammatory Phenotypes in Critical Illness.” American journal of respiratory and critical care medicine (2025). PMID: 39642348 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [263]
Neyton LPA, Sinha P, Sarma A et al.. “Host and Microbe Blood Metagenomics Reveals Key Pathways Characterizing Critical Illness Phenotypes.” American journal of respiratory and critical care medicine (2024). PMID: 38190719 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [264]
Goligher EC, Douflé G, Fan E. “Update in Mechanical Ventilation, Sedation, and Outcomes 2014.” American journal of respiratory and critical care medicine (2015). PMID: 26075422 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management - [265]
Felten M, Ferencik S, Teixeira Alves LG et al.. “Ventilator-induced Lung Injury Is Modulated by the Circadian Clock.” American journal of respiratory and critical care medicine (2023). PMID: 36480958 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [266]
Rubenfeld GD. “Who cares about preventing acute respiratory distress syndrome?” American journal of respiratory and critical care medicine (2015). PMID: 25478722 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [267]
Ranieri VM, Rubenfeld G, Slutsky AS. “Rethinking Acute Respiratory Distress Syndrome after COVID-19: If a "Better" Definition Is the Answer, What Is the Question?” American journal of respiratory and critical care medicine (2023). PMID: 36150099 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [268]
Parhar KKS, Zjadewicz K, Soo A et al.. “Epidemiology, Mechanical Power, and 3-Year Outcomes in Acute Respiratory Distress Syndrome Patients Using Standardized Screening. An Observational Cohort Study.” Annals of the American Thoracic Society (2019). PMID: 31247145 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [269]
Skinner EH, Haines KJ, Howe B et al.. “Health-Related Quality of Life in Australasian Survivors of H1N1 Influenza Undergoing Mechanical Ventilation. A Multicenter Cohort Study.” Annals of the American Thoracic Society (2015). PMID: 25679441 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [270]
Ambrosino N, Guarracino F. “Unusual applications of noninvasive ventilation.” The European respiratory journal (2011). PMID: 21349915 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [271]
Ora J, Puxeddu E, Cavalli F et al.. “Does bronchoscopy help the diagnosis in COVID-19 infection?” The European respiratory journal (2020). PMID: 32527742 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [272]
Anastasio F, Barbuto S, Scarnecchia E et al.. “Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life.” The European respiratory journal (2021). PMID: 33574080 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment - [273]
Vadász I, Husain-Syed F, Dorfmüller P et al.. “Severe organising pneumonia following COVID-19.” Thorax (2020). PMID: 33177230 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [274]
Marmor DB, Farber JL, Gottlieb JE. “Acute respiratory distress syndrome due to pulmonary involvement by neoplastic plasma cells in multiple myeloma.” Thorax (2006). PMID: 16648354 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [275]
Wick KD, Matthay MA, Ware LB. “Pulse oximetry for the diagnosis and management of acute respiratory distress syndrome.” The Lancet. Respiratory medicine (2022). PMID: 36049490 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue - [276]
Khemani RG, Smith L, Lopez-Fernandez YM et al.. “Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study.” The Lancet. Respiratory medicine (2018). PMID: 30361119 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy - [277]
Meyer NJ. “Future clinical applications of genomics for acute respiratory distress syndrome.” The Lancet. Respiratory medicine (2013). PMID: 24461759 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [278]
Matthay MA, Thompson BT, Ware LB. “The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?” The Lancet. Respiratory medicine (2021). PMID: 33915103 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [279]
Files DC, Matthay MA, Chapple AG et al.. “Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study.” The Lancet. Respiratory medicine (2026). PMID: 42140220 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy - [280]
Herridge MS, Tansey CM, Matté A et al.. “Functional disability 5 years after acute respiratory distress syndrome.” The New England journal of medicine (2011). PMID: 21470008 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications - [281]
de Brabander J, Boers LS, Kullberg RFJ et al.. “Persistent alveolar inflammatory response in critically ill patients with COVID-19 is associated with mortality.” Thorax (2023). PMID: 37142421 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [282]
Summers C, Singh NR, Worpole L et al.. “Incidence and recognition of acute respiratory distress syndrome in a UK intensive care unit.” Thorax (2016). PMID: 27552782 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [283]
Chacko B, Peter JV, Tharyan P et al.. “Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).” The Cochrane database of systematic reviews (2015). PMID: 25586462 ↗
L1SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 10. Complications - [284]
Yang SC, Liao KM, Chen CW et al.. “Positive blood culture is not associated with increased mortality in patients with sepsis-induced acute respiratory distress syndrome.” Respirology (Carlton, Vic.) (2013). PMID: 23692513 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [285]
Koh H, Tasaka S, Hasegawa N et al.. “Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome.” Respirology (Carlton, Vic.) (2008). PMID: 18339029 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [286]
Nakano Y, Tasaka S, Saito F et al.. “Endothelin-1 level in epithelial lining fluid of patients with acute respiratory distress syndrome.” Respirology (Carlton, Vic.) (2007). PMID: 17875064 ↗
L4OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [287]
Wang Y, Meng S, Song Y et al.. “Fluorescence optical fibre sensor provides accurate continuous oxygen detection in rabbit model with acute lung injury.” Respirology (Carlton, Vic.) (2009). PMID: 19947997 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue - [288]
Shu W, Guo S, Yang F et al.. “Association between ARDS Etiology and Risk of Noninvasive Ventilation Failure.” Annals of the American Thoracic Society (2022). PMID: 34288830 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue - [289]
Thompson K, Staffa SJ, Nasr VG et al.. “Mortality after Lung Transplantation for Children Bridged with Extracorporeal Membrane Oxygenation.” Annals of the American Thoracic Society (2022). PMID: 34619069 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [290]
Mikacenic C, Fussner LA, Bell J et al.. “Research Bronchoscopies in Critically Ill Research Participants: An Official American Thoracic Society Workshop Report.” Annals of the American Thoracic Society (2023). PMID: 37125997 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [291]
Oh TK, Park HY, Song IA. “Occurrence and Long-Term Prognosis of Insomnia Disorder among Survivors of Acute Respiratory Distress Syndrome in South Korea.” Annals of the American Thoracic Society (2022). PMID: 34793689 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 8. Long-term and Definitive Management, History and Evolution of Treatment - [292]
Yang F, Zou J, Zheng L et al.. “Biomarkers for Pediatric Acute Respiratory Distress Syndrome: A Systematic Review.” Journal of inflammation research (2026). PMID: 42404003 ↗
L2SR_OBSCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [293]
Kharat A, Ribeiro C, Er B et al.. “ERS International Congress 2021: highlights from the Respiratory Intensive Care Assembly.” ERJ open research (2022). PMID: 35615411 ↗
L5OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 7. Acute Management and Exacerbation Rescue, 10. Complications - [294]
González J, Benítez ID, Santisteve S et al.. “Longitudinal recovery trajectories and ventilatory modalities in COVID-19 acute respiratory distress syndrome survivors.” ERJ open research (2025). PMID: 40196714 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [295]
Hinterwaldner L, Obregon CC, Zange S et al.. “Case Report: Severe sepsis due to imported scrub typhus in a German traveler returning from Vietnam.” Frontiers in medicine (2026). PMID: 42180679 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [296]
van de Sand L, Dubler S, Bertram S et al.. “Landouzy sepsis in a young adult with multiorgan failure: successful ECMO-assisted management using an individualized antituberculous regimen.” BMC infectious diseases (2026). PMID: 41987072 ↗
L4CASE_REPORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [297]
Rashid F, Jafri KS, Ghosh N et al.. “Rural-urban disparities in acute pancreatitis outcomes: A retrospective cohort study using the National Inpatient Sample (2016-2021).” Medicine (2026). PMID: 42260827 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [298]
Chang KW, Huang CH, Leu SW et al.. “The relationship between the chronological phases of diffuse alveolar damage and clinical outcomes in acute respiratory distress syndrome.” Journal of intensive care (2026). PMID: 42432748 ↗
L2OTHERCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [299]
Ware LB, Soleymanlou N, McAuley DF et al.. “TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.” Thorax (2023). PMID: 37024277 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications - [300]
Walkey AJ, Del Sorbo L, Hodgson CL et al.. “Higher PEEP versus Lower PEEP Strategies for Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.” Annals of the American Thoracic Society (2017). PMID: 29043834 ↗
L1SR_OBSCited in: 6. Severity, Staging and Risk Stratification - [301]
Chen LYC, Hoiland RL, Stukas S et al.. “Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.” The European respiratory journal (2020). PMID: 32883678 ↗
L5OTHERCited in: 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 10. Complications - [302]
Madotto F, Rezoagli E, McNicholas BA et al.. “Patterns and Impact of Arterial CO2 Management in Patients With Acute Respiratory Distress Syndrome: Insights From the LUNG SAFE Study.” Chest (2020). PMID: 32589951 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications - [303]
Yehya N, Zinter MS, Thompson JM et al.. “Identification of molecular subphenotypes in two cohorts of paediatric ARDS.” Thorax (2024). PMID: 37813544 ↗
L2OTHERCited in: 6. Severity, Staging and Risk Stratification - [304]
Dres M, Ewert R, Conrad SA et al.. “Temporary Transvenous Diaphragm Neurostimulation for Weaning from Mechanical Ventilation (RESCUE-3): A Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2026). PMID: 40498082 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [305]
Yuan X, Zhong M, Li Z et al.. “Electrical impedance tomography-guided positive end-expiratory pressure and mortality of patients with the acute respiratory distress syndrome: the EITVent randomized clinical trial.” American journal of respiratory and critical care medicine (2026). PMID: 41738148 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [306]
Mentzelopoulos SD, Malachias S, Zintzaras E et al.. “Intermittent recruitment with high-frequency oscillation/tracheal gas insufflation in acute respiratory distress syndrome.” The European respiratory journal (2011). PMID: 21885390 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [307]
Ranieri VM, Tonetti T, Navalesi P et al.. “High-Flow Nasal Oxygen for Severe Hypoxemia: Oxygenation Response and Outcome in Patients with COVID-19.” American journal of respiratory and critical care medicine (2022). PMID: 34861135 ↗
L2SR_OBSCited in: 7. Acute Management and Exacerbation Rescue - [308]
Talmor D, Sarge T, Malhotra A et al.. “Mechanical ventilation guided by esophageal pressure in acute lung injury.” The New England journal of medicine (2008). PMID: 19001507 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [309]
Suntharalingam G, Perry MR, Ward S et al.. “Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.” The New England journal of medicine (2006). PMID: 16908486 ↗
L4RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [310]
Barrot L, Asfar P, Mauny F et al.. “Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome.” The New England journal of medicine (2020). PMID: 32160661 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [311]
Glass A, O'Kane CM, Dhrampal A et al.. “Effect of simvastatin on postoperative complications in patients undergoing one-lung ventilation during surgery: the Prevention HARP-2 randomised controlled trial.” Thorax (2026). PMID: 40633931 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 12. Special Populations & Pregnancy - [312]
Brown SM, Wilson E, Presson AP et al.. “Predictors of 6-month health utility outcomes in survivors of acute respiratory distress syndrome.” Thorax (2016). PMID: 27440140 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [313]
Delucchi K, Famous KR, Ware LB et al.. “Stability of ARDS subphenotypes over time in two randomised controlled trials.” Thorax (2018). PMID: 29477989 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [314]
Dinglas VD, Hopkins RO, Wozniak AW et al.. “One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial.” Thorax (2016). PMID: 26936876 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [315]
Perkins GD, Nathani N, McAuley DF et al.. “In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury.” Thorax (2006). PMID: 16928710 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [316]
McNicholas BA, Madotto F, Pham T et al.. “Demographics, management and outcome of females and males with acute respiratory distress syndrome in the LUNG SAFE prospective cohort study.” The European respiratory journal (2019). PMID: 31346004 ↗
L2COHORTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [317]
Reddy K, Sinha P, Antcliffe DB et al.. “Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.” The Lancet. Respiratory medicine (2026). PMID: 41887245 ↗
L2COHORTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [318]
Pratt EH, Pulsipher AM, Moulton NG et al.. “Association of RBC Transfusion Thresholds and Outcomes in Medical Patients With Acute Respiratory Failure Supported With Extracorporeal Membrane Oxygenation: A Single-Center Retrospective Cohort Study.” Chest (2024). PMID: 38986867 ↗
L4COHORTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [319]
Jabaudon M, Futier E, Roszyk L et al.. “Association between intraoperative ventilator settings and plasma levels of soluble receptor for advanced glycation end-products in patients without pre-existing lung injury.” Respirology (Carlton, Vic.) (2015). PMID: 26122046 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [320]
Pereira Romano ML, Maia IS, Laranjeira LN et al.. “Driving Pressure-limited Strategy for Patients with Acute Respiratory Distress Syndrome. A Pilot Randomized Clinical Trial.” Annals of the American Thoracic Society (2020). PMID: 32069068 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [321]
Pham T, Pesenti A, Bellani G et al.. “Outcome of acute hypoxaemic respiratory failure: insights from the LUNG SAFE Study.” The European respiratory journal (2021). PMID: 33334944 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [322]
Oeckler RA, Hubmayr RD. “Ventilator-associated lung injury: a search for better therapeutic targets.” The European respiratory journal (2007). PMID: 18055706 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, History and Evolution of Treatment - [323]
Perez-Nieto OR, Escarraman-Martinez D, Guerrero-Gutierrez MA et al.. “Awake prone positioning and oxygen therapy in patients with COVID-19: the APRONOX study.” The European respiratory journal (2022). PMID: 34266942 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue - [324]
O'Carroll O, MacCann R, O'Reilly A et al.. “Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia.” The European respiratory journal (2020). PMID: 32616588 ↗
L5OTHERCited in: 7. Acute Management and Exacerbation Rescue - [325]
Müller T, Lubnow M, Philipp A et al.. “Extracorporeal pumpless interventional lung assist in clinical practice: determinants of efficacy.” The European respiratory journal (2008). PMID: 19010979 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue - [326]
Del Sorbo L, Cypel M, Fan E. “Extracorporeal life support for adults with severe acute respiratory failure.” The Lancet. Respiratory medicine (2013). PMID: 24503270 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [327]
King CS, Mannem H, Kukreja J et al.. “Lung Transplantation for Patients With COVID-19.” Chest (2021). PMID: 34418410 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 11. Prognosis and Natural History - [328]
Chang DJ, Elkhunovich M, Hotz JC et al.. “Diaphragm Thickening Fraction for Predicting Esophageal Pressure and Ventilator Weaning in Children.” Chest (2026). PMID: 41881144 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 12. Special Populations & Pregnancy - [329]
Torres A, Marin-Corral J, Adalia-Bartolome R et al.. “Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.” Cytotherapy (2026). PMID: 42241901 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [330]
Zalucky AA, Goligher EC, Dianti J et al.. “Elastance as a determinant of the effect of prone positioning on mortality in acute respiratory distress syndrome: a post hoc analysis of the PROSEVA trial.” Critical care (London, England) (2026). PMID: 42143375 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [331]
Heming N, Baron E, Muller G et al.. “HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.” BMJ open (2026). PMID: 42309657 ↗
L5TRIAL_NONRANDOMCited in: 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [332]
Sato R, Kondo S, Ali A et al.. “The Association Between Mechanical Power and Mortality in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 42153811 ↗
L2SR_OBSCited in: 7. Acute Management and Exacerbation Rescue - [333]
Cumpstey AF, Oldman AH, Smith AF et al.. “Oxygen targets in the intensive care unit during mechanical ventilation for acute respiratory distress syndrome: a rapid review.” The Cochrane database of systematic reviews (2020). PMID: 32870512 ↗
L5SR_OBSCited in: 7. Acute Management and Exacerbation Rescue - [334]
Klitgaard TL, Schjørring OL, Nielsen FM et al.. “Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit.” The Cochrane database of systematic reviews (2023). PMID: 37700687 ↗
L5SR_OBSCited in: 7. Acute Management and Exacerbation Rescue - [335]
Afshari A, Brok J, Møller AM et al.. “Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults.” The Cochrane database of systematic reviews (2010). PMID: 20614430 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [336]
Sud S, Sud M, Friedrich JO et al.. “High-frequency ventilation versus conventional ventilation for treatment of acute lung injury and acute respiratory distress syndrome.” The Cochrane database of systematic reviews (2013). PMID: 23450549 ↗
L1SR_OBSCited in: 7. Acute Management and Exacerbation Rescue - [337]
van Vliet R, Melger JWJ, Bem RA et al.. “Epidemiology, ventilation management, and clinical outcomes in children (PRoVENT-PED): first results from the 10-year, investigator-initiated, international, multicentre, prospective cohort study.” The Lancet. Respiratory medicine (2026). PMID: 42081907 ↗
L2COHORTCited in: 7. Acute Management and Exacerbation Rescue - [338]
Nagata K, Tomii K, Otsuka K et al.. “Serum procalcitonin is a valuable diagnostic marker in acute exacerbation of interstitial pneumonia.” Respirology (Carlton, Vic.) (2013). PMID: 23163578 ↗
L3OTHERCited in: 7. Acute Management and Exacerbation Rescue - [339]
Matthay MA. “Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome.” Annals of the American Thoracic Society (2015). PMID: 25830837 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [340]
Sedhai YR, Yuan M, Ketcham SW et al.. “Validating Measures of Disease Severity in Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2021). PMID: 33347379 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue - [341]
Ikonomou L, Wagner DE, Turner L et al.. “Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases.” Annals of the American Thoracic Society (2019). PMID: 30917290 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [342]
Yehya N, Hodgson CL, Amato MBP et al.. “Response to Ventilator Adjustments for Predicting Acute Respiratory Distress Syndrome Mortality. Driving Pressure versus Oxygenation.” Annals of the American Thoracic Society (2021). PMID: 33112644 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue - [343]
Poletto E, Daverio M, Blokpoel RGT et al.. “Lung recruitment manoeuvre strategies in paediatric intensive care units across Europe.” ERJ open research (2025). PMID: 40040904 ↗
L4OTHERCited in: 7. Acute Management and Exacerbation Rescue - [344]
Valentin S, Lopez Padilla D, Nolasco S et al.. “ERS International Congress 2022: highlights from the Respiratory Intensive Care Assembly.” ERJ open research (2023). PMID: 37228293 ↗
L5REVIEW_NARRATIVECited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [345]
See XY, Xanthavanij N, Lee YC et al.. “Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.” ERJ open research (2025). PMID: 40230429 ↗
L2OTHERCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [346]
Celier A, Ordan MA, Lanore A et al.. “Characteristics and prognosis of patients with cirrhosis presenting with acute respiratory distress syndrome: A bicentric retrospective study.” Journal of intensive medicine (2026). PMID: 42396246 ↗
L2COHORTCited in: 7. Acute Management and Exacerbation Rescue, 10. Complications - [347]
Shah FA, Meyer NJ, Angus DC et al.. “A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement.” American journal of respiratory and critical care medicine (2021). PMID: 34652268 ↗
L5GUIDELINECited in: 8. Long-term and Definitive Management - [348]
Matthay MA, Zhuo H, Sarma A et al.. “Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT).” American journal of respiratory and critical care medicine (2026). PMID: 40728562 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [349]
Mazeraud A, Jamme M, Mancusi RL et al.. “Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Respiratory medicine (2021). PMID: 34774185 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [350]
Soin AS, Kumar K, Choudhary NS et al.. “Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Respiratory medicine (2021). PMID: 33676589 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [351]
Honarmand K, Lalli RS, Priestap F et al.. “Natural History of Cognitive Impairment in Critical Illness Survivors. A Systematic Review.” American journal of respiratory and critical care medicine (2020). PMID: 32078780 ↗
L2SR_OBSCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [352]
Ferguson ND, Cook DJ, Guyatt GH et al.. “High-frequency oscillation in early acute respiratory distress syndrome.” The New England journal of medicine (2013). PMID: 23339639 ↗
L1RCTCited in: 8. Long-term and Definitive Management - [353]
van der Heijden M, van Nieuw Amerongen GP, Koolwijk P et al.. “Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients.” Thorax (2008). PMID: 18559364 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [354]
Shimatani T, Yoon B, Kyogoku M et al.. “Frequency and Risk Factors for Reverse Triggering in Pediatric Acute Respiratory Distress Syndrome during Synchronized Intermittent Mandatory Ventilation.” Annals of the American Thoracic Society (2021). PMID: 33326335 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 12. Special Populations & Pregnancy - [355]
Gordon AC, Alipanah-Lechner N, Bos LD et al.. “From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU.” American journal of respiratory and critical care medicine (2024). PMID: 38687499 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [356]
Ventetuolo CE, Muratore CS. “Extracorporeal life support in critically ill adults.” American journal of respiratory and critical care medicine (2014). PMID: 25046529 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [357]
Palakshappa JA, Batt JAE, Bodine SC et al.. “Tackling Brain and Muscle Dysfunction in Acute Respiratory Distress Syndrome Survivors: NHLBI Workshop Report.” American journal of respiratory and critical care medicine (2024). PMID: 38477657 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [358]
Fisler G, Haimed A, Levy CF et al.. “Severe Coronavirus Disease 2019 Infection in an Adolescent Patient After Hematopoietic Stem Cell Transplantation.” Chest (2020). PMID: 33036110 ↗
L4CASE_REPORTCited in: 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy - [359]
Lang C, Ritschl V, Augustin F et al.. “Clinical relevance of lung transplantation for COVID-19 ARDS: a nationwide study.” The European respiratory journal (2022). PMID: 35301249 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [360]
Quijada H, Bermudez T, Kempf CL et al.. “Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody.” The European respiratory journal (2021). PMID: 33243842 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [361]
Kumamoto M, Nishiwaki T, Matsuo N et al.. “Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury.” The European respiratory journal (2009). PMID: 19324956 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [362]
Coppola S, Pelliccia M, Pozzi T et al.. “Effects of High-Flow Nasal Cannula and Helmet Continuous Positive Airway Pressure in Acute Hypoxemic Respiratory Failure.” Critical care medicine (2026). PMID: 41925582 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [363]
Caroli A, Algera AG, van Meenen D et al.. “Effect of a Lower Vs. Higher Positive End-Expiratory Pressure Strategy on Clinically Relevant Outcomes in ICU Patients Without Acute Respiratory Distress Syndrome: Bayesian Re-analysis of the REstricted Vs. Liberal Positive End-Expiratory Pressure in Patients Without Acute Respiratory Distress Syndrome (RELAx) Randomized Clinical Trial.” Critical care medicine (2026). PMID: 41914828 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [364]
Pan T, Xu C, Wang YP et al.. “Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41811317 ↗
L1RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [365]
Liu Y, Ding P, Yang Q et al.. “Efficacy of β-agonists in prevention and treatment of acute lung injury: A meta-analysis of randomized controlled trials.” Annals of thoracic medicine (2026). PMID: 42077222 ↗
L1SR_MA_RCTCited in: 8. Long-term and Definitive Management - [366]
Chase AM, Almuntashiri S, Zhang D et al.. “Predicting mortality with machine learning & biomarkers: A cohort analysis from aerosolized β₂-agonist for treatment of acute lung injury (ALTA) trial.” Physiological reports (2026). PMID: 41866868 ↗
L2RCTCited in: 8. Long-term and Definitive Management, History and Evolution of Treatment - [367]
Yan X, Zhang D, Zhou X et al.. “Association of lactate dehydrogenase to albumin ratio with new-onset acute respiratory distress syndrome and all-cause mortality in patients with sepsis: a retrospective cohort study based on the MIMIC-IV database.” BMC infectious diseases (2026). PMID: 42046077 ↗
L2COHORTCited in: 8. Long-term and Definitive Management - [368]
Zhao X, Liu L, Tu H et al.. “Neonatal hypoxic-ischemic encephalopathy online registry in Shenzhen: protocol for a multicentre, prospective, open, observational cohort study.” BMJ open (2026). PMID: 41857827 ↗
L5COHORTCited in: 8. Long-term and Definitive Management - [369]
Abrams D, Madahar P, Eckhardt CM et al.. “Early Mobilization during Extracorporeal Membrane Oxygenation for Cardiopulmonary Failure in Adults: Factors Associated with Intensity of Treatment.” Annals of the American Thoracic Society (2022). PMID: 34077700 ↗
L4OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 10. Complications - [370]
Martínez-Martínez M, Schmidt M, Broman LM et al.. “Survival and Long-Term Functional Status of COVID-19 Patients Requiring Prolonged Extracorporeal Membrane Oxygenation Support.” Annals of the American Thoracic Society (2024). PMID: 38134435 ↗
L2OTHERCited in: 8. Long-term and Definitive Management, 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [371]
Brown SM, Bose S, Banner-Goodspeed V et al.. “Approaches to Addressing Post-Intensive Care Syndrome among Intensive Care Unit Survivors. A Narrative Review.” Annals of the American Thoracic Society (2019). PMID: 31162935 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term and Definitive Management - [372]
Mikkelsen ME, Anderson B, Christie JD et al.. “Can we optimize long-term outcomes in acute respiratory distress syndrome by targeting normoxemia?” Annals of the American Thoracic Society (2014). PMID: 24621125 ↗
L5OTHERCited in: 8. Long-term and Definitive Management - [373]
Fei S, Huang C, Zhang X et al.. “Extracorporeal Membrane Oxygenation in Immunocompromised Patients With Acute Respiratory Distress Syndrome: A Systematic Review and Meta-analysis.” ASAIO journal (American Society for Artificial Internal Organs : 1992) (2026). PMID: 42007805 ↗
L1SR_OBSCited in: 8. Long-term and Definitive Management, 12. Special Populations & Pregnancy - [374]
Tribuddharat S, Ratanasuwan P, Sathitkarnmanee T et al.. “Impact of FloTrac/EV1000-guided intraoperative hemodynamic optimization on postoperative outcomes in cardiac valve surgery: a randomized controlled trial.” Scientific reports (2026). PMID: 41905981 ↗
L1RCTCited in: 8. Long-term and Definitive Management - [375]
Hu D, Yu Y. “Extracorporeal membrane oxygenation with single-site dual-lumen in a patient with SARS-CoV-2-associated acute respiratory distress syndrome: a case report.” Frontiers in medicine (2026). PMID: 41859157 ↗
L4CASE_REPORTCited in: 8. Long-term and Definitive Management - [376]
Criner GJ, Lang FM, Gottlieb RL et al.. “Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.” American journal of respiratory and critical care medicine (2022). PMID: 35290169 ↗
L1RCTCited in: History and Evolution of Treatment - [377]
Wright PE, Carmichael LC, Bernard GR. “Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS).” Chest (1994). PMID: 7956413 ↗
L1RCTCited in: History and Evolution of Treatment - [378]
Brower RG, Matthay MA, Morris A et al.. “Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.” The New England journal of medicine (2000). PMID: 10793162 ↗
L1RCTCited in: History and Evolution of Treatment - [379]
Brower RG, Lanken PN, MacIntyre N et al.. “Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome.” The New England journal of medicine (2004). PMID: 15269312 ↗
L1RCTCited in: History and Evolution of Treatment - [380]
Amato MB, Barbas CS, Medeiros DM et al.. “Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome.” The New England journal of medicine (1998). PMID: 9449727 ↗
L1RCTCited in: History and Evolution of Treatment - [381]
Perkins GD, Gao F, Thickett DR. “In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury.” Thorax (2007). PMID: 17951278 ↗
L4RCTCited in: History and Evolution of Treatment, 10. Complications - [382]
Esteban A, Ferguson ND, Meade MO et al.. “Evolution of mechanical ventilation in response to clinical research.” American journal of respiratory and critical care medicine (2007). PMID: 17962636 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment - [383]
Combes A, Pesenti A, Ranieri VM. “Fifty Years of Research in ARDS. Is Extracorporeal Circulation the Future of Acute Respiratory Distress Syndrome Management?” American journal of respiratory and critical care medicine (2017). PMID: 28459322 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [384]
Moloney ED, Evans TW. “Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome.” The European respiratory journal (2003). PMID: 12762363 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [385]
Armstrong-Hough M, Lin P, Venkatesh S et al.. “Ethnic Disparities in Deep Sedation of Patients with Acute Respiratory Distress Syndrome in the United States: Secondary Analysis of a Multicenter Randomized Trial.” Annals of the American Thoracic Society (2024). PMID: 38324712 ↗
L2RCTCited in: History and Evolution of Treatment - [386]
Mehter HM, Wiener RS, Walkey AJ. “"Do not resuscitate" decisions in acute respiratory distress syndrome. A secondary analysis of clinical trial data.” Annals of the American Thoracic Society (2014). PMID: 25386717 ↗
L2RCTCited in: History and Evolution of Treatment - [387]
Huang DT, Angus DC, Moss M et al.. “Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome.” Annals of the American Thoracic Society (2017). PMID: 27779896 ↗
L5RCTCited in: History and Evolution of Treatment - [388]
Fan E, Beitler JR, Brochard L et al.. “COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?” The Lancet. Respiratory medicine (2020). PMID: 32645311 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [389]
Riera J, Alcántara S, Bonilla C et al.. “Risk factors for mortality in patients with COVID-19 needing extracorporeal respiratory support.” The European respiratory journal (2022). PMID: 34824058 ↗
L5OTHERCited in: History and Evolution of Treatment - [390]
Riquelme R, Riquelme M, Rioseco ML et al.. “Characteristics of hospitalised patients with 2009 H1N1 influenza in Chile.” The European respiratory journal (2010). PMID: 20185421 ↗
L4OTHERCited in: History and Evolution of Treatment - [391]
Ramanadhan S, Hansen K, Henderson JT et al.. “Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.” The Cochrane database of systematic reviews (2023). PMID: 37184292 ↗
L1SR_OBSCited in: History and Evolution of Treatment, 12. Special Populations & Pregnancy - [392]
Cohen MA, Edelman A, Paynter R et al.. “Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.” The Cochrane database of systematic reviews (2023). PMID: 36622724 ↗
L1SR_OBSCited in: History and Evolution of Treatment, 12. Special Populations & Pregnancy - [393]
Choi EY, Park HH, Kim H et al.. “Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients.” The European respiratory journal (2020). PMID: 32859680 ↗
L5OTHERCited in: History and Evolution of Treatment - [394]
Suchyta MR, Clemmer TP, Elliott CG et al.. “Increased mortality of older patients with acute respiratory distress syndrome.” Chest (1997). PMID: 9149591 ↗
L2OTHERCited in: History and Evolution of Treatment - [395]
Sakamoto O, Ichikado K, Kohrogi H et al.. “Clinical and CT characteristics of Chinese medicine-induced acute respiratory distress syndrome.” Respirology (Carlton, Vic.) (2003). PMID: 12911829 ↗
L4OTHERCited in: History and Evolution of Treatment - [396]
Weinberger J, Rhee C, Klompas M. “Incidence, Characteristics, and Outcomes of Ventilator-associated Events during the COVID-19 Pandemic.” Annals of the American Thoracic Society (2022). PMID: 34170781 ↗
L3OTHERCited in: History and Evolution of Treatment, 13. Prevention, Screening & Surveillance - [397]
Brodie D. “The Evolution of Extracorporeal Membrane Oxygenation for Adult Respiratory Failure.” Annals of the American Thoracic Society (2018). PMID: 29461889 ↗
L5OTHERCited in: History and Evolution of Treatment - [398]
Talaat MK, Ibrahim HM, Bedair HA et al.. “Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric Acute Respiratory Distress Syndrome: A Multicenter, Randomized Controlled Trial.” Archivos de bronconeumologia (2026). PMID: 41760463 ↗
L1RCTCited in: History and Evolution of Treatment - [399]
Kullberg RFJ, de Brabander J, Boers LS et al.. “Lung Microbiota of Critically Ill Patients with COVID-19 Are Associated with Nonresolving Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2022). PMID: 35616585 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [400]
Aguilar OA, Qualls AE, Gonzalez-Hinojosa MDR et al.. “MICB Genomic Variant Is Associated with NKG2D-mediated Acute Lung Injury and Death.” American journal of respiratory and critical care medicine (2024). PMID: 37878820 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [401]
Courtwright AM, Diamond JM, Goldberg HJ. “Retransplant- and bronchiolitis obliterans syndrome-free survival among COVID lung transplant recipients: a national cohort study.” Annals of the American Thoracic Society (2026). PMID: 41134996 ↗
L2COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [402]
Bharat A, Machuca TN, Querrey M et al.. “Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries.” The Lancet. Respiratory medicine (2021). PMID: 33811829 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive), 12. Special Populations & Pregnancy - [403]
Liu ZL, Zhao ZZ, Xiao YQ et al.. “The Effects of Nonintubated Anesthesia onNeutrophil-to-Lymphocyte Ratio and Tumor Markers Among Patients Undergoing Thoracoscopic Lung Resection: A Randomized Controlled Trial.” Journal of cardiothoracic and vascular anesthesia (2025). PMID: 41320620 ↗
L1RCTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [404]
Amarasekera NN, Jha A, Charles WN et al.. “Evaluating the association between bronchoscopic severity of burns-related smoke inhalation injury and clinical outcomes: A systematic review and meta-analysis.” Burns : journal of the International Society for Burn Injuries (2025). PMID: 41101183 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [405]
Beer A, Reed RM, Bölükbas S et al.. “Mechanical ventilation after lung transplantation. An international survey of practices and preferences.” Annals of the American Thoracic Society (2014). PMID: 24640938 ↗
L4OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [406]
Jiang H, Zhao H, Cui W et al.. “EIT Outperforms Quantitative CT in Stratifying ARDS Severity After Lung Transplantation: A Retrospective Study.” The clinical respiratory journal (2025). PMID: 41229381 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [407]
Yanlin L, Ying L, Ya L et al.. “Video-assisted thoracoscopic surgery versus thoracotomy for locally advanced lung cancers: A systematic review and meta-analysis.” Medicine (2026). PMID: 41578576 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [408]
Chen Y, Chen C, Ran D et al.. “Minimally invasive surgery versus thoracotomy for locally advanced lung cancers: A systematic review and meta-analysis.” Medicine (2026). PMID: 41560010 ↗
L1SR_OBSCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [409]
Yan Y, Chandrasekhar A, Yang HC et al.. “Bridge to transplant using a flow-adaptive extracorporeal total artificial lung system following bilateral pneumonectomy.” Med (New York, N.Y.) (2026). PMID: 41619723 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [410]
Herazo-Cubillos AF, Umaña-Gómez D, Montoya-Beltran JS et al.. “Echoes from Macondo: managing disseminated ascariasis with extracorporeal membrane oxygenation therapy. A case report.” BMC infectious diseases (2025). PMID: 41136961 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [411]
Piastra M, Zito G, Orr AM et al.. “Pediatric acute respiratory distress syndrome in children with type I - spinal muscular atrophy: a 12-year case series.” European journal of pediatrics (2025). PMID: 41016950 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [412]
Chen M, Wu H, Xie L et al.. “Successful management of severe pulmonary form of leptospirosis with VV-ECMO, prone ventilation, and bronchoalveolar lavage: two case reports.” Frontiers in medicine (2025). PMID: 40520796 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [413]
Hulot S, Prunet V, Coiffard B et al.. “Fatal acute respiratory distress syndrome caused by donor-derived human metapneumovirus after lung transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2025). PMID: 40389161 ↗
L4CASE_REPORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [414]
Da L, Zhang K. “Early pulmonary rehabilitation in ARDS patients: Effects on respiratory function and long-term outcomes: A retrospective study.” Medicine (2024). PMID: 39705466 ↗
L2COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [415]
Roncon-Albuquerque R, Petit M, Veiga T et al.. “Extracorporeal membrane oxygenation without invasive mechanical ventilation for acute respiratory distress syndrome: an international cohort study.” American journal of respiratory and critical care medicine (2026). PMID: 42092985 ↗
L2COHORTCited in: 10. Complications - [416]
Hariri LP, North CM, Shih AR et al.. “Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review.” Chest (2020). PMID: 33038391 ↗
L4SR_OBSCited in: 10. Complications - [417]
Urner M, Jüni P, Hansen B et al.. “Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 32735841 ↗
L2COHORTCited in: 10. Complications - [418]
Wong AK, Walkey AJ. “Open Lung Biopsy Among Critically Ill, Mechanically Ventilated Patients. A Metaanalysis.” Annals of the American Thoracic Society (2015). PMID: 26065712 ↗
L4SR_OBSCited in: 10. Complications, 11. Prognosis and Natural History - [419]
Sklar MC, Sy E, Lequier L et al.. “Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review.” Annals of the American Thoracic Society (2016). PMID: 27690525 ↗
L4SR_OBSCited in: 10. Complications - [420]
Morrison TJ, Jackson MV, Cunningham EK et al.. “Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer.” American journal of respiratory and critical care medicine (2017). PMID: 28598224 ↗
L5OTHERCited in: 10. Complications - [421]
Papoutsi E, Gkirgkiris K, Tsolaki V et al.. “Association Between Baseline Driving Pressure and Mortality in Very Old Patients with Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2024). PMID: 39388641 ↗
L2OTHERCited in: 10. Complications, 12. Special Populations & Pregnancy - [422]
Vonk-Noordegraaf A, Westerhof N. “Describing right ventricular function.” The European respiratory journal (2013). PMID: 23314901 ↗
L5REVIEW_NARRATIVECited in: 10. Complications, 11. Prognosis and Natural History - [423]
Konstantinides SV. “Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us - and what they don't.” The European respiratory journal (2021). PMID: 33888525 ↗
L5OTHERCited in: 10. Complications, 13. Prevention, Screening & Surveillance - [424]
Karagiannidis C, Bein T, Welte T. “ECMO during the COVID-19 pandemic: moving from rescue therapy to more reasonable indications.” The European respiratory journal (2022). PMID: 35115345 ↗
L5OTHERCited in: 10. Complications, 13. Prevention, Screening & Surveillance - [425]
Lee HE, Yi ES, Rabatin JT et al.. “Histopathologic Findings in Lungs of Patients Treated With Extracorporeal Membrane Oxygenation.” Chest (2017). PMID: 29274319 ↗
L3OTHERCited in: 10. Complications - [426]
Brodie D, Bacchetta M. “Extracorporeal membrane oxygenation for ARDS in adults.” The New England journal of medicine (2011). PMID: 22087681 ↗
L4REVIEW_NARRATIVECited in: 10. Complications - [427]
Saha R, Pham T, Sinha P et al.. “Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials.” Thorax (2023). PMID: 37495364 ↗
L3OTHERCited in: 10. Complications - [428]
Williams AE, José RJ, Mercer PF et al.. “Evidence for chemokine synergy during neutrophil migration in ARDS.” Thorax (2016). PMID: 27496101 ↗
L4OTHERCited in: 10. Complications - [429]
Pandolfi R, Barreira B, Moreno E et al.. “Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction.” Thorax (2016). PMID: 27701117 ↗
L5OTHERCited in: 10. Complications - [430]
Anzueto A, Frutos-Vivar F, Esteban A et al.. “Influence of body mass index on outcome of the mechanically ventilated patients.” Thorax (2010). PMID: 20980246 ↗
L2OTHERCited in: 10. Complications - [431]
Kajiura H, Sawamura A, Taniguchi T et al.. “Prone Positioning During ECPELLA Support for Cardiogenic Shock: A Single-Center Retrospective Study.” Journal of clinical medicine (2026). PMID: 42194589 ↗
L2COHORTCited in: 10. Complications - [432]
Shinno Y, Kage H, Chino H et al.. “Old age and underlying interstitial abnormalities are risk factors for development of ARDS after pleurodesis using limited amount of large particle size talc.” Respirology (Carlton, Vic.) (2017). PMID: 28980363 ↗
L2OTHERCited in: 10. Complications - [433]
Gu M, Xia F, Lu Z et al.. “Association between tidal volume and mortality in patients without acute respiratory distress syndrome: A systematic review and meta-analysis.” Biomedical reports (2026). PMID: 42388450 ↗
L2SR_OBSCited in: 10. Complications - [434]
Bianquis C, Leiva Agüero S, Cantero C et al.. “ERS International Congress 2023: highlights from the Respiratory Intensive Care Assembly.” ERJ open research (2024). PMID: 38651090 ↗
L5OTHERCited in: 10. Complications - [435]
Nilsen JH, Rannestad B, Raatiniemi L. “The Prone Position During Helicopter Transport of Critically Ill Patients: A Case Series from North Norway.” Prehospital emergency care (2026). PMID: 42314024 ↗
L4CASE_REPORTCited in: 10. Complications - [436]
Keelan S, Murphy M, Abrahams M et al.. “Hydrofluoric acid inhalation injury after electric bike battery fire.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2026). PMID: 42243037 ↗
L4CASE_REPORTCited in: 10. Complications - [437]
Davey A, McAuley DF, O'Kane CM. “Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair.” The European respiratory journal (2011). PMID: 21565917 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis and Natural History - [438]
Cereda M, Xin Y, Hamedani H et al.. “Tidal changes on CT and progression of ARDS.” Thorax (2017). PMID: 28634220 ↗
L5OTHERCited in: 11. Prognosis and Natural History - [439]
Lalgudi Ganesan S, Jayashree M, Chandra Singhi S et al.. “Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2018). PMID: 29641221 ↗
L1RCTCited in: 12. Special Populations & Pregnancy - [440]
Schmidt M, Hajage D, Landoll M et al.. “Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study.” The Lancet. Respiratory medicine (2023). PMID: 36640786 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance - [441]
Zinter MS, Delucchi KL, Kong MY et al.. “Early Plasma Matrix Metalloproteinase Profiles. A Novel Pathway in Pediatric Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2019). PMID: 30114376 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy - [442]
Patel BM, Reilly JP, Bhalla AK et al.. “Association between Age and Mortality in Pediatric and Adult Acute Respiratory Distress Syndrome.” American journal of respiratory and critical care medicine (2024). PMID: 38306669 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy - [443]
Khemani RG, Newth CJ. “The design of future pediatric mechanical ventilation trials for acute lung injury.” American journal of respiratory and critical care medicine (2010). PMID: 20732987 ↗
L5REVIEW_NARRATIVECited in: 12. Special Populations & Pregnancy - [444]
Barbaro RP, Xu Y, Borasino S et al.. “Does Extracorporeal Membrane Oxygenation Improve Survival in Pediatric Acute Respiratory Failure?” American journal of respiratory and critical care medicine (2018). PMID: 29373797 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy - [445]
Rowan CM, Klein MJ, Hsing DD et al.. “Early Use of Adjunctive Therapies for Pediatric Acute Respiratory Distress Syndrome: A PARDIE Study.” American journal of respiratory and critical care medicine (2020). PMID: 32130867 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy - [446]
Bateman ST, Borasino S, Asaro LA et al.. “Early High-Frequency Oscillatory Ventilation in Pediatric Acute Respiratory Failure. A Propensity Score Analysis.” American journal of respiratory and critical care medicine (2016). PMID: 26492410 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy - [447]
Ceylan G, Sarac O, Atakul G et al.. “Closed-loop synchronization versus conventional synchronization in spontaneously breathing pediatric patients (CHESTSIPP) - a randomized controlled cross-over study.” Frontiers in medicine (2026). PMID: 41958566 ↗
L1TRIAL_NONRANDOMCited in: 12. Special Populations & Pregnancy - [448]
Journé A, Tessier S, Maisa A et al.. “Factors associated with an unfavorable outcome according to age in patients with COVID-19 admitted to intensive care in mainland France during the first three periods of the pandemic: a nationwide cohort study.” Frontiers in medicine (2026). PMID: 42110412 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy, 13. Prevention, Screening & Surveillance - [449]
Wang T, Lyu Y, Zhang H et al.. “Association between preoperative COVID-19 and major postoperative pulmonary complications: a multicentre observational cohort study in China.” BMJ open (2026). PMID: 41857832 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy - [450]
Tamburro RF, Cooke KR, Davies SM et al.. “Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.” Annals of the American Thoracic Society (2021). PMID: 33058742 ↗
L5OTHERCited in: 12. Special Populations & Pregnancy - [451]
Agarwal S, Patra B, Goyal N et al.. “Comparison of Clinical Profile and Outcomes Associated with Adenovirus and Non-adenovirus Viral Pneumonia in Children Admitted to a Pediatric Intensive Care Unit: A Single-center Retrospective Study.” Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine (2026). PMID: 42146983 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy - [452]
Gangneux JP, Dannaoui E, Fekkar A et al.. “Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study.” The Lancet. Respiratory medicine (2021). PMID: 34843666 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance - [453]
Seng MS, Ng KP, Soh TG et al.. “A phase I/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection.” Cytotherapy (2024). PMID: 38864802 ↗
L4TRIAL_NONRANDOMCited in: 13. Prevention, Screening & Surveillance - [454]
Lin X, Liu Y, Kong L et al.. “Comorbidity-related risk factors for acute respiratory distress syndrome in sepsis patients: A systematic review and meta-analysis.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2025). PMID: 40071790 ↗
L1SR_OBSCited in: 13. Prevention, Screening & Surveillance - [455]
Rufai T, Greenberg LT, Lorch SA et al.. “Association between preterm birth subtypes and severe maternal morbidity: a retrospective cohort study.” BMC pregnancy and childbirth (2025). PMID: 41286739 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance - [456]
Kaenphukhieo T, Trakulsrichai S, Tongpoo A et al.. “Clinical characteristics, treatment, and outcomes of local anesthetic systemic toxicity: a 10-year retrospective study.” Clinical toxicology (Philadelphia, Pa.) (2025). PMID: 41117381 ↗
L4COHORTCited in: 13. Prevention, Screening & Surveillance - [457]
Wang H, Wei Y, Hung CT et al.. “Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.” The Lancet. Infectious diseases (2024). PMID: 38710190 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance - [458]
Tiwari S, Kursange S, Goyal A et al.. “Efficacy of Pulse Methylprednisolone in Treatment of Acute Respiratory Distress Syndrome due to Malaria: A Randomized Controlled Clinical Trial.” The Journal of the Association of Physicians of India (2023). PMID: 38720494 ↗
L1RCTCited in: 13. Prevention, Screening & Surveillance - [459]
Huo S, Liu W, Lv C et al.. “The re-emergence of psittacosis in China: a scoping review of epidemiology, diagnostics, and One Health priorities.” Science in One Health (2026). PMID: 42255501 ↗
L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance - [460]
Williams K, White A, Nana M et al.. “Managing Respiratory Failure in Late Pregnancy.” Journal of clinical medicine (2026). PMID: 42123182 ↗
L5REVIEW_NARRATIVECited in: 13. Prevention, Screening & Surveillance - [461]
Marshall DC, Patel BV, Gordon AC et al.. “Improving retrospective ARDS case-finding using a simple 72-h physiologic persistence rule.” Intensive care medicine experimental (2026). PMID: 42060215 ↗
L4OTHERCited in: 13. Prevention, Screening & Surveillance